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Abbreviations
ABOARD Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention 
ACC American College of Cardiology
ACS acute coronary syndrome
ADP adenosine di-phosphate
AHA American Heart Association
BPM beats per minute
CABG coronary artery bypass grafting
CAD coronary artery disease
CI confidence interval
CK-MB creatine kinase-myocardial band
Cx circumflex coronary artery
DM diabetes mellitus
ECG electrocardiography
eGFR estimated glomerular filtration rate
ELISA early or late intervention in high risk non-ST elevation acute coronary syndromes
ESC European Society of Cardiology
GIIbIIIa glycoprotein IIb/IIIa 
GP1b glycoprotein 1b
GRACE Global Registry of Acute Coronary Events
Hosp Stay  hospital stay
HR hazard ratio
hs high sensitive
Ictus Invasive versus Conservative Treatment in Unstable coronary Syndromes
IRV infarct related vessel 
IQR inter quartile range
ISAR-COOL Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention
ISRCTN International Standard Randomized Controlled Trial Number Register
LAD left anterior descending coronary artery
LBBB left bundle branch block
LIPSIA-NSTEMI  Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl 
in NSTEMI
LVEF left ventricular ejection fraction
MI myocardial infarction 
MRI magnetic resonance imaging
NSTE non-ST-segment elevation
NSTE-ACS Non ST-segment elevation acute coronary syndrome
NSTEMI Non ST-segment elevation myocardial infarction
NVVC Nederlandse Vereniging voor Cardiologie (Netherlands Society of Cardiology)
OPTIMA Optimal timing of coronary intervention in unstable angina
OR odds ratio
PCI percutaneous coronary intervention
Q quartile
RCA right coronary artery
RCT randomised controlled trial
RIDDLE-NSTEMI Randomized study of ImmeDiate versus DeLayed invasivE intervention in patients 
with Non-ST-segment Elevation Myocardial Infarction
RR risk ratio
SD standard deviation
SISCA Comparison of Two Treatment Strategies in Patients With an Acute Coronary 
Syndrome Without ST Elevation
STE ST-segment elevation
STEMI ST-segment elevation myocardial infarction
TAO Treatment of Acute coronary syndrome with Otamixaban
TIA transient ischemic attack
TIMACS Timing of Intervention in Acute Coronary Syndrome
TIMI Thrombolysis In Myocardial Infarction 
TropT troponin T 
TSTE transient ST-segment elevation
Tx thromboxane
UA unstable Angina
ULN upper limit of normal
VD vessel disease
VWF von Willebrand factor
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Introduction
1Introduction 
The term Acute Coronary Syndrome (ACS) refers to a spectrum of conditions characterised 
by acute myocardial ischemia, usually due to an abrupt reduction in blood flow in one or 
more coronary arteries. The underlying mechanism is atherosclerosis, a systemic inflam-
matory process leading to accumulation of lipids and leukocytes like macrophages and 
lymphocytes within the intima of arteries. The most frequent cause of an ACS is rupture 
or erosion of an unstable atherosclerotic plaque located in the coronary artery wall with 
superimposed thrombus formation (1).
Exposition to sub-endothelial collagen and other thrombogenic material initiates a process of 
thrombocyte adherence to the extracellular matrix (figure 1). The GP1b receptor complex on 
the platelet surface binds with Von Willebrand factor on the sub-endothelial collagen (2,3). 
This causes activation and further recruitment of platelets from the circulation and release 
of prothrombotic molecules like ADP and thromboxane. These substances stimulate platelet 
aggregation and adhesion and activate the GIIb/IIIa receptor on the platelet surface. Also, 
the coagulation cascade is activated by tissue factor from the lipid core of the atherosclerotic 
plaque and thrombin is produced. This further stimulates platelet activation and induces the 
formation of fibrin from fibrinogen, contributing to formation and consolidation of the haemo-
static thrombus by interaction with the activated GIIb/IIIa receptors of the platelets.
Patients with ACS can be divided into two groups, depending on ECG abnormalities. Those 
with persistent ST-segment elevation or new left bundle branch block on ECG are classified 
as ST-elevation myocardial infarction (STEMI) and patients without these ECG abnormal-
ities as non-ST-elevation ACS (NSTE-ACS). This latter group can be further subdivided 
depending on cardiac biomarkers of necrosis, like cardiac troponin. If elevated, the patient is 
classified as having a non-ST-segment elevation myocardial infarction (NSTEMI), otherwise 
the patient is considered to have unstable angina (UA) (4).
The median age at presentation of ACS is 68 years (Quartile (Q) 1-3= 56-79 years) and 
approximately two third of patients is male (5). The incidence of STEMI has decreased 
over the last decade with about 70% of ACS patients suffering a NSTE-ACS nowadays 
(5,6). These patients are usually older and have more co-morbidity. Short term mortality is 
lower than in STEMI, but after 1-2 years of follow-up, mortality becomes comparable with 
that of STEMI (7-9). Clinical use of blood test that are more and more sensitive to detect 
biomarkers for myocardial necrosis (like high sensitive [hs] troponin assays) has resulted 
in increase in diagnosis of NSTEMI and decrease of UA (10).
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Jennings: Platelet activation mechanisms
lagen at sites of vascular injury. The interaction between vWF and 
GPIb/V/IX is required for the initial adhesion of platelets to the 
subendothelium under conditions of high shear (as found in small 
arteries, arterioles, and stenosed arteries). Under normal con-
ditions, soluble vWF does not undergo significant interactions with 
GPIb/V/IX. However, when immobilised on exposed collagen at 
sites of injury, it becomes a strong adhesive substrate. 
Platelet activation and recruitment is stimulated by bound 
platelet secretion products and local prothrombotic factors (tis-
sue factor), which lead to generation of haemostatic plugs. 
Multiple pathways lead to platelet activation, including those 
stimulated by collagen, adenosine diphosphate (ADP), thromb-
oxane A2, epinephrine, serotonin and thrombin (1–4). The cumu-
lative action of these activators results in recruitment of platelets 
from the circulation, which also leads to several distinct manifes-
tations of platelet activation (Table 1). These include platelet 
shape change, expression of pro-inflammatory molecules such 
as P-selectin and soluble CD40 ligand (sCD40L), expression of 
platelet procoagulant activity, and conversion of GPIIb/IIIa 
(αIIβ3-integrin) into an active form, which allow platelet aggre-
gation and the potential for pathologic thrombosis. Local ac-
cumulation of these agonists recruits circulating platelets into 
the growing, stable haemostatic plug. Thrombin-mediated gen-
eration of fibrin from fibrinogen also contributes to formation 
and consolidation of the haemostatic plug (1).  
GPIIb/IIIa is the central platelet receptor mediating platelet 
aggregation. Upon activation of this receptor, it promotes pla-
telet adhesion, aggregation and spreading on the exposed extra-
cellular matrix of the injured vessel wall, as well as thrombus 
formation and stability. Bound fibrinogen to GPIIb/IIIa bridges 
activated platelets and contributes to thrombus stabilisation. Fi-
brin-rich clots are generated by thrombin, which is produced in-
itially via tissue factor in ruptured or eroded atherosclerotic 
plaques. Through platelet activation by multiple pathways, a pro-
tective haemostatic plug may progress ultimately to an occlusive, 
platelet-rich thrombus. 
Platelet activation pathways 
Multiple pathways contribute to platelet activation (Table 1) 
(1–4). ADP is stored at high concentrations in dense granules 
and released from adherent platelets during platelet activation. 
ADP contributes to platelet activation occurring both during pro-
tective haemostasis (i.e. formation of the initial platelet mono-
layer) and during formation of occlusive platelet-rich thrombi. 
Release of thromboxane A2 from adherent platelets enhances re-
cruitment and aggregation to the primary plug and activates pla-
telets during both protective haemostasis and pathologic throm-
bus formation. Collagen is a strong thrombogenic substrate. 
Under high-shear conditions, platelet adhesion is mediated by 
Figure 1: Platelet plug formation. Vascular injury results in the ex-
posure of collagen and von Willebrand factor (vWF) in the vessel wall. 
Circulating platelets adhere and form a monolayer of activated platelets 
on the collagen matrix, which drives the release of adenosine diphos-
phate (ADP) and thromboxane (Tx) A2 from the adherent platelets. Se-
cretion of ADP and TxA2 promotes changes in platelet shape and amplifi-
cation of platelet activation. Thrombin, generated by locally produced 
tissue factor (TF), is the most potent platelet activator. In the perpetu-
ation phase, platelet contacts promote growth and stabilisation of the 
platelet plug. Adapted with permission from Brass LF. Chest. 2003;124:18. 
© American College of Chest Physicians. All rights reserved. 
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Figure 1: Platelet plug formation. Vascular injury results in the exposure of collagen and von 
Willebrand facto  (vWF) in the vessel wal . Circula ng platel ts adhere and form a monolayer of 
activated platelets on the collagen matrix, which drives the release of adenosine diphosphate (ADP) 
and thromboxane (Tx) A2 from the ad ere t platelets. Secretion of ADP and TxA2 promotes changes 
in platelet shape and amplification of platelet activation. Thrombin, generated by locally produced 
tissue factor (TF), is the most potent platelet activator. In the perpetuation phase, platelet contacts 
promote growth and stabilisation of the platelet plu . Reproduced with kind permission from L.K. 
Jen ings et al, Thromb Haemost 2009;102:249.
Patients wi h suspected ACS sho ld be urgently referred to an emergency departm nt, pref-
erably a coronary car  unit f r evalu tion and monitoring. A targeted history and physical 
examination, repeated ECG recording and lood samples for analysis of troponin and other 
markers of cardiac necrosis are cornerstones of the diagnostic process. Acute management 
of ACS includes treatment with anti-ischemic and anti-platelet drugs and anti-coagulants. An 
important treatment option is percutaneous revascularisation if this appears to be feasible 
at coronary angiography. According to current guidelines, patients with STEMI, should 
undergo reperfusion therapy as soon as possible (11). In patients with NSTE-ACS, a rou-
tinely invasive strategy is recommended if one or more intermediate or high risk factors 
are present (12) as shown in table 1. Several meta-analyses of randomised trials have 
shown that this strategy, compared to a selective invasive treatment reduces the incidence 
of cardiovascular death and myocardial infarction (MI) in the medium to long term (13-16).
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Table 1: Risk criteria mandating invasive strategy in NSTE-ACS
Very High Risk Criteria High Risk Criteria Intermediate Risk criteria
Haemodynamic instability or
cardiogenic shock
Rise or fall in cardiac tro-
ponin compatible with MI
Diabetes mellitus
Recurrent or ongoing chest
pain refractory to medical
treatment
Dynamic ST- or T-wave 
changes (symptomatic or 
silent)
Renal insufficiency (eGFR
<60 ml/min/1.73 m2)
Life-threatening arrhythmias or 
cardiac arrest
GRACE score >140 LVEF <40% or congestive heart 
failure
Mechanical complications of MI Early post-infarction angina
Acute heart failure with refracto-
ry angina or ST deviation
Recent PCI
Recurrent dynamic ST- or 
T-wave changes, particularly 
with intermittent ST-elevation
Prior CABG
GRACE risk score >109 and <140
After: 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting 
without persistent ST-segment elevation (10)
CABG =coronary artery bypass graft; eGFR= estimated glomerular filtration
rate; GRACE = Global Registry of Acute Coronary Events; LVEF = left ventricular
ejection fraction; PCI = percutaneous coronary intervention; MI = myocardial
infarction.
Recommendations of timing of intervention depend according to current guidelines on 
the risk profile. Patients with one or more very high risk factors should undergo coronary 
angiography as soon as possible but within 2 hours, those without very high risk factors but 
at least one high risk factor within 24 hours and those with only intermediate risk factors, 
within 72 hours of presentation. Although current guidelines are quite straight forward about 
timing, this has been a matter of debate for many years and has been studied in several 
randomised clinical trials. 
Considering the pathophysiological mechanism of NSTE-ACS, described above, an early 
invasive treatment strategy might seem favourable. Like in STEMI patients, early revascu-
larisation may prevent extension of myocardial necrosis by restoring adequate blood flow in 
the culprit vessel. On the other hand, it has been hypothesised that routine early intervention 
might be harmful, because intervention in unstable plaques with fresh thrombus increases 
the risk of periprocedural complications and distal embolisation resulting in micro-infarctions 
(17,18). Therefore, delayed intervention after adequate pre-treatment with antithrombotic 
medication (“cooling down”) might be superior. 
14
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Before the ELISA-3 trial, the main theme of this thesis, 5 major trials compared an early versus 
late invasive treatment strategy (table 2). In three trials, levels of cardiac enzymes were used 
as primary endpoint. In ELISA (17), delayed intervention resulted in lower enzymatic infarct 
size and in LIPSIA-NSTEMI (19) and ABOARD (20), no difference was found between early or 
late intervention. ISAR-COOL (18), the trial with the largest difference between early (median 
2.4 h) and late (86 h) intervention found a significant lower incidence in death or MI at 30 days 
in the first group. The largest trial, TIMACS (21), found no significant difference in incidence 
of death, MI or stroke at 6 months, but a pre-specified subgroup analysis showed a reduction 
with early invasive strategy in the tertile of patients with the highest GRACE risk score (>140). 
The above mentioned guidelines are mainly based on the results of this subgroup analysis of 
this otherwise negative trial. Two meta-analyses on these randomised trials (22,23) and one 
on both randomised and observational studies (24) showed no difference in mortality and 
re-infarction but only a reduction in refractory ischemia with early intervention.
Interpretation of the results of these trials is limited by differences in primary endpoints, 
heterogeneity in definition of early and delayed timing and patient risk profile. Another short-
coming of these trials is that the median age of the patients included in the trials is lower 
than in NSTE-ACS patients in real life. Also, many trials were conducted in high volume, 
tertiary centre, with different patient characteristics than encountered in daily practice in a 
general hospital. Because of this, results from these trials might not be representative for 
NSTE-ACS patients in clinical practice.
Therefore we conducted the ELISA-3 trial, an investigator initiated, randomised, open, 
multicentre study, to compare immediate to delayed invasive strategy in high-risk non-ST-el-
evation acute coronary syndrome patients. The trial was conducted in six Dutch hospitals 
of which one had 24-hour facilities for (primary) PCI and CABG. By defining age above 65 
years as one of the high-risk criteria, inclusion of elderly patients was encouraged.
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Chapter 1
Outline of this thesis 
This thesis addresses three issues. First, the results of the ELISA-3 study are discussed, 
in which immediate invasive treatment strategy is compared to delayed invasive strategy in 
high-risk non-ST-elevation acute coronary syndrome patients. In chapter 2, the main results 
of the ELISA-3 trial are presented. In chapter 3, the long term outcome after 2 years follow 
up is discussed. Chapter 4 to 6 concern results of subgroup analysis of the ELISA-3 trial, 
patients randomised in PCI versus non-PCI centres (chapter 4), patients with transient ST 
elevation (chapter 5) and patients with circumflex related ACS (chapter 6). Second, in chap-
ter 7, results of a real-world registry of consecutive patients hospitalised with NSTE-ACS 
are reported. Use and timing of coronary angiography, associated patient characteristics 
and clinical outcome are investigated. Lastly, in chapter 8 a collaborative meta-analysis 
based on individual patient data of 8 trials (including ELISA-3) on optimal timing of invasive 
strategy in patients with non-ST-elevation acute coronary syndrome is presented.
.
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Abstract 
Aims: To compare an early to a delayed invasive strategy in high-risk patients with NSTE-
ACS. 
Methods and results: In this prospective multicentre trial, 542 patients hospitalised with 
NSTE-ACS were randomised to either an immediate (angiography and revascularisation 
if appropriate < 12 h) or a delayed invasive strategy (> 48 h after randomisation). Patients 
were eligible if they had two of the following three high-risk characteristics: evidence of 
extensive myocardial ischemia on ECG, elevated biomarkers for myocardial necrosis 
(TropT>0.10 μg/L) and an age above 65 years. Primary endpoint of the study was the 
combined incidence of death, reinfarction and/or recurrent ischemia at 30 day follow-up. 
Secondary endpoints were enzymatic infarct size as assessed by a single cardiac troponin 
T, at 72-96 hours after admission or at discharge and the percentage of patients without 
a rise in CKMB during admission. Median age was 71.9 (quartile (Q)1 to 3 = 64.5-78.4) 
years. Median time between randomisation and start of angiography was 2.6 (Q1 to 3=1.2-
6.2) hours in the immediate and 54.9 (44.2-74.5) hours in the delayed intervention group. 
The composite of death, reinfarction and/or recurrent ischemia at 30 days occurred in 12 
% of patients and was not significantly different between the two groups (9.9% and 14.2% 
respectively, p= 0.135). All secondary endpoints and bleeding complications were compa-
rable. Hospital duration was two days shorter in the immediate intervention group (4 days 
[Q1 to3 =2-10] vs 6.days [4-12]). 
Conclusions: Although no definitive conclusion can be drawn due to a lower than expected 
prevalence of the primary endpoint, an immediate invasive strategy was safe and feasible 
but not superior to a delayed invasive strategy in terms of the combined primary endpoint 
of death, reinfarction and/or recurrent ischemia at 30 days. These results are consistent 
with previous randomised trials which studied the effect of timing of angiography in patients 
with NSTE-ACS.
.
Trial Registration: ISRCTN Register 39230163
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Introduction
Current guidelines recommend a routinely invasive strategy (angiography and revasculari-
sation if applicable) in patients presenting with non-ST-elevation acute coronary syndrome 
(NSTE-ACS) (1,2). Several randomised clinical trials (RCTs) and meta-analyses have 
shown that this strategy, compared to a selective invasive treatment strategy reduces the 
incidence of cardiovascular death and myocardial infarction (MI) in the medium to long term 
(3-10). This is especially true in patients at higher risk. Troponin elevation and ST depres-
sion at baseline appear to be among the most powerful individual predictors of benefit from 
a routine invasive treatment. 
With the exception of indication for emergency angiography and revascularisation, con-
troversy remains about the optimal timing of angiography for patients presenting with 
NSTE-ACS who are planned to undergo invasive treatment. Some RCTs have shown that 
early angiography and revascularisation improve clinical outcome (11,12), while others 
showed an increase in infarct size (13). Three other trials showed no significant differences 
in cardiovascular outcome (14-16). In the largest of these trials (14), a pre-specified sub-
group analysis showed a significant reduction in the combined endpoint for death, MI and 
stroke at six months for patients at highest risk (GRACE score > 140).
A meta analysis of five RCT’s (17,18) and a recently published updated meta-analysis 
of RCTs and observational studies (19) showed that little or no benefit was found with 
early intervention. A non-significant decrease in rate of mortality and major bleeding and 
a non-significant increase in MI was found besides a statistically significant decrease in 
refractory ischemia. These findings were limited by heterogeneity in timing of intervention 
and patient risk profiles.
Although the majority of patients with NSTE-ACS are older and the prevalence of ACS-re-
lated complications increase with age, elderly patients are underrepresented in studies 
investigating the efficacy and hazards of pharmacological and invasive management of 
NSTE-ACS. Therefore, it is recommended that trials should enrol elderly subjects propor-
tional to their prevalence among the treated population (20).
The aim of this study was to compare an early to a delayed invasive strategy in a population 
of high risk patients with NSTE-ACS. By defining age above 65 years as one of the high 
risk criteria, inclusion of elderly patients was encouraged.
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Methods
The objective of the ELISA-3 study, an investigator initiated, randomised, open, multicen-
tre study, was to test the hypothesis that immediate angiography and revascularisation 
are superior to delayed angiography no earlier than 48 hours after admission, in high risk 
non-ST elevation acute coronary syndrome patients. The trial was conducted in six Dutch 
hospitals of which one had 24-hour facilities for (primary) PCI and CABG. The study com-
plied with the Declaration of Helsinki, was approved by the ethics committee of the Isala 
klinieken, Zwolle, The Netherlands and all patients gave written informed consent before 
study entry. The study was registered in the ISRCTN Register (ISRCTN39230163).
Patients
Patients were eligible if they were hospitalised with ischaemic chest pain or dyspnoea at 
rest with the last episode occurring 24 hours or less before randomisation and had at least 
two out of three of the following high-risk characteristics: (1) evidence of extensive myo-
cardial ischemia on ECG (shown by new cumulative ST depression >5 mm or temporary 
ST-segment elevation in 2 contiguous leads < 30 min), (2) elevated biomarkers (troponin 
T >0.10 μg/l or myoglobin > 150 μg/l) or elevated CKMB fraction (> 6% of total CK) (3) 
age above 65 years. Exclusion criteria were persistent ST-segment elevation, symptoms 
of ongoing myocardial ischemia despite optimal medical therapy, contraindication for diag-
nostic angiography, active bleeding, cardiogenic shock, acute posterior infarction and life 
expectancy less than one year.
Randomisation and treatment
After giving written informed consent, patients were randomly assigned to an immediate 
or delayed treatment strategy by a web-based computerised system, stratified to the 
symptoms of patients: chest pain or dyspnoea. In patients assigned to the immediate 
treatment strategy, angiography was performed as soon as possible but within 12 hours 
of randomisation. Patients assigned to the delayed treatment strategy underwent angiog-
raphy no sooner than 48 hours after randomisation, unless clinical instability or recurrent 
ischemia despite optimal medical therapy warranted emergency angiography. In patients 
recruited at a non-PCI centre, the patient was urgently transferred to the interventional 
centre for angiography and revascularisation in case of randomisation to the immediate 
intervention group. In case of assignment to delayed intervention, angiography was per-
formed at the local non-PCI centre. Angioplasty was performed according to the local 
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standards of the intervention centre. All patients were treated according to the guidelines. 
Concomitant medication included a loading dose of aspirin (500 mg orally or I.V), clopi-
dogrel (600 mg orally) and 5000 IU unfractionated heparin I.V. as soon as possible after 
diagnosis. In case of angioplasty, Aggrastat (bolus of 25 mg/kg followed by continuous 
infusion of 0,15mg /min.kg) was given in both groups starting shortly before the interven-
tion for 12 hours. Nitrates, beta-blockers and calcium channel blockers were given at the 
discretion of the investigator.
Endpoints
The primary endpoint of the study was the combined incidence of death, reinfarction and/
or recurrent ischemia at 30 day follow-up. Death was defined as death from any cause. 
Recurrent ischemia was defined as recurrent chest pain associated with new or recurrent 
ECG abnormalities requiring urgent or repeat angiography or repeat hospitalisation. The 
definition of reinfarction was related to the presence of elevated CKMB on admission: Early 
reinfarction in patients presenting with a CKMB >upper limit of normal (ULN) was defined 
as a decrease in CKMB of at least 50% of ULN from a prior peak level to a valley followed 
by a new increase with a value above the sum of the preceding valley and three times the 
ULN or the development of new Q waves in two or more contiguous leads (defined as Q 
waves greater than or equal to 0.04 s in duration or having a depth greater than or equal to 
one-fourth of the corresponding R-wave amplitude). Early reinfarction in patients presenting 
with CKMB not exceeding the upper limit of normal was defined as a peak CKMB greater 
than three times the ULN with the exception of cases where the CKMB release curve was 
unequivocally related to the chest pain episode before randomisation and not to the chest 
pain episodes after randomisation or development of new Q waves in 2 or more contiguous 
leads. Late reinfarction in patients whose CKMB had returned to (or had remained) normal 
was defined as peak CKMB greater than three times the ULN or the development of new Q 
waves in two or more contiguous leads. MI in patients who underwent CABG was defined 
as the development of new Q waves in 2 or more contiguous leads.
Secondary endpoints were enzymatic infarct size as assessed by a single cardiac troponin 
T, at 72-96 hours after admission or at discharge and the percentage of patients without a 
rise in CKMB during admission. In addition, bleeding complications were assessed. Major 
bleeding was defined as bleeding with Hb drop of ³2 mmol/l or a blood transfusion of two 
or more units.
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Pre-specified subgroups included heart rate on admission (under or above 100 beats per 
minute), pro-BNP, troponin T values (both below versus above median value), cumulative 
ST-segment depression on admission (<5 mm vs. ≥5 mm), patients presenting with dysp-
noea versus chest pain, patients with and without diabetes and gender. Post hoc defined 
subgroups were age, GRACE risk score (both below versus above median value), ST 
deviation (cumulative ST depression < 5 mm versus ≥5 mm or temporary ST elevation) 
and PCI vs. non-PCI centres.
Statistical analysis
Data were analysed according to the intention-to-treat analysis. Continuous variables were 
expressed as median and quartile 1 and 3 and were compared between the intervention 
groups using a Mann-Whitney U test. Categorical data were described by proportions 
and compared with the chi square or Fisher’s exact test. Logistic regression was used 
to calculate the p-value of the interaction between the effect of the intervention and the 
prespecified subgroups upon the primary endpoint. All tests were two-sided and an alpha 
of 5% was used. Statistical analysis was performed with SPSS (version 20), SPSS Inc. 
Chicago, IL, USA.
Sample Size
The sample size of the study was calculated to demonstrate the superiority of immediate 
angiography compared to delayed angiography. The primary end point was the incidence of 
death, reinfarction or recurrent ischemia within 30 days of admission. The 30-day incidence 
of the combined endpoint in the delayed angiography group in this high risk study popula-
tion was estimated to be 25% (5% mortality, 8% MI, 12% recurrent ischemia, based upon 
previous data in high risk patients (21). An absolute risk reduction of 10% was expected 
in the patients treated with the immediate catheterisation approach (4% mortality, 4% MI, 
7% recurrent ischemia). At an alpha level of 5% and a beta level of 20%, the number of 
patients required was 540 (270 per group). An interim analysis was performed according 
to the probability stopping rules of Snapinn (22) after inclusion of 380 patients.
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Results
Patient and procedure characteristics
The trial flow chart is shown in figure 1. Between July 2007 and June 2012, 542 patients 
were randomised in six hospitals. Ninety-two patients (17 %) were randomised at a non-
PCI centre. Eight patients were excluded, five because of withdrawn consent and three 
for major protocol violation. Two hundred and sixty-nine patients were allocated to the 
immediate intervention and 265 to the delayed intervention group. Baseline characteristics 
were well balanced between the treatment groups (table 1). Median age was 72 years, 74% 
of patients were older than 65 years and the median GRACE risk score was 135.0 (IQR 
117-154). Thirty day follow-up was obtained in 97.9% of the patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomized (n=542) 
Excluded  (n=8) 
 Withdrawn consent (n=5) 
 Major protocol violation (n =3)  
 
30 day follow up (n = 262) 
 
Allocated to immediate treatment (n=269) 
 
 No angio (n = 5) 
 
30 day follow up (n = 261) 
Allocated to delayed treatment (n=265) 
 
 No angio (n = 8) 
 
 
Allocation 
Follow-Up 
Analysis (n=534) 
Enrollment 
Figure 1: Consort trial flow chart
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Table 1: Patient baseline characteristics 
Variable Immediate treatment 
n=269
delayed treatment
n=265
Demographics
Age (y; med, Q1-Q3) 72.1 (65.5-78.4) 71.8 (62.5-78.4)
Male gender, n (%) 187 (69.5) 174 (65.7)
Randomised in (%)
PCI – centre 83.3 83.0
Non PCI-centre 16.7 17.0
GRACE score (med, Q1-Q3) 136 (118-154) 133 (117-154)
Medical history, n (%)
Hypertension 146 (54.3) 154 (58.1)
Smoking 57 (21.2) 70 (26.4)
Diabetes mellitus 64 (23.8) 54 (20.4)
Previous MI 48 (17.8) 52 (19.6)
Previous TIA 15 (5.6) 13 (4.9)
Previous stroke 9 (3.3) 12 (4.5)
Previous coronary procedures (%)
Previous PCI 49 (18.2) 55 (20.8)
Previous CABG 37 (13.8) 32 (12.1)
y = years, med = median, Q=quartile, MI = Myocardial Infarction, TIA = Transient Ischaemic Event, 
PCI = Percutaneous Coronary Intervention, CABG = Coronary Arterial Bypass Graft
Angiography was performed in 98.1% of the patients in the immediate treatment group and 
in 97.0% in the delayed treatment group with median time from randomisation to angiogra-
phy 2.6 (quartile (Q) 1 to 3=1.2-6.2) hours and 54.9 (Q1 to 3= 44.2-74.5) hours respectively. 
Of the patients assigned to immediate intervention, 39 (14%) underwent angiography more 
than 12 hours after randomisation (median 16.7 h, Q1to 3= 13.6-19.4) because of logistic 
reasons. Of the patients randomised to delayed intervention, 18 (6.8%) underwent angi-
ography within 48 hours of randomisation due to recurrent ischemia, five (1.9%) for other 
medical reasons and 69 patients (26%) for logistic reasons (median time to angiogram 
42.7 h, Q1 to 3= 31.4-46.2 h). One, two and three vessel disease were equally distributed 
between the two groups, as was the rate of PCI, successful PCI and CABG (table 2). The 
use of drug eluting stents did not differ between the immediate and the delayed treatment 
group (54.5% and 55.6% respectively of patients who received a stent at PCI, p= 0.86).
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Table 2: procedural characteristics
Variable Immediate 
treatment
n=269 
delayed 
treatment
n=265
P Value
Time admission – randomisation(h, med, Q1-Q3) 2.0 (0.9-4.5) 2.1 (1.0-4.2) 0.97
Time randomisation - start angiography (h, med, 
Q1-Q3)
2.6 (1.2-6.2) 54.9 (44.2-74.5) <0.001
Extent CAD (%) 0.285
One-vessel 27.7 26.2
Two-vessel 29.2 35.5
Three-vessel 33.0 26.6
Infarct related artery (%) 0.039
LAD 37.7 34.7
RCA 16.5 25.3
Cx 22.2 22.2
Left main 0.4 3.1
Graft 9.7 6.7
Treatment (%) 0.55
PCI 66.7 61.9
CABG 23.2 25.7
Medical 10.1 12.4
h= hours, Q = Quartile, CAD = Coronary artery disease, PCI = Percutaneous Coronary Intervention, 
CABG = Coronary Arterial Bypass Graft. 
Study endpoints
The primary endpoint of the study, the combined incidence of death, re-infarction and/or 
recurrent ischemia at 30 day follow-up, occurred in 9.9% of the patients in the immediate 
treatment group and 14.2% of the patients in the delayed treatment group (p=0.135) (table 
3). There was no statistically significant difference between the groups in the individual com-
ponents of the primary endpoint, the rates of death (both groups 1.1%, p>0.99), (recurrent) 
myocardial infarction (1.9 vs 0.8%,p=0.45) and recurrent ischemia (7.6 vs. 12.6%,p=0.058). 
Analysis of pre-specified and post hoc defined subgroups showed no significant interaction 
with immediate or delayed treatment upon the primary endpoint (figure 2 and 3).
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Table 3: Study endpoints and clinical outcomes
Variable Immediate 
treatment 
n=269
delayed 
treatment
n=265
P Value
Primary endpoint (%)
Combined incidence of death, re-infarction 
and recurrent ischemia at 30 days follow up
9.9 14.2 0.135
Death 1.1 1.1 >0.99
MI 1.9 0.8 0.450
Recurrent ischemia 7.6 12.6 0.058
Secondary endpoints
Enzymatic infarct size assessed by single 
Troponin T 72-96 h after admission (μg/l, 
median, Q1-Q3)
0.31 (0.12-0.68) 0.31 (0.10-0.99) 0.983
% patients without CKMB rise during ad-
mission
35.4 36.5 0.801
Bleeding(%)
Any bleeding 22.9 19.9 0.407
Major bleeding 11.8 11.1 0.796
CABG related bleeding 19.1 16.5 0.435
CABG related major bleeding 10.7 10.0 0.785
Hospital stay (d), median, Q1-Q3) 4.0 (2.0-10.0) 6.0 (4.0-12.0) <0.001
MI = Myocardial Infarction, Q = Quartile, d = days
The first secondary endpoint, median enzymatic infarct size as assessed by a single car-
diac troponin T measured at 72-96 hours after admission or at discharge was similar in 
both groups (0.31 μg/l, p=0.98 ). The percentage of patients without a rise in CKMB during 
admission, the second secondary endpoint, was 35.4% in the immediate treatment group 
and 36.5% in the delayed treatment group (p=0.80). 
Incidence of bleeding and hospital stay
No difference in the occurrence of bleeding events between the two treatment groups was 
found. Major bleeding occurred in 11.8% of the patients in the immediate treatment group 
and 11.1% in the delayed treatment group (p=0.80), while any bleeding was reported in 
22.9% and 19.9% of the patients respectively (p=0.41). Hospital stay for patients allocated 
to immediate treatment was significantly shorter than for patients in the delayed treatment 
group (median 4.0 vs 6.0 days, p<0.001). The use of evidence based medication at dis-
charge was similar in both groups. 
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Figure 2: Forest plot of relative risk of primary endpoint at 30 days in pre-specified patient 
subgroups. Data are number or number (%), unless otherwise indicated. Percentages are number 
of patients with primary endpoint divided by number of patients. Squares and horizontal bars repre-
sent within-subgroup relative risk and 95% CIs, respectively, on a log scale.
Figure 3:  Forest plot of relative risk of primary endpoint at 30 days in post hoc selected 
patient subgroups. Data are number or number (%), unless otherwise indicated . Percentages are 
number of patients with primary endpoint divided by number of patients. Squares and horizontal bars 
represent within-subgroup relative risk and 95% CIs, respectively, on a log scale. 
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Discussion
The main finding of our study is that in high risk NSTE-ACS patients, angiography and 
revascularisation within 12 hours did not significantly improve clinical outcome as compared 
to intervention 48 hours or more after admission. Although we found a relative risk reduction 
(RRR) of about 30% for the combined endpoint of death, reinfarction or recurrent ischemia 
at 30 days in the immediate group, this difference was not statistically significant. This dif-
ference was largely driven by a reduction in recurrent ischemia (RRR=40%, p=0.058). Both 
secondary endpoints, enzymatic infarct size and the percentage of patients without a rise in 
CKMB during admission were similar. This indicates that an early intervention does not lead 
to an increase in infarct size, as found by previous trials. Given this finding and the finding 
of similar rates of bleeding events, no difference in safety existed between both strategies. 
Of all trials investigating the optimal timing of intervention in high risk NSTE-ACS patients, 
our study included patients with the highest median age (71.9 years). More than 70% of 
patients were above 65 years of age. As a result, this study reflects very well the age dis-
tribution of patients presenting with NSTE-ACS in real life, with a median age of 68 years 
(20). A median GRACE risk score of 135 indicates that about half of the included patients 
had a high risk profile.
The possibility of comparing our results with those of previously published trials on this topic 
is limited due to differences in endpoints and timing of early and delayed intervention. More-
over, some trials took a non-clinical parameter as primary endpoint and clinical parameters 
only as secondary endpoints. However, taking these limitations into account, the results of 
our trial are largely consistent with randomised trials in table 4 and with the conclusion of 
several meta analyses (17-19) and suggest that immediate intervention does not seem to 
be associated with a reduction in death or myocardial infarction, but at most reduces the 
incidence of recurrent ischemia. However, a new meta-analysis should be performed. To 
address this question, this new meta-analysis should include the most recent trials.
The results of the subgroup analyses showed that patient at higher risk, as indicated by a 
higher GRACE risk score, a higher troponin level and/or more ST-T segment deviation on 
admission, tend to benefit more from an early invasive strategy. These findings are in line 
with those of previously published trials and meta analyses and support the most recent 
ESC guideline for management of acute coronary syndromes in patients presenting without 
persistent ST-segment elevation (1).
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To our knowledge, this is the first trial which also recruited patients in non-PCI centres. For 
these centres, immediate angiography and intervention’ is not easy to perform on a 24/7 
basis. Patients assigned to immediate intervention were transported immediately to the 
PCI centre by ambulance, whereas patients assigned to delayed intervention underwent 
angiography at their own centre. This resulted in a lower rate of ad hoc revascularisation 
(PCI) in this group of delayed angiography further delaying revascularisation. Subgroup 
analysis showed that patients randomised at a non-PCI centre tended to benefit most from 
immediate intervention as compared to patients randomised at a PCI centre. This finding 
should be interpreted with caution but merits further investigation.
Although no definite conclusions can be drawn from this study with regard to economic 
consequences of a routine early intervention strategy, a 2 day shorter hospital stay might 
indicate a reduction in health costs. Extra costs for 24 hours a day, every day availability of 
PCI facilities and emergency transportation of these patients by ambulance from hospitals 
without a primary PCI facility to an intervention centre must be taken into account. 
A major limitation of our study is the lower than expected incidence of the primary endpoint 
at 30 day follow-up. It was assumed to be 25% (see sample size calculation). After comple-
tion of the trial however, this appeared to be considerably lower (14%), which means that 
the study was underpowered to prove superiority of immediate intervention. Therefore we 
cannot exclude that a larger number of included patients might have resulted in a different 
outcome. Another limitation in trial of this kind is that the occurrence of periprocedural MI’s 
is very difficult to assess accurately when patients undergo angioplasty at the moment of 
elevated cardiac enzymes which may therefore result in a lack of detection of these MI’s in 
patients who undergo immediate angioplasty. This is the reason why additional secondary 
end points concerning enzymatic infarct size during admission were assessed (troponin 
T at 72-96 hours after admission or at discharge and the percentage of patients without a 
rise in CKMB during admission).
In summary, in this population of high-risk NSTE-ACS patients, we found that an immediate 
invasive strategy is safe and feasible, but not superior to a delayed invasive strategy in 
terms of prevention of the composite endpoint of death, re-infarction or recurrent ischemia 
at 30 days follow-up. These results are consistent with previous trials and meta analyses.
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Abstract 
Objective: To compare long-term outcome of an early to a delayed invasive strategy in 
high-risk patients with non-ST-elevation acute coronary syndrome (NSTE-ACS).
Methods: This prospective, multicentre trial, included patients with NSTE-ACS and at least 
two out of three of the following high risk criteria:(1) evidence of extensive myocardial 
ischemia on ECG, (2) elevated biomarkers for myocardial necrosis and (3) age above 65 
years. Patients were randomised to either an early (angiography and revascularisation if 
appropriate <12 hours) or a delayed invasive strategy (>48 hours after randomisation). 
Endpoint for this prespecified long-term follow-up was the composite incidence of death 
or reinfarction after 2 years. Data collection was performed by telephone contact with the 
patients, their relatives or general practitioner and by review of hospital records.
Results: Endpoint status after 2-year follow-up was collected in 521 of 542 initially enrolled 
patients. Incidence of death or reinfarction was 11.8% in the early and 13.1 % in the delayed 
treatment group (relative risk(RR)=0.90, 95% CI 0.57 to 1.42). No significant differences 
were found in occurrence of the individual components of the primary endpoint: death 6.1% 
vs 8.9 % RR 0.69 (95% CI 0.37 to 1.27), reinfarction 6.5% vs 5.4% RR 1.20 (95% CI 0.60 
to 2.38). Post-hoc subgroup analysis showed statistical significant interaction between age 
and treatment strategy on outcome (p=0.02).
Conclusions: After 2 years follow-up, no difference in incidence of death or reinfarction 
was seen between early to late invasive strategy. These findings are in line with results of 
other studies with longer follow-up. Older patients seem to benefit more from early invasive 
treatment.
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Introduction
Although numerous trials have investigated the outcome of an early versus a delayed 
invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome 
(NSTE-ACS), controversy remains about the optimal timing of angiography and revas-
cularisation in this patient group. Several meta-analyses,(1-5) pooled the results of these 
trials to systematically address this question. The main conclusion is that early intervention 
results in a reduction of the incidence of recurrent ischemia and duration of hospital stay, 
but not in mortality or reinfarction. Based on these results, current guidelines recommend 
intervention within 24 hours in NSTE-ACS patients with one or more high risk criteria (6).
Follow-up in the majority of the above mentioned trials has been limited to one to sev-
eral months. However, long-term clinical outcome is essential to decide about the optimal 
timelines of intervention in these patients. In this publication we present the results of the 
prespecified analysis after 2-year follow-up of the ELISA-3 trial, an investigator initiated, 
randomised, open, multicentre study, comparing early versus late angiography and revas-
cularisation in high risk patients with NSTE-ACS. 
Methods
The design and the results at 30-day follow-up of the ELISA-3 trial have been published pre-
viously (7). In short, patients were eligible if they were hospitalised with ischemic chest pain 
or dyspnoea at rest and had at least 2 out of 3 of the following high risk characteristics:[1] 
evidence of extensive myocardial ischemia on ECG (shown by new cumulative ST depression 
> 5 mm or temporary ST-segment elevation in two contiguous leads < 30 min), [2] elevated 
biomarkers (troponin T >0.10 μg/l or myoglobin > 150 μg/l) or elevated creatine kinase-myo-
cardial band (CKMB) fraction (> 6% of total creatine kinase (CK)) and [3] age above 65 years. 
Randomisation had to take place within 24 hours of the last episode of ischemic symptoms. 
Exclusion criteria were persistent ST segment elevation, symptoms of ongoing myocardial 
ischemia despite optimal medical therapy, contraindication for diagnostic angiography, active 
bleeding, cardiogenic shock, acute posterior infarction and life expectancy less than 1 year. 
Patients were 1:1 randomly assigned by a web-based randomisation system to an early 
treatment strategy (angiography and subsequent revascularisation as soon as possible but 
within 12 hours of randomisation) or a delayed treatment strategy (no sooner than 48 hours 
after randomisation). The primary endpoint was the combined incidence of death, reinfarction 
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and/or recurrent ischemia at 30-day follow-up. Follow-up for 2 years after the index event for 
incidence of mortality or reinfarction was pre-specified in the protocol. Patients were contacted 
by telephone to collect information about vital status and potential endpoints. If patients could 
not be contacted by telephone, their relatives or general practitioner was contacted to obtain 
information. In case of re-hospitalisation, hospital records were reviewed. 
Data were analysed according to the intention to treat principle. Continuous variables were 
expressed as median and first and third quartiles and were compared between the interven-
tion groups using a Mann-Whitney U test. Categorical data were described by proportions 
and compared with the χ2 or Fisher exact test. Logistic regression was used to calculate 
the p-value of the interaction between the effect of the intervention and the subgroups on 
the primary endpoint. All tests were two sided and an alpha of 5% was used. Statistical 
analysis was performed with SPSS (version 20). Cumulative event rates were estimated 
with the Kaplan Meier method and compared with log-rank test.
The study complied with the Declaration of Helsinki, was approved by the ethics committee 
of the Isala Klinieken, Zwolle, The Netherlands and was registered in the ISRCTN Register 
(ISRCTN39230163). More information about this trial can be found on the website http://
www.isrctn.com
Results
Between July 2007 and June 2012, 542 patients were included in 6 Dutch hospitals of which 
one had 24-hour facilities for (primary) percutaneous intervention (PCI) and coronary artery 
bypass graft (CABG). Eight patients were excluded. Two hundred and sixty-nine patients 
were randomised to early and 265 to delayed invasive strategy (figure 1). Baseline char-
acteristics were well balanced between the groups (table 1). 
Median time from admission to randomisation was 2.0 hours in the immediate group and 
2.1 hours in the delayed treatment group (p=0.97); median interval between randomisation 
and angiography was 2.6 hours and 54.9 hours respectively (p<0.001). Pharmacological 
therapy after 30 days and one- and two-year follow-up is shown in table 2 and was com-
parable between both treatment groups. The use of medication for secondary prevention 
was high; almost all patients not treated with oral anticoagulants used aspirin and over 80% 
used betablockers and statins. 
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Figure 1: Trial flow chart
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Table 1: Patient baseline characteristics 
Variable Immediate treatment 
n=269
delayed treatment
n=265
Demographics
Age (y; med, Q1-3) 72.1 (65.5-78.4) 71.8 (62.5-78.4)
Male gender, n (%) 187 (69.5) 174 (65.7)
Randomised in (%)
PCI – centre 83.3 83.0
Non PCI-centre 16.7 17.0
Grace score (med, Q1-3) 136 (118-154) 133 (117-154)
Medical history, n (%)
Hypertension 146 (54.3) 154 (58.1)
Smoking 57 (21.2) 70 (26.4)
Diabetes mellitus 64 (23.8) 54 (20.4)
Previous MI 48 (17.8) 52 (19.6)
Previous TIA 15 (5.6) 13 (4.9)
Previous stroke 9 (3.3) 12 (4.5)
Previous coronary procedures n (%)
Previous PCI 49 (18.2) 55 (20.8)
Previous CABG 37 (13.8) 32 (12.1)
y = years, med = median, Q1-3= 1st and 3rd quartile , MI = Myocardial Infarction, TIA = Transient 
Ischemic Event, PCI = Percutaneous Coronary Intervention, CABG = Coronary Arterial Bypass Graft
Table 2: Medication therapy after 30 days, 1 and 2 year follow-up in early and late inter-
vention group.
30 days 1 year 2 years
Early
n=262
Late
n=261
Early
n=262
Late
n=259
Early
n=262
Late
n=259
aspirin 84.0% 84.8% 79.4% 80.0% 78.8% 75.1%
clopidogrel 67.2% 64.6% 42.6% 46.7% 11.0% 10.5%
anticoagulance 14.4% 15.2% 20.1% 14.6% 19.2% 18.6%
Beta blocker 91.2% 91.8% 83.5% 87.1% 81.2% 83.1%
ACE-Inhibitors 62.0% 56.8% 62.7% 50.8% 55.5% 49.4%
AII-receptor blocker 12.4% 11.5% 18.5% 18.8% 19.6% 19.0%
Statin 90.0% 88.1% 87.6% 85.8% 85.3% 81.9%
Calciumblocker 20.4% 22.6% 24.1% 26.3% 25.7% 25.7%
Nitrate 14.1% 17.3% 18.1% 20.8% 18.4% 16.9%
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The original publication of the ELISA-3 trial showed a non-significant reduction of 30% in 
the early invasive treated patients on the primary composite endpoint of death, reinfarc-
tion or recurrent ischemia after 30-day follow-up, (7). Median duration of hospitalisation in 
this group was statistically significant shorter (4 days, versus 6 days in the late treatment 
group). Two years follow-up could be performed in 521 patients, 96% of the initially enrolled 
patients. The cumulative incidence of death or reinfarction after 2-year follow-up did not 
differ significantly (figure 2; log rank test p= 0.67). This combined endpoint occurred in 
11.8% of patients in the early invasive group and 13.1 % in the delayed treatment group 
(relative risk (RR) =0.90, 95% CI 0.57 to 1.42, table 3). No significant differences were found 
in the occurrence of the individual components of the primary endpoint: the rate of death 
(6.1 vs. 8.9 %, RR 0.69 95% CI 0.37 to 1.27) and recurrent myocardial infarction (6.5 vs 
5.4% RR 1.20 95% CI 0.60 to 2.38). 
Results of prespecified and post-hoc subgroup analysis are shown in figure 3 and 4 respec-
tively. Only statistical significant interaction was found between age group (above vs. below 
median age of 71.9 years) and treatment strategy on outcome (p=0.022). In the 50% oldest 
patients, the combined endpoint occurred in 13.6% of patients in the early intervention as 
compared with 21.7% of those in the delayed intervention group. For the patients aged 
under 71.9 years, the combined endpoint occurred in 10% and 4.6% respectively. 
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Figure 2: Kaplan-Meier curve for event free survival of primary endpoint with early and delayed 
treatment strategy. Inset shows same data on an enlarged scale of y-axis. p=0.67 (log-rank test)
Table 3: Study endpoints after 30 days and 2 year follow-up
Variable Immediate 
treatment 
delayed 
treatment
RR (95% CI) P Value
30 days follow-up n=262 n=261
Combined incidence of death, 
reinfarction and recurrent ischemia
9.9% 14.2% 0.70 (0.43-1.12) 0.14
Death 1.1% 1.1% 1.00 (0.20-4.89) >0.99
Reinfarction 1.9% 0.8% 2.49 (0.49-12.72) 0.45
Recurrent ischemia 7.6% 12.6% 0.60 (0.36-1.02) 0.06
2 year follow-up n=262 n=259
Combined incidence of death or
reinfarction 
11.8% 13.1% 0.90(0.57-1.42) 0.66
Death 6.1% 8.9% 0.69 (0.37-1.27) 0.23
Reinfarction 6.5% 5.4% 1.20 (0.60-2.38) 0.60
RR = Relative Risk, CI= Confidence interval
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Discussion
These long-term follow-up results of the ELISA-3 trial show that in high risk patients with 
NSTE-ACS, early angiography and revascularisation (median 2.6 hours after admission) is 
not better than intervention 48 hours or more after admission in terms of mortality or rein-
farction after 2 years follow-up. Considering the results after 30- day follow-up, in which we 
found a non-significant reduction of 30% (p=0.135) on the combined endpoint of mortality, 
reinfarction or recurrent ischemia, effects of timing of intervention on short-term and long 
term clinical outcome are comparable. 
Only a few other studies described the long term effects of timing of intervention in 
patients with NSTE-ACS. The SISCA trial(8), comparing early versus delayed invasive 
strategy in high risk NSTE-ACS patients reported only mortality after 4 years as sec-
ondary endpoint, which was equal in both treatment arms. The OPTIMA trial,(9) recently 
reported 5-year outcome in NSTE-ACS patients after immediate versus deferred PCI 
and found no differences in the primary composite endpoint of death and spontaneous 
myocardial infarction (MI), but an increased risk of late spontaneous MI for patients 
treated with immediate PCI. We could not confirm this finding, but the studies are 
difficult to compare because of difference in patient population due to the fact that in 
the OPTIMA trial, patients were only randomised after coronary angiography, exclud-
ing patients not feasible for PCI or without significant coronary stenosis. Potential 
mechanisms of excess of MI in the immediate PCI group could be an increased risk of 
malpositioning and improper stent sizing or stenting of non- significant lesions due to 
overestimating of lesion severity in the acute setting.
One publication reported long-term outcome after early or delayed angiography in patients 
with NSTE-ACS undergoing a routine invasive management (10). In this post-hoc col-
laborative analysis of individual patient data from three trials comparing routinely versus 
selective invasive strategy, relationship between timing and outcome of patients originally 
randomised to the routine invasive arm of the trials was investigated. No difference in inci-
dence of cardiovascular mortality or myocardial infarction after 5-year follow-up was found 
between early (within 2 days) or delayed (within 3-5 days) angiography in the routinely 
invasive treatment arm. Because timing of intervention was not randomised, these results 
might have been biased by unequal distribution of prognostic factors associated with timing 
of angiography. Also, the timing of the early angiography group in this study was comparable 
with that of the late treatment strategy of the ELISA-3 trial. 
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Although methodological differences between studies are hampering the interpretation of 
results, overall these findings are in line with our results, showing no clear benefit of early 
invasive treatment strategy in terms of mortality or reinfarction in short and longer term. This 
is confirmed by all published meta-analyses on this topic (1-5) showing that early interven-
tion- despite the large number of patients included- only results in a statistically significant 
reduction of the incidence of recurrent ischemia and duration of hospital stay, but not in 
mortality or reinfarction. Therefore, the basis of the I-A indication for early invasive strategy 
(<24 hours) for NSTE-ACS patients with at least one high risk criterion in the guidelines 
of the European Society of Cardiology  for management of NSTE- ACS,(6) is somewhat 
questionable and puts a heavy burden on the capacity of cardiac catheterisation facilities. 
Subgroup analysis
Of all trials comparing early versus later intervention in NSTE-ACS, the ELISA-3 included 
the oldest patient population with a median age of 72 years. We found a significant inter-
action between the age and treatment strategy and on the primary endpoint (figure 4). 
This means that in this relatively old population, in the oldest half aged over 72 years, the 
benefit of early intervention was more pronounced than in the youngest half. Other trials 
comparing early versus delayed intervention that performed subgroup analysis did not 
find this interaction with age(11-14). Although results of subgroup analysis should always 
be taken with caution, this finding is relevant because in clinical practice, elderly patients 
with NSTE-ACS less often receive aggressive invasive care treatment due to fear for 
complications with catheterisation and revascularisation procedures (15,16). Despite more 
comorbidities, polypharmacy and physical frailty in this group of patients, a routine inva-
sive treatment has shown to be superior over a selective invasive strategy,(16-18). Future 
studies or meta-analysis of data in elderly patients are needed to investigate the value of 
early angiography and revascularisation, if indicated. 
Limitations
Our study has some limitations. The study was not powered to detect a difference in death 
or MI at 2 year follow-up. Furthermore, the data for the 2-year follow-up were collected by 
contacting patients or their general practitioner by telephone and review of hospital records 
in case of rehospitalisation. This might have led to under-reporting of endpoints. Also, two 
patients were lost to follow up. Furthermore, the guidelines for treatment of patients with 
NSTE-ACS have changed since this trial that was performed between 2007 and 2012. For 
example, we did not use high-sensitive troponin assays and patients were treated with 
 49
Two-year outcome after early or late intervention in non-ST elevation Acute Coronary Syndrome
3
clopidogrel instead of ticagrelor, which is now standard of care. This might influence the 
external validity of our results. Therefore, a new, adequately powered trial using contem-
porary diagnostic and therapeutic strategies on this topic is needed. 
In conclusion, in patients with high-risk NSTE-ACS, we found that an immediate invasive 
strategy is not superior to a delayed invasive strategy in terms of incidence of the composite 
endpoint of death or reinfarction at 2 year follow-up. However, shorter hospital stay and 
possibly lower costs are in favour of early intervention. Furthermore, older patients seem 
to benefit more from early invasive treatment. 
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Abstract 
Aims: To compare the effect of timing of intervention in patients with non-ST-elevation 
acute coronary syndrome (NSTE-ACS) in percutaneous coronary intervention (PCI) versus 
non-PCI centres.
Methods and results: A post-hoc sub-analysis was performed of the ELISA-3 trial, a 
randomised multicentre trial investigating outcome of early (<12 h) versus late (>48h) angi-
ography and revascularisation in 542 patients with high risk NSTE-ACS. 90 patients were 
randomised in non-PCI centres and tended to benefit more from an early invasive strategy 
than patients included in the PCI centre (relative risk 0.23 vs 0.85 [p for interaction = 0.089] 
for incidence of the combined primary endpoint of death, reinfarction and recurrent ischemia 
after 30 days follow-up). This was largely driven by reduction in recurrent ischemia. In 
non-PCI centres, patients randomised to the late group had a 4 and 7 day longer period 
until PCI or coronary artery bypass grafting (CABG) respectively. This difference was less 
pronounced in the PCI centre.
Conclusions: This post-hoc analysis from the ELISA-3 trial suggests that NSTE-ACS 
patients, initially hospitalised in non-PCI centres show the largest benefit from early angi-
ography and revascularisation, associated with a shorter waiting time to revascularisation. 
Improved patient logistics and transfer between non-PCI and PCI centres might therefore 
result in better clinical outcome. 
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Introduction
A routinely invasive strategy (angiography and revascularisation if applicable) is recom-
mended by the current guidelines (1,2) in high risk patients with non-ST-elevation acute 
coronary syndrome (NSTE-ACS). The majority of trials and meta-analysis on this topic 
showed a reduction in the incidence of cardiovascular death and myocardial infarction 
(MI) in the medium to long term (3-9), although for example the Dutch Ictus study (Inva-
sive versus conservative treatment in unstable coronary syndromes (10)) did not. Studies 
investigating optimal timing of intervention showed conflicting results. Meta-analysis of 
RCT’s (11,12) and observational studies (13) comparing early to later timing showed that 
early timing of intervention does not lead to reduction in incidence of death or myocardial 
infarction but at most reduces the incidence of recurrent ischemia.
A limitation of these studies is that they were largely conducted in tertiary care, high volume, 
percutaneous coronary intervention (PCI) centres. In the Netherlands, as in many other 
European countries, however, a considerable number of these patients is initially hospital-
ised in non-PCI centres. After medical stabilisation and coronary angiography the patient 
is then transferred to the PCI centre for revascularisation, if needed. This makes general-
isability of the study results to clinical practice questionable. 
Observational studies (14,15) showed that patients admitted to a centre with angiography 
and PCI facilities were more likely to receive an invasive strategy, had a lower risk for 
refractory or recurrent angina at the cost of higher risk for stroke and major bleeding. No 
difference was found in the incidence of cardiovascular death, myocardial infarction or 
stroke at 6 months. According to the investigators, these findings support the strategy of 
directing patients with suspected ACS to the nearest hospital with acute care, irrespective 
of the availability of interventional facilities. Because these studies were non-randomised 
and performed about 15 years ago, when background medication was different from today, 
these data should be interpreted with caution.
The ELISA-3 trial compared an early versus delayed invasive strategy in a population of 
high-risk patients hospitalised for NSTE-ACS in 6 centres (5 non-PCI and 1 PCI ) in the 
Netherlands. The aim of the current sub-study is to investigate the clinical effect of timing 
of invasive strategy in patients randomised in the participating non-PCI centres and to 
compare this to patients randomised in the PCI centre.
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Methods
The ELISA-3 study was an investigator initiated, randomised, open, multicentre study. 
Rationale, design and results have been published previously (16). Patients were eligible if 
they were hospitalised with ischemic chest pain or dyspnoea at rest and had at least 2 out 
of 3 of the following high risk characteristics: (1) evidence of extensive myocardial ischemia 
on ECG (shown by new cumulative ST depression > 5 mm or temporary ST-segment 
elevation in 2 contiguous leads < 30 min), (2) elevated biomarkers (troponin T >0.10 μg/l 
or myoglobin > 150 μg/l) or elevated CKMB fraction (> 6% of total CK) and (3) age above 
65 years. Randomisation had to take place within 24 hours of the last episode of ischemic 
symptoms. Exclusion criteria were persistent ST segment elevation, symptoms of ongoing 
myocardial ischemia despite optimal medical therapy, contra-indication for diagnostic angi-
ography, active bleeding, cardiogenic shock, acute posterior infarction and life expectancy 
less than 1 year. The trial was conducted in six Dutch hospitals of which one had 24-hour 
facilities for (primary) PCI and coronary artery bypass grafting (CABG). The study was 
registered in the ISRCTN Register (ISRCTN39230163).
Patients
After giving written informed consent, patients were randomly assigned to an immediate 
or delayed treatment strategy. In patients assigned to the immediate treatment strategy, 
angiography was performed as soon as possible but within 12 h of randomisation. Patients 
assigned to the delayed treatment strategy underwent angiography no sooner than 48 h 
after randomisation, unless, despite optimal medical therapy, clinical instability or recurrent 
ischemia warranted emergency angiography. Patients recruited at a non-PCI centre and 
randomised to the immediate intervention group were urgently transferred to the PCI centre 
for angiography and subsequent revascularisation; in case of assignment to delayed inter-
vention, angiography was performed at the non-PCI centre and the patient was transferred 
to the PCI centre for intervention if necessary. All patients were treated according to the 
current guidelines. 
Endpoints
Primary endpoint of the ELISA-3 study as well for the current sub-analysis was the com-
bined incidence of all cause mortality, re-infarction and/or recurrent ischemia at 30-day 
follow-up. Secondary endpoints were enzymatic infarct size as assessed by a single cardiac 
troponin T, at 72-96 h after admission or at discharge and the percentage of patients with-
out a rise in CK-MB during admission. In addition, bleeding complications were assessed. 
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4
Major bleeding was defined as bleeding with a haemoglobin drop of ³ 2 mmol/l or a blood 
transfusion of 2 or more units. All endpoints were adjudicated by an independent endpoint 
committee.
Statistical analysis
Data were analysed according to the intention-to-treat analysis. Continuous variables were 
expressed as median and first and third quartile (Q) and were compared between the 
intervention groups using a Mann-Whitney U test. Categorical data were described by 
proportions and compared with the Chi square or Fisher’s exact test. Logistic regression 
was used to calculate the p-value of the interaction between the effect of the intervention 
and the subgroups upon the primary endpoint. All tests were two-sided and an alpha of 5% 
was used. Statistical analysis was performed with SPSS (version 20).
Results
Comparison of PCI vs. non-PCI centres
Of the total number of 542 patients in the trial, 444 (82%) were included in the PCI centre 
and 90 in one of the 5 non-PCI centres. Eight patients were excluded, 5 for withdrawn 
consent and 3 for major protocol violations. Baseline characteristics and clinical outcome 
are shown in Table 1. Patients in non-PCI centres were older and there were less smokers. 
Time from admission to randomisation was comparable. Time from randomisation to start of 
angiography was longer in the non-PCI centres (23.8 vs 15.1 h, p=0.07) as was time from 
angiography to PCI (0.75 vs 0.37 h, p<0.001) and angiography to CABG (189.9 vs 122.8 
h, p=0.037). No difference was found in the incidence of the primary endpoint between 
the two groups or in the individual components. The percentage of patients without a rise 
in CK-MB during admission was significantly higher in patients from the non-PCI centres 
(52.6 vs. 33.1%, p=0.01). Incidence of bleeding events was comparable. 
Effect of early versus delayed treatment in patients included in non-PCI centres
Of the 90 patients who were included in a non-PCI centre, 45 (50%) were randomised to 
an immediate treatment and 45 to a delayed invasive treatment strategy. Baseline char-
acteristics were largely comparable (Table 2), with exception of gender and percentage 
of smokers. As intended by the protocol, median time from randomisation to angiography 
was 3.0 h in the immediate and 70 h in the delayed treatment group. In addition, time from 
the start of the coronary angiography to revascularisation (PCI or CABG, if any) was 0.7 h 
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vs 146 h; for PCI 0.37 vs 96.5 h [4.0 days] and for CABG 115 h [4.8 days] vs 275 h [11.5 
days]. The combined primary endpoint occurred in 4.7 % of the patients in the immediate 
treatment group and 20.5% of the patients in the delayed treatment group (p=0.027). This 
difference was driven by a reduction in the occurrence of recurrent ischemia in the immedi-
ately treated patients (2.3 vs. 18.2%, p=0.03 in the immediate and delayed treatment group 
respectively). The incidence of the secondary endpoints and bleeding events did not differ. 
Effect of timing of intervention in patients from PCI centre vs. non-PCI centres
The effect of the timing of the intervention on the primary endpoint is shown in Figure 1. 
Patients included in a non-PCI centre tended to benefit more from an early invasive strategy 
than those included in the PCI centre (relative risk 0.23 vs 0.85) but this difference was 
not statistically significant (p-value for interaction =0.089) and largely driven by reduction 
in recurrent ischemia. No differences were found in the incidence of secondary endpoints 
and bleeding. 
Discussion
This sub-study, comparing the effect of timing of intervention in high-risk non-ST-eleva-
tion acute coronary syndromes between patients hospitalised in PCI and non-PCI centres 
shows that non-PCI centre patients tend to benefit more from an early invasive strategy, 
mainly due to reduction in recurrent ischemia. These results were found in relationship to 
a much larger difference in revascularisation times between early and late treated patients 
in the patients admitted primarily in a non-PCI centre. 
In patients initially hospitalised in non-PCI centres, median time from coronary angiography 
to revascularisation was longer in those randomised to a delayed strategy compared with 
an early invasive strategy (Figure 2). This was caused by a difference in patient logistics: 
patients randomised to an immediate strategy were urgently transferred to the PCI centre, 
where the coronary angiography and – when appropriate– in the same procedure a PCI 
was performed. Patients randomised to a delayed invasive strategy underwent a coronary 
angiography in the non-PCI centre and underwent a PCI later on, after their angiogram 
was discussed with the heart team consisting of interventional cardiologists and thoracic 
surgeons and transfer to the PCI centre. This resulted in an additional waiting time after 
angiography of 4 days for PCI and even 7 days for CABG. For patients randomised in the 
PCI centre, this difference did not occur, because all patients underwent coronary angi
 63
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ography and PCI (if feasible) in the same procedure, irrespective of the group they were 
randomised to. Median waiting time for CABG in patients hospitalised in the PCI centre 
was 123 h (5.1 days), comparable with patients randomised to the early invasive strategy 
in non-PCI centres.
0 100 200 300 400 
Early 
Late 
Early 
Late 
Early 
Late 
Early 
Late 
Hosp-Random 
Random-CAG 
CAG-CABG 
CAG-PCI 
PCI centre 
PCI centre 
non-PCI centre 
non-PCI centre 
Figure 2: Timing of procedures in PCI and non-PCI-centres for patients randomised to early 
or late intervention. Hosp hospitalisation random randomisation, CAG coronary angiography, PCI 
percutaneous coronary intervention
This difference in logistics of patients with NSTE-ACS between PCI and non-PCI centres 
also exists in daily practice. In PCI centres, angiography and revascularisation are mostly 
performed in the same procedure, while patients in non-PCI centres first undergo a coro-
nary-angiography, then are discussed with the team of the PCI centre and are scheduled 
for revascularisation a couple of days later. In the meantime, these patients are prone to 
recurrent ischemic symptoms, as can been seen in the Kaplan-Meyer curve of this group 
of patients for event free survival from recurrent ischemia in the first week (Figure 3). 
Considering this, shortening the time between angiography and revascularisation might 
reduce the recurrence of ischemia and improve clinical outcome in patients initially hos-
pitalised in a non-PCI centre. Agreements with PCI centres to assure short access time 
for revascularisation and application of information technologies for fast distant evaluation 
of angiograms may be helpful. Periodic national audits, like for example snapshot regis-
tries of the National Cardiovascular Data Registry (NCDR) could be used to monitor the 
 65
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4
achievement of pre-determined quality indicators. Because the role of the ECG in initial ACS 
triage is limited (17), other factors should also be taken into account with the assessment 
of urgency for revascularisation.
Figure 3: Kaplan-Meyer curves for event-free survival from recurrent ischemia for each of 
the 4 treatment groups
 
As far as we know, the ELISA-3 trial is the first randomised trial investigating the effect of 
timing of intervention in high-risk NSTE-ACS patients that included patients in both PCI and 
non-PCI centres, giving the opportunity to compare outcome in these two types of centres. 
No significant differences in clinical outcome were found, showing that initial medical sta-
bilisation and angiography in non-PCI centres is safe and feasible.
This study has the following limitations. Clinical characteristics of both patient groups differ. 
For example, slightly more patients in the PCI centre had no significant coronary artery 
disease (11.5 vs. 8.1%) which might have influenced our findings. Further, this sub-study 
is based on a post-hoc sub-group analysis with a relatively small number of patients. 
Therefore, our findings should be interpreted with caution. From our data, the cause of the 
trend towards a higher risk of recurrent ischemia in patients randomised to delayed invasive 
strategy in non-PCI clinics cannot be proven. Therefore, our hypothesis that this might be 
caused by a longer time interval between angiography and revascularisation needs further 
investigation. If new studies were to confirm our hypothesis, a change in the management 
of this large group of patients might be considered.
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The main finding of the ELISA-3 study was that in high risk NSTE-ACS patients, early angi-
ography and revascularisation led to a non-significant 30% relative risk reduction (RRR) 
for the combined endpoint of death, re-infarction or recurrent ischemia at 30 days, driven 
by a reduction in recurrent ischemia (RRR =40%, p=0.058). These results are largely con-
sistent with previously conducted randomised trials and meta analyses (9-11) and show 
that immediate intervention is not associated with a reduction in hard clinical endpoints 
(death or myocardial infarction) but at most reduces the incidence of recurrent ischemia. 
This post-hoc analysis shows that that the sub-group of patients, initially hospitalised in 
non-PCI centres especially benefit from an early invasive strategy. A plausible explanation 
is the shorter waiting time between angiography and revascularisation in these patients. 
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Abstract 
Objectives: To investigate incidence and patient characteristics of transient ST-segment 
elevation (TSTE) ACS and to compare outcome of early versus late invasive treatment.
Background: Optimal timing of treatment in TSTE–ACS patients is not outlined in current 
guidelines and no prospective randomised trials have been done so far.
Methods: Post-hoc subgroup analysis of patients with TSTE randomised in the ELISA-3 
trial. This study compared early (<12h) versus late (>48h) angiography and revascularisa-
tion in 542 patients with high-risk NSTE-ACS. Primary endpoint was incidence of death, 
reinfarction or recurrent ischemia at 30 days follow-up. 
Results: TSTE was present in 129 patients (24.2%) and associated with male gender, 
smoking and younger age. The primary endpoint occurred in 8.9% of patients with and 
13.0% of patients without TSTE (RR=0.681, p=0.214). Incidence of death or MI after 2 
year follow-up was 5.7 and 14.6% respectively (RR=0.384, p=0.008). Within the group of 
patients with TSTE, incidence of the primary endpoint was 5.8% in the early and 12.7% in 
the late treatment group (RR=0.455, p=0.213), driven by reduction in recurrent ischemia. 
Enzymatic infarct size, bleeding and incidence of death or recurrent MI at 2 years follow-up 
was comparable between the treatment groups. 
Conclusions: In high-risk patients with NSTE-ACS, TSTE is frequently seen. Similar to 
findings in patients with high-risk NSTE-ACS, immediate angiography and revascularization 
in these patients is feasible but not superior to later treatment. Prospective randomised 
trials are needed to provide more evidence in the optimal timing of treatment in patients 
with TSTE-ACS.
Trial Registration: ISRCTN Register 39230163
Indexing words
NSTE-ACS, PCI, Timing, Transient ST-elevation 
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Introduction
In clinical practice, distinction is made between acute coronary syndromes (ACS) with and 
without ST-segment elevation (STE) on ECG (1). This differentiation is especially important 
for the sake of treatment strategy. In patients with clinical presentation of a myocardial 
infarction and persistent ST-segment elevation (STEMI) reperfusion therapy is indicated as 
early as possible, preferably by PCI (2). In non-ST-segment elevation coronary syndromes 
(NSTE-ACS), a routinely invasive strategy is recommended, especially in patients at higher 
risk (3,4) but optimal timing is less clear. Several meta-analysis of RCTs(5-9) only showed 
a statistically significant decrease in refractory ischemia with early intervention but no 
decrease in rate of death, myocardial infarction or major bleeding. According to the latest 
guidelines, an early invasive strategy (within 24 h of hospital admission) is recommended 
in patients with at least one high risk criterion (positive biomarkers, dynamic ST-segment 
or T-wave changes, GRACE score > 140).
Some patients with ACS however, initially present with ST-segment elevation but show 
complete resolution of ST-segment elevation and symptoms before planned reperfusion 
therapy has started. For this condition, the term transient ST-segment elevation (TSTE) is 
used. In observational studies, TSTE is seen in 15-22% of patients initially diagnosed with 
STEMI (10,11). In patients, hospitalised for NSTE-ACS, transient ST-segment elevation is 
present in 3-22% (12-14).
Optimal timing of coronary angiography in patients with TSTE–ACS is not addressed in the 
current guidelines given the absence of randomised clinical trials. Transient ST-segment 
elevation might be caused by complete coronary artery occlusion that needs urgent inter-
vention to prevent prolonged ischemia or infarction. However, it might also be considered 
as a sign of reperfusion, allowing a less aggressive treatment strategy. Early coronary 
intervention might potentially be harmful, considering the risk of distal embolization and 
subsequent more extensive myocardial damage (15). Therefore, we performed a subgroup 
analysis of the ELISA-3 trial to evaluate the incidence and characteristics of patients with 
TSTE and to compare outcome of an early versus late invasive strategy. 
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Materials and methods
The ELISA-3 study was an investigator-initiated, randomised, open, multicentre study. 
Rationale, design and results have been published previously (16). In short, between July 
2007 and June 2012, 542 patients with high-risk NSTE-ACS were screened (figure 1), of 
which 534 were randomised in six Dutch hospitals to either an early (angiography and 
revascularization if appropriate, preferably within 3 h but not later than 12 h after randomi-
zation) or late invasive strategy (more than 48 h after randomization). All participants gave 
written informed consent before any study specific procedure was performed. Patients were 
eligible if they were hospitalised with ischemic chest pain or dyspnoea at rest and had at 
least two out of three of the following high-risk characteristics: (1) evidence of extensive 
myocardial ischemia on ECG (shown by new cumulative ST-segment depression >5 mm or 
temporary ST-segment elevation in 2 contiguous leads <30 min), (2) elevated biomarkers 
(troponin T >0.10 μg/l or myoglobin >150 μg/l) or elevated creatine kinase-myocardial band 
(CK-MB) fraction (>6% of total CK) and (3) age above 65 years. Randomization had to take 
place within 24 h of the last episode of ischemic symptoms. Exclusion criteria were per-
sistent ST-segment elevation, symptoms of ongoing myocardial ischemia despite optimal 
medical therapy, contraindication for diagnostic angiography, active bleeding, cardiogenic 
shock, acute posterior infarction and life expectancy less than 1 year. 
Primary endpoint of the ELISA-3 study as well for the current subanalysis was the combined 
incidence of all-cause mortality, reinfarction and/or recurrent ischemia at 30-day follow-up. 
Secondary endpoints were enzymatic infarct size as assessed by a single cardiac troponin 
T at 72 to 96 h after admission or at discharge and the percentage of patients without 
a rise in CK-MB during admission. In addition bleeding complications were assessed. 
Major bleeding was defined as bleeding with a haemoglobin drop of ³2 mmol/l or a blood 
transfusion of 2 or more units. Outcome at 2 years follow-up was investigated, defined 
as incidence of all-cause mortality or reinfarction. All endpoints were adjudicated by an 
independent endpoint committee.
The aim of the current subgroup analysis was to evaluate incidence, characteristics and 
clinical outcome of patients with TSTE-ACS and to compare the effect of an early with a 
late invasive strategy in this subgroup. Transient ST-segment elevation was defined as 
ST-segment elevation of 1 mm or more in 2 contiguous leads and complete resolution of 
ST-segment elevation and symptoms within 30 min with or without pharmacological therapy.
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Randomized 542 
Excluded  8 
 Withdrawn consent (5) 
 Major protocol violation(3) 
 
 
Early treatment 269 
 
TSTE 71  No TSTE 198 
 
 
Late treatment 265 
 
TSTE  58   No TSTE 207  
 
 
Allocation 
30 d Follow-Up 
Analysis n=534 
Enrollment 
 Only oral consent ( 1) 
 Decision of the family (1) 
 Language barrier (1) 
 F.U. out of window (2) 
 Withdrawal consent (2)    
cccccccccccccccccc(n = 2) 
  
 
 Only oral consent (1) 
 Withdrawal informed consent (3) 
 
TSTE 69 No TSTE 193 No TSTE 206 TSTE 55 
Figure 1: Trial flow chart
Statistical analysis
Continuous variables were expressed as median and first and third quartile and were 
compared using a Mann-Whitney U test. Categorical data were described by proportions 
and compared with the Chi square or Fisher exact test. Logistic regression was used to 
calculate the p-value of the interaction between the effect of the intervention and the sub-
group upon the primary endpoint. All tests were two-sided and an alpha of 5% was used. 
Statistical analysis was performed with SPSS (version 20). The ELISA-3 trial complied with 
the Declaration of Helsinki, was approved by the ethics committee of the Isala Klinieken, 
Zwolle, the Netherlands and was registered in the ISRCTN Register (ISRCTN39230163). 
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Results
Incidence of Transient ST-segment elevation, patient characteristics and clinical outcome
Of the 534 patients randomised in the ELISA-3 trial, 129 (24.2%) fulfilled the criteria of 
transient ST-segment elevation before randomization. Demographic and clinical charac-
teristics are shown in table 1. In the group of patients with TSTE, the percentage male 
gender, patients without hypertension and smokers was higher, age was lower (median age 
68.8 vs. 72.5 years) and Grace risk score higher (median 140 vs 132). Troponin T levels at 
baseline were comparable. In addition, the infarct related artery in patients with TSTE was 
more often the left anterior descending and right coronary artery; in patients without TSTE, 
the circumflex and left main coronary artery. No significant differences existed in the extent 
of coronary artery disease (presence of one, or more vessel disease), TIMI flow pre- and 
post PCI or PCI success rate. Patients without TSTE were treated less aggressively with 
anti-trombotic medication. This might be explained by the higher age and prevalence of 
comorbidity in these patients. 
The primary endpoint of the study, the combined incidence of death, reinfarction or recur-
rent ischemia at 30 days follow-up (table 2) occurred in 8.9% of patients with TSTE versus 
13.0% of patients without. This difference was not statistically significant. Enzymatic infarct 
size, percentage of patients without CK-MB rise and incidence of bleeding events were also 
comparable. After 2 years follow-up, the combined incidence of death or MI was significantly 
lower in patients with TSTE (5.7 vs 14.6%, p=0.008), driven by a reduction in incidence of 
death (1.6 vs 9.3%, p=0.004).
Outcome of early versus late treatment in patients with TSTE
Of the 129 patients with TSTE, 71 patients were randomised to an early and 58 to a late 
invasive treatment strategy with median time from admission to angiography of 5.4 and 
53.3 h respectively. Baseline and demographic characteristics and medical treatment were 
comparable (table 1). Incidence of the primary combined endpoint of death, reinfarction or 
recurrent ischemia at 30 days follow-up was lower with early treatment (5.8% vs. 12.7%, RR 
0.455). This difference was not statistically significant (p=0.213, table 3) and entirely driven 
by incidence of recurrent ischemia. Two out of 12 patients with recurrent ischemia showed 
recurrent ST elevation treated with urgent PCI. Median enzymatic infarct size, measured 
by a single Troponin-T sample 48 to 96 h after admission or at discharge was identical in 
the two treatment groups (0.27ug/l, p=0.100) and incidence of bleeding events did not differ 
significantly. After 2 years of follow-up, the difference of the composite endpoint of death 
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or recurrent MI was not statistically significant (7.2 vs. 3.7%, p=0.465) for early versus late 
treatment respectively).
Effect of timing of intervention in patients with versus without TSTE
Effects of timing of intervention in patients with and without TSTE on the study endpoint 
are shown in figure 2. Both in patients with and without TSTE, early intervention resulted 
in a lower incidence of the primary endpoint at 30 days follow-up, the combined incidence 
of death, MI and recurrent ischemia, but these differences were not statistically significant. 
No statistically significant interaction was found between the timing of treatment and the 
presence of TSTE on the endpoints and its components, meaning that the effect timing of 
treatment on outcome in patient with and without TSTE is comparable. The same findings 
apply to results after 2 years of follow-up.
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Discussion
This post hoc subgroup analysis of the ELISA-3 trial is the first to study the effect of early 
versus later invasive treatment in patients hospitalised with TSTE ACS in a prospective, 
randomised manner. Our main finding is that immediate angiography and revascularization 
in these patients is feasible but not superior compared with treatment after 48 hours. 
In this high risk population of patients hospitalised for non ST-segment elevation acute 
coronary syndrome, TSTE was not uncommon: in almost 25% of patients, ST-segment 
elevation was seen on ECG before randomization that lasted less than 30 min with com-
plete resolution. This prevalence is higher than reported in observational studies in this 
patient population (12-14), probably due to the fact that all patients had a pre-hospital 
ECG performed in the ambulance, making it more likely to detect any ECG changes before 
hospitalization.
As reported in previously published studies ,TSTE was associated with male gender, 
younger age and smoking. However, while observational studies (12-14) found lower car-
diac biomarkers, more often single vessel disease and better initial TIMI flow at angiography 
in patients with TSTE, we saw no difference in the extent of coronary artery disease, Tro-
ponin levels at baseline, multivessel disease or initial TIMI flow. Median Grace risk score 
in patients with TSTE was slightly higher (140 vs. 132, p<0.01).
We found no difference in clinical outcome at 30 days, the percentage of patients without 
rise in CK-MB or enzymatic infarct size between patients with versus without TSTE. This is 
compatible with observational studies from Patel et al.(12) and Drew et al.(13) that found no 
difference in outcome during hospitalization. However, the incidence of death or reinfarction 
at 2 years in our study was significant lower in patients with TSTE. This is probably due to 
the difference in demographic characteristics, such as age and medical history. 
Concerning the effect of timing of intervention in patients with TSTE, angiography and 
revascularization within 12 h resulted in a 55% relative risk reduction in incidence of the 
primary endpoint, very much in agreement with overall study results of the ELISA-3 study. 
In this regard, the effect of timing of intervention in patients with TSTE-ACS is comparable 
with that in patients with NSTE-ACS in general, as is shown in figure 2. No significant 
interaction was present on the effect of timing of intervention on outcome between patients 
with versus without TSTE. One might think that temporary ST elevation patients require 
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the same approach as in patients with persistent ST elevation, however, this subgroup 
analysis shows that immediate angiography was not associated with improved outcome. 
Also no difference was seen in enzymatic infarct size. All these findings suggest that early 
treatment does not result in myocardial salvage and that the presence of temporary ST 
segment elevation does not require a STEMI-like approach with urgent revascularization. 
The observation of a two days shorter hospital stay with early invasive treatment might 
indicate reduction in health cost but must be compared with extra costs for 24/7 availability 
of PCI facilities. 
Transient ST segment elevation can be caused by thrombus formation as a result of rupture 
of an atherosclerotic plaque. Subsequent counter regulatory mechanisms of the endothe-
lium can result in partial degradation of the thrombus and restoration of the blood flow in the 
coronary artery with resolution of ST elevation. Treatment with platelet aggregation inhibi-
tors is important in improving coronary patency and to avoid recurrent ischemia. Meneveau 
et al (17) performed a non-randomised, matched comparison of immediate versus delayed 
angioplasty in 78 TSTE myocardial infarction patients with patent infarct related artery and 
>70% ST-segment resolution at the time of angiography. They found that delaying PCI with 
24 hours and administration of dual antiplatelet therapy and GPIIb-IIIa inhibitors, resulted 
in a higher procedural success rate and lower peak CK-MB levels without an increased 
risk of MACE or bleeding complication in hospital. In our analysis of patients with TSTE, 
we could not confirm this advantage of postponement of revascularization, although in the 
ELISA-3 study GPIIbIIIa inhibitors were not routinely prescribed. 
Another suggested mechanism of TSTE is spasm of a coronary artery (18). Cyclic variation 
in tone of coronary smooth muscle cells with secondary transient occlusion can result in 
transient ST elevations on ECG. Smoking is one of the precipitating factors for coronary 
spasm. The greater prevalence of smokers in the TSTE group indicates that coronary 
spasms might play a role in our population Fixed coronary stenosis and plaque rupture 
with platelet activation and thrombin generation also increase the propensity for coronary 
vasoconstriction. 
To provide additional evidence in the optimal treatment of patients with TSTE-ACS a 
randomised clinical trial called TRANSIENT (19) is being performed. In this study 142 
consecutive patients initially diagnosed with STEMI with ST resolution upon admission are 
randomised to immediate or delayed intervention. Primary endpoint is infarct size measured 
by cardiac MRI.
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Limitations
The following limitations of our study should be mentioned. First of all, due to the problem 
with multiple hypothesis testing, results from subgroup analysis should be interpreted with 
caution. Although registration of temporary ST segment elevation was prespecified, the 
subgroup analysis of patients with TSTE was not pre-defined in the protocol nor was the 
substudy powered to detect a difference in clinical endpoints. Our findings, however, are 
supported by similar sized infarcts as assessed by biomarkers. Finally, our results only 
apply to hemodynamically stable patients without ongoing ischemia. 
Conclusion
In this high risk population with NSTE-ACS patients, TSTE before angiography is frequently 
seen. In line with the findings in patients with high risk NSTE-ACS, immediate angiogra-
phy and revascularisation in these patients is feasible but not superior to later treatment. 
However, prospective randomised trials are needed to provide more evidence in optimal 
treatment. 
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Summary 
Background: Previous studies found that patients with an acute coronary syndrome (ACS) 
due to occlusion of the circumflex (Cx) coronary artery often present without ST-elevation 
on the ECG leading to a delay in diagnosis and revascularisation, larger infarct size and 
a worse prognosis.
Purpose: To evaluate incidence, characteristics and prognosis of Cx-related ACS without 
persistent ST-elevation and to compare outcome of an early versus a late invasive strategy. 
 
Methods: We performed a subgroup analysis of the ELISA-3 study, a randomised mul-
ticentre trial comparing outcome of early versus late invasive strategy in 542 patients 
with a high risk non-ST segment elevation ACS (NSTE-ACS). Incidence, character-
istics and outcome of Cx and non-Cx related ACS were compared. In patients with 
Cx-related ACS, outcome of an early versus a late invasive strategy was assessed. 
 
Results: In 383 patients (71%) the culprit vessel could be identified, with the Cx artery 
in 112 (29%) of them. Compared to non-CX related ACS, patients with Cx related 
ACS had more often single vessel disease (37.6 vs 27.7%) and underwent PCI more 
and CABG less frequently (81.2 vs. 66.0% and 15.2 vs 25.1% respectively). The pri-
mary endpoint of combined incidence of death, myocardial infarction and recurrent 
ischemia at 30 days follow-up occurred in 9.0% of Cx vs 16.5% of non Cx related 
ACS (p=0.057). Enzymatic infarct size and incidence of bleeding events were compa-
rable. Of patients with Cx-related ACS, 62 patients were assigned to an early and 50 
to a late invasive treatment with median time from admission to angiography of 5.5 h 
and 65.7 h respectively. The primary endpoint occurred in 9.7 and 8.0% respectively 
(p=1.00). Enzymatic infarct size and bleeding events were also not significantly different. 
 
Conclusions: No significant differences in outcome were found between patients with a Cx 
and a non Cx related NSTE-ACS. In Cx related NSTE-ACS, angiography within 12 hours 
of admission is feasible but not superior to angiography after more than 48 hours.
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Background
Prognosis of patients with acute coronary syndrome (ACS) has considerably improved in 
the last decades (1,2). One of the main causes is the application of urgent revascularisa-
tion in patients with occlusion of one or more epicardial coronary arteries(3). Therefore, it 
is of the utmost importance to identify these patients as soon as possible. The most used 
diagnostic tool to do so, is the electrocardiogram (ECG). ST segment elevation on the ECG 
of patients with clinical symptoms of ACS indicate transmural myocardial ischemia caused 
by occlusion of one or more coronary arteries. According to current guidelines(5), urgent 
coronary angiography and revascularisation, if appropriate, is indicated. In absence of ST 
segment elevation, transmural ischemia and complete occlusion of a coronary artery is less 
likely. The majority of these patients is at first treated with antithrombotic and –ischemic 
medication to stabilize them and undergo invasive strategy at a later time, depending on 
the presence of risk factors.
From the literature (6-11) it is known that a myocardial infarction with the circumflex cor-
onary (Cx) artery as culprit vessel, often does not result in ST segment elevation, even if 
complete occlusion is present. One of presumed causes is the localisation of this coronary 
artery at the posterior side of the heart. Occlusion of the Cx artery can therefore lead to 
misclassification of patients and delay in revascularisation, resulting in larger infarct size 
and worse prognosis in these patients (6,7). Earlier angiography and revascularisation 
might prevent these adverse outcomes. To test this hypothesis, we performed a subgroup 
analysis of the ELISA-3 trial population(12).
Method
Design and results of the ELISA-3 trial were published before(12). In this investigator 
initiated, open, multi-centre trial, between 2007 and 2012, 542 high-risk patients with a non-
ST-segment elevation acute coronary syndrome (NSTE-ACS) presenting within 24 hours 
of symptom onset were randomised to either an early (angiography and revascularisation 
preferably within 3 but no later than 12 h after randomisation) or late invasive strategy (more 
than 48 h after randomisation).
Patients were eligible if hospitalised with ischemic chest pain or dyspnoea at rest and at 
least two of the following high-risk characteristics: (1) evidence of extensive myocardial 
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ischemia on ECG (shown by new cumulative ST-segment depression >5 mm or temporary 
ST-segment elevation in two contiguous leads <30 min), (2) elevated biomarkers (troponin 
T >0.10 ug/l or myoglobin >150 ug/l) or elevated creatine kinase-myocardial band (CK-MB) 
fraction (>6% of Total CK), and (3) age above 65 years. Main exclusion criteria were per-
sistent ST-segment elevation, symptoms of ongoing myocardial ischemia despite optimal 
medical therapy, acute posterior infarction and cardiogenic shock. Primary endpoint of 
the ELISA-3 study was the combined incidence of all-cause mortality, reinfarction, and/or 
recurrent ischemia at 30-day follow-up. Secondary endpoints were enzymatic infarct size as 
assessed by a single cardiac troponin T at 72 to 96 h after admission or at discharge and 
the percentage of patients without a rise in CK-MB during admission. In addition, bleeding 
complications were assessed. Major bleeding was defined as bleeding with a haemoglobin 
drop of ≥2 mmol/l or a blood transfusion of 2 or more units. All endpoints were adjudicated 
by an independent endpoint committee. The ELISA-3 trial complied with the Declaration of 
Helsinki, was approved by the ethics committee of the Isala Klinieken, Zwolle, the Nether-
lands and was registered in the ISRCTN Register (ISRCTN39230163). Written informed 
consent was given before any study specific procedure was performed. 
For the current substudy, patients in which an infarct related coronary artery could be 
identified, were selected. Patients with a graft related ACS were excluded. Incidence, char-
acteristics and outcome of patients in whom the Cx coronary artery was culprit vessel were 
compared with patients with non-Cx related ACS. Within the group of patients with Cx-re-
lated ACS, outcome of an early versus a late invasive strategy was assessed. Endpoints 
were identically to those of the main ELISA-3 trial.
Statistical Analysis
Continuous variables were expressed as median and first and third quartile and were com-
pared using a Mann-Whitney U test. Categorical data were described by proportions and 
compared with Chi square or Fisher exact test. Logistic regression was used to calculate 
the p- value of the interaction between the effect of the intervention and the subgroup upon 
the primary endpoint and to adjust for potential confounding factors. A two-sided P-value 
<0.05 was considered statistically significant. Statistical analysis was performed with IBM 
SPSS version 22.0 (IBM corp, NY, USA).
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6
Results
In 383 out of 542 patients (71%) randomised in the ELISA-3 trial, a native infarct related 
coronary artery could be identified (figure 1). In 112 patients (29%), the Cx artery was 
the culprit vessel. Clinical and procedural characteristics of patients with Cx and non-Cx 
related infarction are shown in table 1. No differences were found between the groups in 
demographics, medical history, clinical symptoms, risk profile and ST segment depression 
on ECG, but in patients with non-CX related ACS patients, temporary ST-elevation was 
present more often (28.0 vs 13.4%, p=0.002). More patients with non-Cx-related ACS had 
multi-vessel disease (72.3 vs 62.4%, p=0.063) and underwent CABG (25.1 vs 15.2%) 
while PCI was performed more often in Cx-related ACS (81.2 vs 66.0%). The percentage 
of patients with an initial TIMI flow of 0 or 1 in the culprit vessel was 18.4% in Cx related 
versus 12.3% in non-Cx related ACS (p=0.148).
The primary endpoint of the combined incidence of death, re-infarction and recurrent 
ischemia after 30 days follow up occurred in 9.0% of patients with Cx and 16.5% with non 
Cx-related ACS (table 2). This difference was almost statistically significant (p=0.057). No 
differences were found in enzymatic infarct size and incidence of bleeding events. 
Of the 112 patients with a Cx-related ACS, 62 were randomised to an early and 50 to a 
late invasive treatment strategy. Median time from admission to CAG was 5.46 (Q1-3= 
3.00-11.18) and 65.7 (41.85-94.88) hours respectively. The clinical outcomes and study 
endpoints are shown in table 3. No significant differences were found in the incidence of 
the primary endpoint, infarct size or bleeding events and no significant interaction was 
found between treatment strategy and culprit vessel on the primary endpoint (p interaction= 
0.179). Duration of hospitalisation was significantly shorter after early invasive treatment 
(median hospital stay = 3.0 vs 5.0 days, P<0.001).
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542 enrolled in ELISA 3 
534 analysed 
 383 
 
40 IRV unknown 
 
521 CAG performed  
13 No CAG performed 
60 No vessel disease 
 
271 no Cx related ACS 
 
 
112 Cx related ACS 
 
 
8 excluded 
 
62 
Early treatment 
50 
Late treatment 
129 
Early treatment 
142 
Late treatment 
38 IRV=Graft 
 
Figure 1: Flowchart of ELISA-3 patients CAG=coronary angiography, IRV= infarct related vessel, 
Cx = circumflex coronary artery
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Discussion 
Objective of the ELISA-3 study was to investigate in patients with high-risk NSTE-ACS, 
whether early angiography and subsequent revascularisation is superior to late angiogra-
phy no earlier than 48 hours after admission. One of the assumptions was that especially 
in the subgroup with an ACS due to occlusion of the CX coronary artery, early intervention 
would result in better outcomes because previous studies showed that in these patients 
complete coronary occlusion and transmural myocardial infarction frequently occurs without 
characteristic ST-segment elevation on the ECG.
In the current study we could not confirm this hypothesis. Incidence of the combined end-
point of death, re-infarction or recurrent ischemia at 30 days follow-up was even lower in 
Cx-related than in non-Cx related NSTE-ACS (9.0 vs. 16.2%, OR= 0.50). This difference 
almost reached statistical significance (p=0.057). Although PCI was performed significantly 
more often in Cx related ACS, no confounding of the relationship between culprit vessel 
and primary endpoint outcome was found. In addition, clinical outcome after early or later 
intervention in CX-related NSTE-ACS infarctions was comparable.
No significant difference was found in initial TIMI flow in the culprit vessel in Cx related 
or non-CX related NSTE-ACS patients (TIMI 0 or 1 flow in 18.4 and 12.3% respectively, 
p=0.148). However, within the group of patients that underwent early invasive treatment, 
a trend was seen towards more frequent TIMI 0 or 1 flow in patients with Cx related ACS 
(19.6% versus 9.5%, p=0.062). This might suggest that in CX-related ACS, the flow in the 
culprit vessel is more severely compromised only in the acute phase and is restored later 
on, possibly by the effect of anti-thrombotic and vasodilative medication or decrease of 
spasm of the coronary artery. Despite this difference in TIMI flow, clinical outcome in Cx 
and non-Cx related ACS was comparable.
The results of this study are in contradiction with previous publications that showed more 
frequently total occlusion of the culprit vessel and worse clinical outcome in Cx related 
NSTE-ACS (6,7). This could be explained by a number of reasons. First of all, signs of pos-
terior myocardial infarction and symptoms of ongoing myocardial ischemia despite optimal 
medical therapy were exclusion criteria in the ELISA-3 trial. This might have caused selec-
tion bias by reducing the number of patients with total occlusion of the Cx artery. Another 
reason for the unexpected result of this study is the growing awareness of the importance 
to identify patients with Cx related ACS due to publications about this topic (6-11) in the 
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recent years. As a result, the use of additional diagnostic techniques like posterior ECG 
and echocardiography in the acute setting to search for regional wall motion abnormalities 
might have increased, resulting in exclusion of these patients in the ELISA-3 trial. 
Furthermore, it is possible that in patients with Cx related ACS, the early invasive strategy 
with a median time from admission to intervention of 5.5 hours was not early enough. 
From our results, we cannot preclude the possibility that an “STEMI-like” approach with 
immediate intervention could have been superior in these patients. Finally, results from a 
subgroup analysis should be taken with caution, especially because the ELISA-3 trial was 
underpowered to show superiority of early treatment due to a lower incidence of the primary 
endpoint than initially expected. 
Early invasive treatment strategy resulted in a significant reduction in hospital stay of 2 
days. These benefits should be measured against the costs and feasibility of 24-hour a 
day, everyday availability of PCI facilities and emergency transportation of these patients 
by ambulance from hospitals without a primary PCI faciltity to an intervention centre.
Conclusion
In this subgroup analysis, no significant differences in outcome were found between 
patients with a Cx and a non Cx related NSTE-ACS. Like in NSTE-ACS patients in gen-
eral, angiography within 12 hours of admission is feasible but not superior to angiography 
after more than 48 hours. 
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Abstract
Background: Guidelines recommend an early invasive strategy (EIS) in high-risk patients 
with non-ST-elevation acute coronary syndrome (NSTE-ACS), defined as coronary angi-
ography (CA) within 24 hours of admission. The aim of the present study is to investigate 
guideline adherence, patient characteristics associated with timing of intervention and clin-
ical outcome. 
Methods: The BAMI registry is a prospective, single centre registry of consecutive patients 
hospitalised with ACS in a large, non academic hospital. Use and timing of CA and char-
acteristics and clinical outcome associated with timing were evaluated in high-risk patients 
using multivariate logistic regression analysis. Outcome of early versus delayed invasive 
strategy (DIS) was compared.
 
Results: Between 2006 and 2014, 2299 high-risk NSTE-ACS patients were included in 
the study. The use of CA increased from 77% in 2006 to 90% in 2014 (p trend<0.001) 
together with a decrease of median time to CA from 23.3 to 14.5 hours (p trend<0.001) 
and increase of percentage of patients undergoing EIS from 50 to 60% (p trend =0.002). 
Patient factors independently related to DIS were higher GRACE risk score and age and 
presence of comorbidities. No difference was found in incidence of mortality, reinfarction 
and bleeding at 30 days follow-up. All cause mortality after 1 year follow-up was 4.1 vs. 
7.0% in EIS and DIS respectively (HR 1.67, 95% CI 1.12-2.49) but was comparable after 
adjustment for confounding factors.
Conclusion: The percentage of high risk NSTE-ACS patients undergoing CA and EIS has 
increased in the past decade. In contrast with the guidelines, patient with higher risk profile 
are less likely to undergo EIS. However, no difference in outcome after 30 days and 1 year 
was found after multivariate adjustment for this higher risk. 
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Background
In the past decades, numerous randomised clinical trials have been performed to investigate 
optimal timing of intervention in patients with non-ST-elevation acute coronary syndrome 
(NSTE-ACS). The results of these studies have been summarised in several meta-analyses 
(1-6). In summary, earlier intervention showed no significant difference in mortality or reinfarc-
tion but only a reduction in the incidence of refractory ischemia and in duration of hospital stay.
A pre-specified subgroup analysis of the largest trial, TIMACS (7), showed a statistically 
significant reduction of 35% in the combined endpoint of death, MI, and stroke with early 
invasive strategy in patients with a GRACE risk score of more than 140. The Elisa-3 trial 
(8) showed a similar, non significant trend. Based on these findings, current guidelines (9) 
recommend timing of angiography guided by individual risk stratification. An early invasive 
treatment strategy is recommended in patients with at least one of the following high-risk 
factors: rise or fall in cardiac troponin, dynamic ST- or T-wave changes and GRACE risk 
score >140. This treatment strategy is defined as coronary angiography performed within 
24 hours of hospital admission. 
The aim of the present study is to investigate to what extent these guidelines are followed 
in clinical practice in patients hospitalised with a NSTE-ACS and at least one high-risk cri-
terion. The application of early and delayed invasive treatment and the association between 
patient characteristics and timing of invasive treatment were investigated. In addition, clin-
ical outcome at 30 days and 1 year follow-up was compared between early and delayed 
invasive strategy.
Method
The BAMI (Dutch abbreviation for “Treatment of Acute Myocardial Ischemia”)-registry is 
a database with all consecutive patients hospitalised with an acute coronary syndrome 
(ACS) in Isala, a large, non-academic hospital with 24/7 interventional cardiology facilities 
in Zwolle, the Netherlands. For the present study, we selected patients hospitalised with 
NSTE-ACS between 2006 and 2014 with at least one high-risk criterion (rise or fall in 
cardiac troponin compatible with MI, dynamic ST- or T-wave changes and GRACE risk 
score >140) but without very-high risk criteria. Patients referred from non- interventional 
hospitals were excluded. 
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The rate of patients undergoing coronary angiography and time between hospitalization 
and start of coronary angiography was calculated and compared over the years. Based on 
timing, patients were divided in two groups: those undergoing early invasive treatment (EIS, 
coronary angiography performed within 24 hours after hospitalization) and those undergo-
ing delayed invasive treatment (DIS, angiography after more than 24 hours of admission). 
Clinical, demographical and procedural characteristics were prospectively collected and 
compared between the two groups as well as all cause mortality, reinfarction and bleeding 
events within 30 days of hospitalization. All cause mortality after 1 year was investigated 
by consulting the Dutch Municipal Personal Records Database of the last known residence 
of the patient.
Definition of myocardial infarction were in accordance with the most recent universal defini-
tions (10). Bleeding events at 30 days follow-up were defined as clinical overt bleeding with 
a drop in haemoglobin level of at least 2 mmol/l or a blood transfusion of 2 units of packed 
cells or more. Cut-off values for cardiac enzymes changed over time. Until February 2011, 
Troponin T level of 0.1 ng/ml was considered elevated. After this date, a high sensitive tro-
ponin essay was used with cut-off value of 0.014 ng/l. Reference values for CK and CK-MB 
remained stable during the study with cut –off points for CK of 200 U/L (men) and 170 U/L 
(women) and for CK-MB of 24 U/L or 6% of CK in case CK>200 U/L).
Statistical analysis
Continuous variables are presented as means and standard deviation if normally distributed, 
otherwise as medians with 25th and 75th percentiles. Categorical variables are presented 
as percentages. A graph with timing of coronary angiography over time was constructed. 
Comparison of continuous variables in patients receiving early or delayed invasive angiog-
raphy were performed by independent samples t-test or ANOVA if normally distributed (and 
after log transformation, if necessary) or Kruskal-Wallis test. For categorical data, the Chi 
square test was used. Multivariate logistic regression analysis was used to identify patient 
factors independently related to timing of angiography. Outcome of early and delayed treat-
ment strategy was compared. A  Kaplan-Meyer survival curve for all cause mortality was 
constructed. Hazard-ratios were calculated using Cox-regression analysis for total mortality, 
reinfarction and bleeding events.  Determinants which affected the regression coefficient of 
the association between treatment strategy and outcome with more than 10%, were added 
to the multivariate regression model. Furthermore, hazard-ratios were calculated adjusted 
for GRACE Risk score, a validated predictor of adverse cardiovascular events after ACS 
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(11). A two-sided p-value <0.05 was considered statistically significant. Statistical analysis 
was performed with IBM SPSS version 22.0 (IBM corp,NY, USA).
Results
Patients
Between January 2006 and December 2014, 9198 consecutive patients with discharge 
diagnosis of ACS were enrolled in the BAMI registry. In figure 1, the flow chart is shown. 
For the current study, 3580 patients with a NSTE-ACS were included of whom 2673 were 
hospitalised directly in Isala . In 2299 patients at least one high-risk and no very-high-risk 
criterion was present and 1805 of them underwent coronary angiography. 
 
9198 ACS 
3580 NSTE-ACS 
2673 
2299 high risk 
1805 CAG 
972 early  
invasive 
833 delayed 
invasive 
5618 STEMI 
907 referred from 
other hospitals 
87 very high risk 
287 intermediate 
or low risk 
494 no CAG 
Figure 1: Flowchart of selection of patients with high-risk NSTE-ACS from the BAMI- registry.
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Temporal trends in use of angiography 
The percentage of patients with NSTE-ACS and at least one high-risk criterion that under-
went coronary angiography increased gradually from about 77% in 2006 to 90% in 2014 
(p trend<0.001). Median time from admission to angiography decreased from 1400 to 870 
minutes (23.3 to 14.5 h) over the years (p<0.001 analysis of variance, after log transfor-
mation, figure 2). The proportion of patients undergoing early invasive treatment increased 
from about 50% in 2006 to 60% in 2014 (p trend =0.002).
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Figure 2: Box and whiskers plot of time in minutes from hospitalization to coronary angi-
ography. Horizontal line depicts 1440 minutes (24 hours). Boxes depict median and 25th and 75th 
percentiles, whiskers 5th and 95th percentiles. CA= coronary angiography, min=minutes.
Timing of coronary angiography.
In 972 of 1805 high-risk NSTE-ACS patients (53.9%) coronary angiography was performed 
within 24 hours of hospitalization. Demographical, clinical and procedural characteristics 
are shown in table 1. Patients in the delayed treatment group were significantly older and 
the percentage of patients with diabetes, family and personal history of cardiovascular 
disease was higher. GRACE risk score, percentages of patients with positive biomarkers at 
hospitalization, Killip class >1 and plasma creatinin above median were also higher in this 
group. In the early treated patients, more patients with ST deviation > 0.5 mm on admission 
 107
Coronary angiography in patients with high risk NSTE-ACS in daily clinical practice
7
ECG were seen. Of the patients hospitalised at weekend days, 56% underwent angiography 
after more than 24 hours, compared to 47% of those admitted at week days (p<0,001) with 
median time from hospitalization to angiography of 36 versus 21.6 hours respectively (p=0.07, 
after logarithmic transformation). 
Table 1: Demographical, clinical and procedural characteristics of patients undergoing early 
(<24 h) or delayed invasive treatment strategy (>24 h after hospitalisation) 
All Treatment strategy p-value
early delayed
n (%) 1805 972 (53.9) 833 (46.1)
Time admission-angiography
Minutes(median, Q1-3) 1330 (360-3457) 406 (209-940) 4008 (2436-6723)
Demographics
Male gender (%) 68.1 69.1 67.0 0.352
Age (years; mean, SD) 66.8 (12.1) 65.0 (12.2) 68.9 (11.7) <0.001
Medical History (%)
Diabetes 20.6 16.8 25.2 <0.001
Smoking 31.0 33.2 28.5 0.032
Hypercholesterolaemia 34.1 33.2 35.2 0.366
Positive family history 38.4 40.6 35.8 0.035
Previous MI 17.2 13.9 21.1 <0.001
Previous PCI 18.0 14.5 22.0 <0.001
Previous CABG 12.4 9.4 15.8 <0.001
Previous CVA 3.6 2.8 4.5 0.060
Hypertension 55.0 50.3 60.4 <0.001
Admission parameters
Elevated cardiac enzymes(%) 93.8 92.6 95.2 0.023
GRACE risk score >140*(%) 37.0 32.5 42.1 <0.001
ST segment deviation >0.5mm(%) 42.4 47.6 36.4 <0.001
CK-max <24(umol/l; median, SD) 168 (100-347) 190 (108-425) 146 (92-250) <0.001 
GRACE score* (median, Q1-3) 130 (109-155) 126 (105-150) 135 (112-163) <0.001
Killip class > 1(%) 27.7 26.4 29.2 0.175
Creatinin > median(%) 51.0 47.7 54.9 0.003
Vessel disease (%) <0.001
0 11.6 9.3 14.2
1 30.4 33.2 27.2
>1 58.0 57.5 58.6
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Table 1: Continued
All Treatment strategy p-value
early delayed
n (%) 1805 972 (53.9) 833 (46.1)
Treatment (%) <0.001
Conservative 22.6 17.7 28.5
CABG performed 18.2 18.0 18.5
PCI performed 59.2 64.3 53.1
Hospitalization day
Weekend days (%) 26.3 23.0 30.2 0.001
Medication (%)
Before angiography
ASA 81.2 85.3 76.4 <0.001
Clopidogrel 88.6 91.9 85.0 0.488
G2b3a inhibitor 16.9 22.1 10.9 <0.001
Heparin 63.7 68.9 57.7 <0.001
At discharge
ACE-I 59.0 60.6 57.2 0.159
AII Blockers 11.8 9.3 14.6 0.001
RAS inhibition** 70.7 70.8 70.6 0.926
ASA 83.1 86.2 79.6 <0.001
Beta Blockers 91.3 91.1 91.6 0.742
Calcium antagonist 20.8 17.1 25.0 <0.001
P2Y12 inhibitor 70.7 72.6 68.5 0.055
Coumarin 17.5 12.1 23.5 <0.001
Nitrate 18.0 12.3 24.5 <0.001
Statin 85.0 85.1 84.8 0.842
* Based on 90% of patients
** ACE-I and/or AII-Blockers
AII= angiotensin II, ACE-I= angiotensin converting enzyme inhibitor, ASA = acetyl salicylacid, CABG= 
coronary arterial bypass grafting, CK= creatinin kinase, CVA=cerebro vascular accident, GRACE= 
Global Registry of Acute Coronary Events, MI= myocardial infarction, PTCA= percutaneous translumi-
nal coronary angioplasty, Q = quartile, RAS=Renin Angiotensin System, S.D.= standard deviation.
Significantly more patients in the early invasive treatment group were treated with anti-throm-
botics and anti-coagulants before angiography and underwent PCI. The percentages of patients 
undergoing CABG was comparable. Discharge medication differed in prescription of acetylsa-
licylacid (more often in the early group) and coumarins, calciumblockers and nitrates (more 
often in the delayed group). Use of beta blockers, RAS blockers and P2Y12 inhibitors was 
comparable. Factors independently related to delayed angiography are shown in table 2 and 
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include higher age, absence of ST-segment deviation > 0.5 mm, history of hypertension, 
diabetes, a previous PCI or CABG as well as hospitalization at weekend days. Patients 
that were included earlier in the registry were more likely to undergo delayed angiography. 
Table 2: Multivariate regression analysis of factors independently related with timing of CAG 
(Odds Ratio of delayed versus early angiography). 
OR 95% CI P-value
Age (per year) 1.024 1.015-1.034 <0.001
ST segment deviation >0.5mm 0.538 0.435-0.667 <0.001
Year of inclusion 0.913 0.872-0.956 <0.001
Hypertension 1.303 1.051-1.615 0.016
Diabetes 1.419 1.090-1.848 0.009
Previous PCI 1.386 1.042-1.845 0.025
Previous CABG 1.389 0.997-1.936 0.052
Hospitalisation in weekend 1.702 1.345-2.153 <0.001
CABG= coronary arterial bypass grafting, CI= confidence interval, OR= odds ratio. 
Outcome
All cause mortality at 30 days follow-up was 1.3% in the early and 1.4% in the delayed 
treated patients (HR 1.07, 95% CI 0.49-2.35, table 3). This difference was not statistically 
significant. Recurrent MI occurred in 0.8% of both groups (HR 1.02, 95% CI 0.37-2.81). 
Incidence of total bleeding events was 18.2% in the early and 16.7% (HR 0.89, 95% CI 
0.71-1.11). in the delayed treatment group and of non-CABG related bleeding 3.4% and 
3.2 % respectively (HR 0.92, 95% CI 0.55-1.53).  After 1 year follow-up, all-cause mortality 
was significantly higher in the delayed treatment group (7.0 vs. 4.1%, HR 1.67, 95% CI 
1.12-2.49; figure 3). However, after adjustment for GRACE risk score and other confounding 
factors, this difference was no longer statistically significant (table 3).
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Table 3: Incidence, HR, 95% CI and p-value for outcome parameters in delayed versus early 
intervention with univariate analysis and adjusted for confounding factors.
Early 
intervention
Delayed 
intervention
HR 95% CI P-value
All cause mortality 30 days follow-up
Incidence (%) 1.3 1.4 1.07 0.49-2.35 0.86
Adjusted for GRACE Risk score 0.68 0.29-1.62 0.39
Adjusted for serum creatinin, age, ST-deviation and previ-
ous CABG
0.74 0.31-1.73 0.48
Reinfarction 30 days follow-up
Incidence (%) 0.8 0.8 1.02 0.37-2.81 0.97
Adjusted for GRACE Risk score 1.19 0.40-3.57 0.75
Adjusted for diabetes, previous MI and age 0.66 0.23-1.88 0.44
Total Bleeding events 30 days follow-up
Incidence (%) 18.2 16.7 0.89 0.71-1.11 0.28
Adjusted for GRACE Risk score 0.86 0.67-1.10 0.24
Adjusted for age, ST- deviation, previous CABG, max CK 0.88 0.69-1.12 0.29
non CABG related bleeding events - 30 days follow-up
Incidence (%) 3.4 3.2 0.92 0.55-1.53 0.75
Adjusted for GRACE Risk score 0.73 0.41-1.27 0.26
Adjusted for age, previous PCI and ST- deviation 0.85 0.50-1.43 0.53
All cause mortality 1 year follow-up
Incidence (%) 4.1 7.0 1.67 1.12-2.49 0.01
Adjusted for GRACE Risk score 0.71 0.44-1.13 0.15
Adjusted for age, diabetes, previous CABG 0.83 0.55-1.25 0.37
CABG= coronary arterial bypass grafting, CI= confidence interval, CK= creatinin kinase, GRACE = 
Global Registry of Acute Coronary Syndromes, MI= myocardial infarction, HR= hazard ratio. 
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Figure 3: Kaplan-Meyer survival curve comparing all cause mortality with early and delayed 
treatment strategy. Inset shows same data on an enlarged scale of y-axis. HR=Hazard ratio of 
delayed versus early treatment strategy.
Discussion 
In this prospective registry of 2299 high-risk NSTE-ACS patients hospitalised between 2006 
and 2014, the percentage of patients that underwent coronary angiography increased from 
77 to 90% between 2006 and 2014. Concurrently, median time from admission to angi-
ography decreased from 23.3 to 14.5 hours with an increase from 50 to 60% of patients 
being treated within 24 hours after admission and fulfilling the criteria of early invasive 
treatment used in the guidelines. These changes over time are in line with findings in other 
registries (12–16) and reflect the more stringent guidelines concerning timing of treatment 
in this patient category. In 2010, the recommended time interval between admission and 
angiography was reduced from maximal 48 to 24 hours (17)
Patient factors independently related to delayed coronary angiography were higher GRACE 
score and age and presence of comorbidities like hypertension, diabetes and established 
cardiovascular disease. This inverse relationship between risk profile and the use of inva-
sive treatment has been found in many other observational studies. (14,18-21). In contrast 
to the guidelines, that advise early invasive strategy especially in higher risk NSTE-ACS 
patients, this is not applied in daily routine and is common practice in many centres. The 
GRACE (15,18), Canadian ACS (14,19) and CRUSADE (20) registries found that invasive 
treatment was paradoxically more often applied in lower-risk patients. Waiting time for 
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angiography was also longer in higher risk patients (21). Despite the sharpened guide-
lines concerning timing of intervention in NSTE-ACS patients, our results are similar to 
those found in previous studies. Likewise, aggressive anti-thrombotic pharmacotherapy 
was prescribed more often in low-risk patients in our study, compatible with findings in 
registries in Canada and the U.S. (14,19). However, the decreased prescription of GPIIb/
IIIa receptor blockers in the delayed group could be explained by the lower rate of percu-
taneous intervention.
A possible explanation for this so called “risk-paradox” is that cardiologists have more 
safety concerns with early invasive treatment in older patients presenting with NSTE-ACS. 
Although invasive treatment is associated with significant benefits independent of age 
(22-24), age appeared to be underrated as a risk factor in decision making to perform angi-
ography (25,26). However, it is also possible that other valid reasons existed for reluctance 
with invasive procedures in older patients, like functional status, patient’s preference and 
frailty that has shown to be related to worse outcome in NSTE-ACS (27). 
Patients hospitalised at weekend days were more likely to receive angiography after more 
than 24 hours. Although this is a well known phenomenon, this was not seen in other reg-
istries (21,28) and is probably related to logistics and planning of angiographies.
Despite the fact that patients in the delayed treatment group had a higher risk profile, no 
differences were found in incidence of mortality, reinfarction and bleeding after 30 days 
follow-up, both with univariate analysis and when adjusted for confounding factors. Although 
one should always take into account that unidentified confounders may be present, this 
suggests that timing of treatment does not impact clinical outcome to a great extent. The 
higher all cause mortality after 1 year follow-up in the delayed treatment group was driven 
by higher age and other risk factors and was no longer present after correction by multi-
variate logistic regression.
Our study has the following limitations. First of all, it is possible that important predictive 
factors associated with timing of intervention have not been taken into account in our study, 
like frailty, patient preference and co-morbidity. Next, as this was a single centre study, the 
generalizability of our findings to high risk NSTE-ACS patients in general is questionable 
because local procedures may differ between hospitals and regions. However, similar 
results were found by previous multicenter studies (14, 18-21). Also, we excluded patients 
that were initially hospitalised in non-interventional hospitals to avoid bias by logistic fac-
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tors. Characteristics of this group of patients might differ from those hospitalised directly in 
a interventional centre. Outcome in the delayed treatment group may be flattered due to 
survival bias, the effect of patients who die early after hospitalization are missed. Finally, 
results of observational, non-randomised studies should always be interpreted with caution 
because unidentified confounders may be present. 
Conclusions
The percentage of high risk NSTE-ACS patients undergoing coronary angiography has 
increased in the past decade, together with a decrease in time from admission to hospi-
talisation. In contrast with the guidelines, patient with higher risk profile were less likely to 
receive an early invasive treatment strategy. However, after adjustment for this higher risk, 
no difference in outcome after 30 days and 1 year was found. 
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Summary 
Background A routine invasive strategy is recommended for patients with non-ST-elevation 
acute coronary syndromes (NSTE-ACS). However, optimal timing of invasive strategy is 
less clearly defined. Individual clinical trials were underpowered to detect a mortality benefit; 
we therefore did a meta-analysis to assess the effect of timing on mortality. 
Methods We identified randomised controlled trials comparing an early versus a delayed 
invasive strategy in patients presenting with NSTE-ACS by searching MEDLINE, Cochrane 
Central Register of Controlled Trials, and Embase. We included trials that reported all-cause 
mortality at least 30 days after in-hospital randomisation and for which the trial investiga-
tors agreed to collaborate (ie, providing individual patient data or standardised tabulated 
data). We pooled hazard ratios (HRs) using random-effects models. This meta-analysis is 
registered at PROSPERO (CRD42015018988). 
Findings We included eight trials (n=5324 patients) with a median follow-up of 180 days 
(IQR 180–360). Overall, there was no significant mortality reduction in the early invasive 
group compared with the delayed invasive group HR 0·81, 95% CI 0·64–1·03; p=0·0879). 
In pre-specified analyses of high-risk patients, we found lower mortality with an early inva-
sive strategy in patients with elevated cardiac biomarkers at baseline (HR 0·761, 95% 
CI 0·581–0·996), diabetes (0·67, 0·45–0·99), a GRACE risk score more than 140 (0·70, 
0·52–0·95), and aged 75 years older (0·65, 0·46–0·93), although tests for interaction were 
inconclusive. 
Interpretation An early invasive strategy does not reduce mortality compared with a delayed 
invasive strategy in all patients with NSTE-ACS. However, an early invasive strategy might 
reduce mortality in high-risk patients.
 
 119
Optimal timing of invasive strategy in patients with NSTE-ACS: a meta-analysis of randomised trials
8
Introduction 
Guidelines for the management of patients with non-ST-elevation acute coronary syndromes 
(NSTE-ACS) recommend an invasive strategy in moderate to high-risk patients.(1,2) Rec-
ommendations for the timing of intervention in these patients depend on patient’s baseline 
risk. Immediate coronary angiography within 2 h of presentation is recommended for all 
patients with a very high risk of in-hospital mortality (ie, those with haemodynamic instability, 
life-threatening arrhythmia, or recurrent or refractory angina); the recommendation is based 
on expert opinion without any evidence from clinical trials. Coronary angiography within 24 
h is advised for patients not meeting these criteria but presenting with elevated troponin or 
ischemic ST-wave or T-wave changes as well as patients with a Global Registry of Acute 
Coronary Events (GRACE) risk score of more than 140 points. The recommendation is 
primarily based on a pre-specified subgroup analysis of the TIMACS trial,(3) in which the 
early invasive strategy was superior to the delayed invasive strategy with regard to the 
composite endpoint of death, myocardial infarction, or stroke at 6 months in the highest 
GRACE risk score tertile. However, the effect of an early invasive strategy on individual 
clinical endpoints such as mortality or non-fatal myocardial infarction is unknown; individual 
trials were underpowered to detect an effect on these outcomes. 
Moreover, previous meta-analyses pooling published data did not detect a difference on 
these outcomes. Only recurrent or refractory ischemia and length of hospital stay have 
been shown to be improved by an early invasive strategy compared with a delayed invasive 
strategy (4–8). Because of inconsistent trial reporting, no subgroup analyses of high-risk 
patients were possible in these meta-analyses. 
To overcome shortcomings of conventional meta-analyses, we did a collaborative meta-anal-
ysis of randomised controlled trials investigating optimal timing of coronary angiography 
in patients with NSTE-ACS, based on individual patient or standardised tabulated data 
not previously published. We analysed all-cause mortality overall and in four pre-specified 
high-risk subgroups.
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Methods 
Search strategy and selection criteria 
We identified randomised controlled trials (RCTs) of potential interest by searching MED-
LINE (up to Dec 20, 2016), Cochrane Central Register of Controlled Trials (up to Dec 21, 
2016), and Embase (up to Jan 2, 2017), without language restrictions. We used three 
groups of search terms, of which at least one term in each was required to match: (1) “acute 
coronary syndrome”, “unstable coronary syndrome”, “unstable angina”, “without persistent 
ST-segment elevation”, “non-ST-elevation acute coronary syndrome”, “non-ST-elevation 
myocardial infarction”, ”NSTE-ACS”, and “NSTEMI”; (2) “angiography”, “intervention”, “inva-
sive evaluation”, and “invasive intervention”; (3) “timing”, “early”, “immediate”, “late”, and 
“delayed” (see appendix for specific search strategies).
We included randomised controlled trials comparing an early versus delayed coronary 
angiography in patients presenting with NSTE-ACS, reporting mortality at least 30 days 
after in-hospital randomisation, and for which the principal investigators agreed to provide 
data for patient characteristics (demographics, medical history, baseline risk evaluation, and 
procedural data) and outcomes as individual patient data or tabulated data on standardised 
table sheets in an ordinary spreadsheet format with uniform coding. In case of tabulated 
data, table sheets were prepared to ensure that the provided data facilitated pre-specified 
analyses. We excluded randomised controlled trials with pre-hospital randomisation and 
those comparing a routine invasive strategy with a selective invasive strategy or early 
versus delayed percutaneous coronary intervention.
Data analysis 
After removal of duplicates, title and abstract of search items were screened and sequen-
tially excluded according to the eligibility criteria (by AJ). Whenever uncertainty remained 
after screening title and abstract, full text articles were scrutinised independently by two 
investigators (SD and HT) and discrepancies resolved by consensus after discussion. 
Provided data were centrally checked for completeness, plausibility, and integrity before 
they were combined in a single database. 
Two independent investigators assessed the risk of bias in the included trials (AJ and SD) 
according to the Cochrane Collaboration’s tool (9) for assessing risk of bias using primarily 
original trial reports. Discrepancies were resolved by consensus after discussion. Principal 
investigators were contacted in case of missing information. 
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The primary outcome was all-cause mortality. To investigate a time-dependent effect of 
timing of invasive strategy, we divided the follow-up into distinct periods (ie, from randomi-
sation to hospital discharge, and from hospital discharge to end of follow-up). Moreover, 
we analysed the effect of timing in four pre-defined high-risk subgroups (ie, patients with 
positive cardiac biomarkers at baseline, with diabetes, aged ≥75 years, or with a GRACE 
risk score >140 points). The secondary outcome was non-fatal myocardial infarction. The 
definitions of non-fatal myocardial infarction differed considerably between trials and each 
trial definition was used for the present meta-analysis (appendix). 
We analysed data by the intention-to-treat principle. We summarised baseline character-
istics by treatment group as mean and SD, or if skewed, as median and IQR. We used 
frequencies and percentages to summarise categorical variables. Under the assumption 
that hazard rates are constant over time, HRs are more reliable for pooling data of trials 
with different durations of follow-up (10). Therefore, we used HRs with 95% CIs for both 
outcomes. Clinical events were considered as in-hospital events when they occurred 
between randomisation and hospital discharge or as post-discharge events if they occurred 
between hospital discharge and the end of follow-up. Analysis of post-discharge events 
excludes patients who died before discharge. Trials without clinical events or only few 
events resulting in infinite HRs were weighted with zero. We used a two-step approach for 
the meta-analysis to preserve clustering of patients in trials (11). All trials were analysed 
separately and respective principal investigators were asked to confirm the results. Dis-
crepancies were resolved by discussion. We obtained individual patient data for ABOARD 
(12), ELISA (13), ELISA-3 (14), ISAR-COOL (15), LIPSIA-NSTEMI (16), Sciahbasi et al 
(17) and RIDDLE-NSTEMI (18), which we analysed centrally. Because of legal issues, 
TIMACS (3) provided standardised tabulated data compatible with the pre-specified central 
analysis of other trials. For each outcome, we pooled HRs using inverse variance weighting 
and calculated DerSimonian and Laird random-effects models since all trials were done 
independently and we assumed that clinical heterogeneity will be present even despite 
a negative Cochrane’s Q statistic. We assessed heterogeneity between trials using τ² as 
measure of between-study variance and Higgins’ and Thompson’s I². We evaluated inter-
actions in subgroups by random-effects models (combined from the final results). We did 
post-hoc meta-regression to assess the relationship between the median difference in time 
to angiography and outcomes. All analyses were pre-specified unless otherwise stated. All 
p values were two-sided and judged as significant if less than 0·05. We used R (version 
3.1.0) and its package meta (version 4.3.2) for all statistical analyses. This meta-analysis 
is registered with PROSPERO (CRD42015018988). 
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Role of the funding source 
There was no funding source for this meta-analysis. The first author and the corresponding 
author had full access to all data (standardised tabulated data for TIMACS and individual 
patient data for all other trials). The corresponding author had final responsibility for the 
decision to submit for publication. 
Results 
Our search retrieved 2190 items, of which 433 were duplicates. After screening titles and 
abstracts, 26 reports of randomised controlled trials remained and were evaluated in detail. 
Of these, we excluded 12 trials because they compared routine versus selective invasive 
strategy, two trials (19,20) because patients were randomised before hospital admission, 
one trial (21) because patients were randomised after coronary angiography, and three trials 
because their principal investigators did not respond to our request (22–24). Eight trials 
involving 5324 patients met the eligibility criteria and were included in the meta-analysis 
(table 1, figure 1). 
All included trials had a low risk of bias overall (appendix). Table 1 shows key design fea-
tures of the included trials; table 2 shows baseline and procedural characteristics. With the 
exception of LIPSA-NSTEMI, all trials assigned patients to two groups. In LIPSIA-NSTEMI, 
patients were assigned to either an immediate, early, or selective invasive strategy. We 
excluded patients assigned to the selective invasive group. Median follow-up was 180 days 
(IQR 180–360), ranging from 30 days in ABOARD to 732 days in ELISA-3. The maximum 
follow-up varied in ELISA and ELISA-3, depending on the time of inclusion; other trials had 
a fixed end of follow-up for each patient. This meta-analysis included longer follow-up than 
in the original reports of three trials: ELISA (372 days vs 30 days), ELISA-3 (732 days vs 
30 days), and ISAR-COOL (360 days vs 30 days). During the extended follow-up period 
two deaths and no non-fatal myocardial infarctions occurred in ELISA, 33 deaths and 24 
non-fatal myocardial infarctions occurred in ELISA-3, and 18 deaths and ten non-fatal 
myocardial infarctions occurred in ISAR-COOL. LIPSIA-NSTEMI and RIDDLE-NSTEMI 
only enrolled patients with positive cardiac biomarkers (ie, NSTEMI rather than NSTE-ACS). 
Three trials used a strategy of immediate (primary) percutaneous coronary intervention for 
the early invasive group (ABOARD, LIPSIA-NSTEMI, and RIDDLE-NSTEMI), whereas for 
the others, the timing in the early invasive group differed by several hours, up to 24 h. The 
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heterogeneity in timing is even more obvious for the delayed invasive group. Trials such 
as ABOARD and LIPSIA-NSTEMI, which tested primary percutaneous coronary interven-
tion for NSTEMI, had control groups with the fastest procedural times. Thus, there was 
considerable overlap between the fast procedural times in the delayed invasive groups of 
these trials and the early invasive strategy of other trials (figure 2). The remaining baseline 
characteristics were well-balanced between included trials and therefore allowed pooling 
for meta-analysis. 
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hospital discharge or as post-discharge events if they 
occurred between hospital discharge and the end of follow-
up. Analysis of post-discharge events excludes patients 
who died before discharge. Trials without clinical events or 
only few events resulting in infinite HRs were weighted 
with zero. We used a two-step approach for the meta-
analysis to preserve clustering of patients in trials.11 All 
trials were analysed separately and respective principal 
investigators were asked to confirm the results. 
Discrepancies were resolved by discussion. We obtained 
individual patient data for ABOARD,12 ELISA,13 ELISA-3,14 
ISAR-COOL,15 LIPSIA-NSTEMI,16 Sciahbasi et al,17 and 
RIDDLE-NSTEMI,18 which we analysed centrally. Because 
of legal issues, TIMACS3 provided standardised tabulated 
data com patible with the pre-specified central analysis of 
other trials. For each outcome, we pooled HRs using 
inverse variance weighting and calculated DerSimonian 
and Laird random-effects models since all trials were done 
independently and we assumed that clinical heterogeneity 
will be present even despite a negative Cochrane’s Q 
statistic. We assessed heterogeneity between trials using τ² 
as measure of between-study variance and Higgins’ and 
Thompson’s I². We evaluated interactions in subgroups by 
random-effects models (combined from the final results). 
We did post-hoc meta-regression to assess the relationship 
between the median difference in time to angiography and 
outcomes. All analyses were pre-specified unless otherwise 
stated. All p values were two-sided and judged as significant 
if less than 0·05. We used R (version 3.1.0) and its package 
meta (version 4.3.2) for all statistical analyses.
Early invasive group Delayed invasive group Major inclusion criteria Biomarker positive Biomarker 
positivity as 
inclusion criteria
GRACE risk 
score
ABOARD (IPD)12 Immediate invasive 
strategy
Invasive strategy 
scheduled on the next 
working day (ie, 8–60 h) 
after enrolment
At least two of: symptoms of myocardial ischaemia; 
ST-segment abnormalities on ECG; elevated troponin I
Troponin I >ULN Not mandatory Not available
ELISA (IPD)13 Angiography within 
12 h without tirofiban 
pre-treatment
Pre-treatment with 
tirofiban for ≥12 h
At least two of: symptoms of myocardial ischaemia; 
ST-segment abnormalities on ECG; elevated troponin T
Troponin I 
>0·05 ng/mL
Not mandatory Not available
ELISA-3 (IPD)14 Angiography within 
12 h after 
randomisation
Angiography ≥48 h after 
randomisation
Symptoms of myocardial ischaemia plus at least two of: 
evidence of extensive myocardial ischaemia on ECG (ie, new 
cumulative ST depression >5 mm or temporary ST-segment 
elevation in two contiguous leads <30 min); elevated 
troponin T, myoglobin, or CK-MB fraction; age >65 years
Troponin T >0·1 µg/L, 
myoglobin >150 µg/L, 
CK-MB fraction >6% 
of total CK
Not mandatory Available
ISAR-COOL 
(IPD)15
Angiography within 
6 h with 
anti-thrombotic 
pre-treatment
Angiography ≥72 h with 
antithrombotic 
pre-treatment
Symptoms of myocardial ischaemia plus at least one of: 
ST-segment abnormalities on ECG; elevated troponin T value, 
myoglobin, or CK-MB fraction
Troponin T 
≥0·03 mg/L
Not mandatory Not available
LIPSIA-NSTEMI 
(IPD)16
Angiography within 
2 h after 
randomisation
Angiography on the next 
working day (ie, 10–48 h) 
after randomisation
Symptoms of myocardial ischaemia plus elevated troponin T Troponin T 
≥0·1 ng/mL
Mandatory Available
RIDDLE-NSTEMI 
(IPD)18
Angiography within 
2 h after 
randomisation
Angiography within 72 h 
after randomisation
Symptoms of myocardial ischaemia; elevated troponin I; 
ST-segment abnormalities or T-wave inversion on ECG
Troponin I >ULN Mandatory Available
Sciahbasi and 
colleagues 
(IPD)17
Angiography within 
6 h after hospital 
admission
Angiography within 72 h 
after hospital admission
Symptoms of yocardial ischaemia plus at least one of: 
ST-segment abnormalities on ECG; elevated troponin T or 
CK-MB fraction
Troponin T >2 × ULN, 
CK-MB >2 × ULN
Not mandatory Not available
TIMACS (ATD)3 Angiography within 
24 h after 
randomisation
Angiography ≥36 h after 
randomisation
Symptoms of myocardial ischaemia plus at leas  two of: 
ST-segment abnormalities on ECG; elevated troponin T, 
myoglobin, or CK-MB fraction; age ≥60 years
Cardiac biomarke s 
>ULN
Not mandatory Available
ATD=trial provided additional tabulated data. CK-MB=creatine kinase–myocardial band. ECG=electrocardiograph. GRACE=Global Registry of Acute Coronary Events. IPD=trial provided individual patient data. 
ULN=upper limit of normal. 
Table 1: Key features of includes trials
Figure 1: Trial selection
2190 articles found 
1731 excluded (not a randomised 
trial of interest)
1757 titles and abstracts screened
26 randomised trials
8 trials included
18 excluded
12 compared routine versus 
selective invasive 
(conservative) strategy
2 randomised before 
hospital admission
1 randomised after coronary 
angiography
3 principal investigators did 
not respond
433 duplicates removed
Figure 1: Trial selection
Data for ll-cause mortality and non-fatal myo ardial infarction w re complete for all 
patients. In total, 277 (5%) of 5324 patients died during the entire follow-up period. Of 
these, 121 (44%) deaths occurred during in-hospital treatment and 156 (56%) occurred 
after hospital discharge. The assigned treatment strategy did not have a significant effect 
on all-cause mortality when analysing the total population (HR 0·81, 95% CI 0·64–1·03; 
p=0·0879; figure 3). Treatment strategy did not have a significant effect when follow-up was 
divided into periods from randomisation to hospital discharge and from hospital discharge 
to end of follow-up (appendix). There was no evidence of heterogeneity in the outcome of 
mortality (I²=0% and p>0·5 for heterogeneity for each period; figure 3, appendix). 
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Table 1: Key Design Features of Includes Trials.
Trial Early invasive 
group
Delayed invasive 
group 
Major inclusion criteria Biomarker positive if Biomarker positivity as in-
clusion criteria
GRACE risk score
ABOARD 
(12) 
(IPD)
immediate inva-
sive strategy
invasive strategy sched-
uled on the next work-
ing day = 8 to 60 h after 
enrolment
2 out of 3:
•	symptoms of myocardial ischemia
•	ST-segment abnormalities on ECG
•	 elevated troponin I value
Troponin I >ULN not mandatory not available
ELISA 
(13)
(IPD)
angiography with-
in 12 h without 
tirofiban pre-treat-
ment
pre-treatment with ti-
rofiban for at least 12 h
2 out of 3:
•	symptoms of myocardial ischemia
•	ST-segment abnormalities on ECG
•	elevated troponin T value
Troponin I >0·05 ng/ml not mandatory not available
ELISA-3 (14)
(IPD)
angiography 
within 12 h after 
randomisation
angiography no sooner 
than 48 h after rando-
misation
symptoms of myocardial ischemia plus 
at least 2 out of 3:
•	evidence of extensive myocardial 
ischemia on ECG (shown by new 
cumulative ST depression >5 mm or 
temporary ST-segment elevation in 
two contiguous leads <30 min)
•	elevated troponin T value, myoglobin 
value or, CK-MB fraction
•	age >65 years
Troponin T >0·1 µg/l
myoglobin >150 µg/l
CKMB fraction >6% of total CK
not mandatory available
ISAR-COOL 
(15)
(IPD)
angiography 
within 6 h with 
antithrombotic 
pre-treatment
angiography no sooner 
than 72 h with an-
tithrombotic pre-treat-
ment
symptoms of myocardial ischemia plus 
1 out of 2:
•	ST-segment abnormalities on ECG
•	elevated troponin T value, myoglobin 
value, or CK-MB fraction
Troponin T ≥0·03 mg/l not mandatory not available
LIPSIA-NSTEMI
(16)
(IPD)
angiography with-
in 2 h after rando-
misation
angiography on the next 
working day = 10 to 48 
h after randomisation
symptoms of myocardial ischemia plus 
elevated troponin T value
Troponin T ≥0·1 ng/ml Mandatory available
RIDDLE-NSTEMI
(18)
(IPD)
angiography with-
in 2 h after rando-
misation
angiography within 72 h 
after randomisation
symptoms of myocardial ischemia plus 
elevated troponin I value plus ST-seg-
ment abnormalities and/or T-wave inver-
sion on ECG 
Troponin I >ULN Mandatory available
Sciahbasi et al. 
(17)
(IPD)
angiography with-
in 6 h after hospi-
tal admission
angiography within 72 h 
after hospital admission
symptoms of myocardial ischemia plus 
1 out of 2:
•	ST-segment abnormalities on ECG
•	elevated troponin T value or CKMB 
fraction
Troponin T >2x ULN
CK-MB >2x ULN
not mandatory not available
TIMACS
(3) 
(ATD)
angiography 
within 24 h after 
randomisation
angiography no sooner 
than 36 after randomi-
sation
symptoms of myocardial ischemia plus 
2 out of 3:
•	ST-segment abnormalities on ECG
•	elevated troponin T value, myoglobin 
value or, CKMB fraction
•	age ≥60 years
Cardiac biomarkers >ULN not mandatory available
Abbreviations: ATD, trial provided additional tabulated data; CK-MB, creatine kinase - myocardial band; 
ECG, electrocardiogram; GRACE, Global Registry of Acute Coronary Events; IPD, trial provided individual 
patient data; ULN, upper limit of normal.
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Table 1: Key Design Features of Includes Trials.
Trial Early invasive 
group
Delayed invasive 
group 
Major inclusion criteria Biomarker positive if Biomarker positivity as in-
clusion criteria
GRACE risk score
ABOARD 
(12) 
(IPD)
immediate inva-
sive strategy
invasive strategy sched-
uled on the next work-
ing day = 8 to 60 h after 
enrolment
2 out of 3:
•	symptoms of myocardial ischemia
•	ST-segment abnormalities on ECG
•	 elevated troponin I value
Troponin I >ULN not mandatory not available
ELISA 
(13)
(IPD)
angiography with-
in 12 h without 
tirofiban pre-treat-
ment
pre-treatment with ti-
rofiban for at least 12 h
2 out of 3:
•	symptoms of myocardial ischemia
•	ST-segment abnormalities on ECG
•	elevated troponin T value
Troponin I >0·05 ng/ml not mandatory not available
ELISA-3 (14)
(IPD)
angiography 
within 12 h after 
randomisation
angiography no sooner 
than 48 h after rando-
misation
symptoms of myocardial ischemia plus 
at least 2 out of 3:
•	evidence of extensive myocardial 
ischemia on ECG (shown by new 
cumulative ST depression >5 mm or 
temporary ST-segment elevation in 
two contiguous leads <30 min)
•	elevated troponin T value, myoglobin 
value or, CK-MB fraction
•	age >65 years
Troponin T >0·1 µg/l
myoglobin >150 µg/l
CKMB fraction >6% of total CK
not mandatory available
ISAR-COOL 
(15)
(IPD)
angiography 
within 6 h with 
antithrombotic 
pre-treatment
angiography no sooner 
than 72 h with an-
tithrombotic pre-treat-
ment
symptoms of myocardial ischemia plus 
1 out of 2:
•	ST-segment abnormalities on ECG
•	elevated troponin T value, myoglobin 
value, or CK-MB fraction
Troponin T ≥0·03 mg/l not mandatory not available
LIPSIA-NSTEMI
(16)
(IPD)
angiography with-
in 2 h after rando-
misation
angiography on the next 
working day = 10 to 48 
h after randomisation
symptoms of myocardial ischemia plus 
elevated troponin T value
Troponin T ≥0·1 ng/ml Mandatory available
RIDDLE-NSTEMI
(18)
(IPD)
angiography with-
in 2 h after rando-
misation
angiography within 72 h 
after randomisation
symptoms of myocardial ischemia plus 
elevated troponin I value plus ST-seg-
ment abnormalities and/or T-wave inver-
sion on ECG 
Troponin I >ULN Mandatory available
Sciahbasi et al. 
(17)
(IPD)
angiography with-
in 6 h after hospi-
tal admission
angiography within 72 h 
after hospital admission
symptoms of myocardial ischemia plus 
1 out of 2:
•	ST-segment abnormalities on ECG
•	elevated troponin T value or CKMB 
fraction
Troponin T >2x ULN
CK-MB >2x ULN
not mandatory not available
TIMACS
(3) 
(ATD)
angiography 
within 24 h after 
randomisation
angiography no sooner 
than 36 after randomi-
sation
symptoms of myocardial ischemia plus 
2 out of 3:
•	ST-segment abnormalities on ECG
•	elevated troponin T value, myoglobin 
value or, CKMB fraction
•	age ≥60 years
Cardiac biomarkers >ULN not mandatory available
Abbreviations: ATD, trial provided additional tabulated data; CK-MB, creatine kinase - myocardial band; 
ECG, electrocardiogram; GRACE, Global Registry of Acute Coronary Events; IPD, trial provided individual 
patient data; ULN, upper limit of normal.
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Table 2: Patient and Treatment Characteristics of Included Trials.
ABOARD (12) ELISA (13) ELISA-3 (14) ISAR-COOL (15) LIPSIA-NSTEMI (16) RIDDLE-NSTEMI (18) Sciahbasi et al. (17) TIMACS (3)
Group Early Delayed Early Delayed Early Delayed Early Delayed Early Delayed Early Delayed Early Delayed Early Delayed
No. of patients 175 177 109 111 269 265 203 207 200 200 162 161 27 27 1593 1438
Median follow-up (days) 30 30 373 371 732 732 360 360 180 180 365 365 365 365 184 184
Age, mean (SD), y 65 (12) 65 (12) 63 (11) 65 (11) 71 (10) 70 (11) 68 (12) 69 (11) 66 (12) 68 (13) 60 (11) 62 (10) 57 (54-64) 59 (51-68) 65 (11) 66 (11)
Age ≥75 y, n (%) 48 (27) 44 (25) 16 (15) 29 (26) 105 (39) 105 (40) 65 (32) 72 (35) 52 (26) 62 (31) 19 (12) 21 (13) 1 (4) 2 (7) 328 (21) 313 (22)
Male, n (%) 127 (73) 125 (71) 79 (72) 76 (68) 187 (70) 174 (66) 134 (66) 140 (68) 132 (66) 139 (70) 114 (70) 106 (66) 22 (81) 24 (89) 1038 (65) 940 (65)
Hypertension, n (%) 115 (66) 108 (61) 49 (46) 43 (39) 146 (54) 154 (58) 174 (86) 180 (87) 163 (82) 165 (82) 106 (65) 116 (72) 13 (48) 18 (67) 1084 (68) 996 (69)
Diabetes, n (%) 38 (22) 57 (32) 16 (15) 16 (14) 64 (24) 54 (20) 53 (26) 65 (31) 77 (39) 86 (43) 35 (22) 52 (32) 7 (26) 5 (19) 422 (27) 394 (27)
Smoking, n (%) 56 (32) 60 (34) 40 (37) 36 (33) 57 (21) 70 (26) 49 (24) 38 (18) 57 (28) 50 (25) 84 (52) 62 (39) 16 (59) 12 (44) 441 (28) 394 (27)
Previous stroke, n (%) 9 (5) 8 (5) 3 (3) 4 (4) 9 (3) 12 (5) NA NA 9 (4) 11 (6) 9 (6) 16 (10) 0 (0) 0 (0) 114 (7) 108 (8)
Previous MI, n (%) 29 (17) 33 (19) 19 (17) 14 (13) 48 (18) 52 (20) 44 (22) 52 (25) 36 (18) 47 (24) 31 (19) 34 (21) 0 (0) 0 (0) 313 (20) 300 (21)
Previous PCI, n (%) 43 (25) 54 (31) 16 (15) 16 (14) 49 (18) 55 (21) 42 (21) 48 (23) 33 (17) 32 (16) 17 (10) 15 (9) 0 (0) 0 (0) 221 (14) 204 (14)
Previous CABG, n (%) 9 (5) 12 (7) 12 (11) 8 (7) 37 (14) 32 (12) 20 (10) 28 (14) 10 (5) 15 (8) 8 (5) 12 (7) 0 (0) 0 (0) 111 (7) 105 (7)
Biomarker elevation, n (%) 132 (75) 129 (73) 66 (61) 55 (50) 211 (78) 210 (79) 134 (66) 140 (68) 200 (100) 200 (100) 162 (100) 161 (100) 19 (70) 22 (81) 1245 (78) 1120 (78)
ST-T segment changes, n (%) 122 (70) 136 (77) NA NA 196 (73) 182 (69) 134 (66) 134 (65) 158 (79) 163 (82) 159 (98) 160 (99) 19 (70) 20 (74) 1282 (81) 1149 (80)
GRACE risk score (med, Q1-3) NA NA NA NA 136 
(118-154)
133
(117-154)
NA NA 133 
(115-154)
137 
(112-160)
131 
(115-144)
129 
(115-150)
NA NA 129 
(109-148)
129 
(111-147)
GRACE risk score >140 n (%) NA NA NA NA 119 (45) 112 (43) NA NA 85 (42) 96  (48) 56 (35) 67  (42) NA NA 520  (33) 464 (32)
Time to randomisation, h (med, Q1-3) 2.0
(0.8-5.6)
2.5
(1.1-5.4)
2.3
(1.1-3.9)
2.0
(1.1-4.3)
2.0
(0.9-4.5)
2.1
(1.0-4.1)
NA NA 2.1
(1.0-3.8)
2.5
(1.6-4.1)
NA NA 8.0
(4.0-10.0)
8.0
(5.5-12.0)
NA NA
Time to angiography, h (med, Q1-3) 1.2
(0.8-2.0)
20.7
(17.4-24.6)
3.3 
(1.0-11.2)
48.0
(39.4-68.9)
2.6
(1.2-6.1)
54.9
(44.3-74.2)
2.4
(1.0-4.3)
87.4
(78.2-106.7)
1.1
(0.8-1.5)
18.3
(14.0-21.2)
1.4
(1.0-2.4)
61.0
(37.2-85.0)
5.0
(2.0-6.0)
24.0
(13.0-33.0)
14
(3-21)
50
(41-80)
Number of diseased vessels n (%)
 0 32 (18) 28 (16) 11 (10)a 14 (13) 26 (10)b 28 (11)b 21 (10) 25 (12) 19 (10) 17 (8)c 5 (3) 4 (2)c 0 (0) 0 (0) 427 (27) 427 (30)
 1 63 (36) 51 (29) 36 (33)a 37 (33) 74 (28)b 67 (26)b 39 (19) 40 (19) 63 (32) 53 (27)c 48 (30) 37 (23)c 17 (63) 17 (63) 504 (32) 447 (31)
 2 48 (27) 54 (31) 29 (27)a 25 (23) 77 (29)b 93 (36)b 49 (24) 50 (24) 59 (30) 65 (33)c 52 (32) 54 (34)c 9 (33) 8 (30) 390 (25) 337 (23)
 3 32 (18) 44 (25) 32 (30)a 35 (32) 87 (33)b 69 (27)b 94 (46) 92 (44) 59 (30) 65 (33)c 57 (35) 65 (41)c 1 (4) 2 (7) 272 (17) 227 (16)
Mode of revascularisation, n (%)
Conservative 46 (26) 55 (31) 27 (25)a 26 (26) 27 (10) 33 (12) 44 (22) 58 (28) 33 (16) 34 (17) 15 (9) 18 (11)c 0 (0) 0 (0) 409 (26) 449 (31)
 PCI 113 (65) 105 (59) 66 (61)a 64 (58) 179 (67) 164 (62) 143 (70) 133 (64) 151 (76) 141 (70) 127 (78) 104 (65)c 27 (100) 27 (100) 949 (60) 792 (55)
 CABG 16 (9) 17 (10) 15 (14)a 21 (19) 63 (23) 68 (26) 16 (8) 16 (8) 16 (8) 25 (12) 20 (12) 38 (24)c 0 (0) 0 (0) 235 (15) 197 (14)
Abbreviations: ABOARD, Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention study; CABG, coronary 
artery bypass graft; ELISA, Early or Late Intervention in unStable Angina pilot study; ELISA-3, Early or Late Intervention in unSta-
ble Angina - 3 study; GRACE, Global Registry of Acute Coronary Events;ISAR-COOL, Intracoronary Stenting With Antithrombotic 
Regimen Cooling-Off trial; LIPSIA-NSTEMI, Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl in 
NSTEMI; na, not available; PCI, percutaneous coronary intervention; RIDDLE-NSTEMI, Randomized study of ImmeDiate versus 
DeLayed invasivE intervention in patients with Non-ST-segment Elevation Myocardial Infarction; TIMACS, Timing of Intervention in 
Acute Coronary Syndrome.
a ELISA: Coronary angiography was not performed in 1 patient.
b ELISA-3: Coronary angiography were not performed in 5 and 8 patients randomised to the early invasive and delayed invasive 
group, respectivel
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Table 2: Patient and Treatment Characteristics of Included Trials.
ABOARD (12) ELISA (13) ELISA-3 (14) ISAR-COOL (15) LIPSIA-NSTEMI (16) RIDDLE-NSTEMI (18) Sciahbasi et al. (17) TIMACS (3)
Group Early Delayed Early Delayed Early Delayed Early Delayed Early Delayed Early Delayed Early Delayed Early Delayed
No. of patients 175 177 109 111 269 265 203 207 200 200 162 161 27 27 1593 1438
Median follow-up (days) 30 30 373 371 732 732 360 360 180 180 365 365 365 365 184 184
Age, mean (SD), y 65 (12) 65 (12) 63 (11) 65 (11) 71 (10) 70 (11) 68 (12) 69 (11) 66 (12) 68 (13) 60 (11) 62 (10) 57 (54-64) 59 (51-68) 65 (11) 66 (11)
Age ≥75 y, n (%) 48 (27) 44 (25) 16 (15) 29 (26) 105 (39) 105 (40) 65 (32) 72 (35) 52 (26) 62 (31) 19 (12) 21 (13) 1 (4) 2 (7) 328 (21) 313 (22)
Male, n (%) 127 (73) 125 (71) 79 (72) 76 (68) 187 (70) 174 (66) 134 (66) 140 (68) 132 (66) 139 (70) 114 (70) 106 (66) 22 (81) 24 (89) 1038 (65) 940 (65)
Hypertension, n (%) 115 (66) 108 (61) 49 (46) 43 (39) 146 (54) 154 (58) 174 (86) 180 (87) 163 (82) 165 (82) 106 (65) 116 (72) 13 (48) 18 (67) 1084 (68) 996 (69)
Diabetes, n (%) 38 (22) 57 (32) 16 (15) 16 (14) 64 (24) 54 (20) 53 (26) 65 (31) 77 (39) 86 (43) 35 (22) 52 (32) 7 (26) 5 (19) 422 (27) 394 (27)
Smoking, n (%) 56 (32) 60 (34) 40 (37) 36 (33) 57 (21) 70 (26) 49 (24) 38 (18) 57 (28) 50 (25) 84 (52) 62 (39) 16 (59) 12 (44) 441 (28) 394 (27)
Previous stroke, n (%) 9 (5) 8 (5) 3 (3) 4 (4) 9 (3) 12 (5) NA NA 9 (4) 11 (6) 9 (6) 16 (10) 0 (0) 0 (0) 114 (7) 108 (8)
Previous MI, n (%) 29 (17) 33 (19) 19 (17) 14 (13) 48 (18) 52 (20) 44 (22) 52 (25) 36 (18) 47 (24) 31 (19) 34 (21) 0 (0) 0 (0) 313 (20) 300 (21)
Previous PCI, n (%) 43 (25) 54 (31) 16 (15) 16 (14) 49 (18) 55 (21) 42 (21) 48 (23) 33 (17) 32 (16) 17 (10) 15 (9) 0 (0) 0 (0) 221 (14) 204 (14)
Previous CABG, n (%) 9 (5) 12 (7) 12 (11) 8 (7) 37 (14) 32 (12) 20 (10) 28 (14) 10 (5) 15 (8) 8 (5) 12 (7) 0 (0) 0 (0) 111 (7) 105 (7)
Biomarker elevation, n (%) 132 (75) 129 (73) 66 (61) 55 (50) 211 (78) 210 (79) 134 (66) 140 (68) 200 (100) 200 (100) 162 (100) 161 (100) 19 (70) 22 (81) 1245 (78) 1120 (78)
ST-T segment changes, n (%) 122 (70) 136 (77) NA NA 196 (73) 182 (69) 134 (66) 134 (65) 158 (79) 163 (82) 159 (98) 160 (99) 19 (70) 20 (74) 1282 (81) 1149 (80)
GRACE risk score (med, Q1-3) NA NA NA NA 136 
(118-154)
133
(117-154)
NA NA 133 
(115-154)
137 
(112-160)
131 
(115-144)
129 
(115-150)
NA NA 129 
(109-148)
129 
(111-147)
GRACE risk score >140 n (%) NA NA NA NA 119 (45) 112 (43) NA NA 85 (42) 96  (48) 56 (35) 67  (42) NA NA 520  (33) 464 (32)
Time to randomisation, h (med, Q1-3) 2.0
(0.8-5.6)
2.5
(1.1-5.4)
2.3
(1.1-3.9)
2.0
(1.1-4.3)
2.0
(0.9-4.5)
2.1
(1.0-4.1)
NA NA 2.1
(1.0-3.8)
2.5
(1.6-4.1)
NA NA 8.0
(4.0-10.0)
8.0
(5.5-12.0)
NA NA
Time to angiography, h (med, Q1-3) 1.2
(0.8-2.0)
20.7
(17.4-24.6)
3.3 
(1.0-11.2)
48.0
(39.4-68.9)
2.6
(1.2-6.1)
54.9
(44.3-74.2)
2.4
(1.0-4.3)
87.4
(78.2-106.7)
1.1
(0.8-1.5)
18.3
(14.0-21.2)
1.4
(1.0-2.4)
61.0
(37.2-85.0)
5.0
(2.0-6.0)
24.0
(13.0-33.0)
14
(3-21)
50
(41-80)
Number of diseased vessels n (%)
 0 32 (18) 28 (16) 11 (10)a 14 (13) 26 (10)b 28 (11)b 21 (10) 25 (12) 19 (10) 17 (8)c 5 (3) 4 (2)c 0 (0) 0 (0) 427 (27) 427 (30)
 1 63 (36) 51 (29) 36 (33)a 37 (33) 74 (28)b 67 (26)b 39 (19) 40 (19) 63 (32) 53 (27)c 48 (30) 37 (23)c 17 (63) 17 (63) 504 (32) 447 (31)
 2 48 (27) 54 (31) 29 (27)a 25 (23) 77 (29)b 93 (36)b 49 (24) 50 (24) 59 (30) 65 (33)c 52 (32) 54 (34)c 9 (33) 8 (30) 390 (25) 337 (23)
 3 32 (18) 44 (25) 32 (30)a 35 (32) 87 (33)b 69 (27)b 94 (46) 92 (44) 59 (30) 65 (33)c 57 (35) 65 (41)c 1 (4) 2 (7) 272 (17) 227 (16)
Mode of revascularisation, n (%)
Conservative 46 (26) 55 (31) 27 (25)a 26 (26) 27 (10) 33 (12) 44 (22) 58 (28) 33 (16) 34 (17) 15 (9) 18 (11)c 0 (0) 0 (0) 409 (26) 449 (31)
 PCI 113 (65) 105 (59) 66 (61)a 64 (58) 179 (67) 164 (62) 143 (70) 133 (64) 151 (76) 141 (70) 127 (78) 104 (65)c 27 (100) 27 (100) 949 (60) 792 (55)
 CABG 16 (9) 17 (10) 15 (14)a 21 (19) 63 (23) 68 (26) 16 (8) 16 (8) 16 (8) 25 (12) 20 (12) 38 (24)c 0 (0) 0 (0) 235 (15) 197 (14)
Abbreviations: ABOARD, Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention study; CABG, coronary 
artery bypass graft; ELISA, Early or Late Intervention in unStable Angina pilot study; ELISA-3, Early or Late Intervention in unSta-
ble Angina - 3 study; GRACE, Global Registry of Acute Coronary Events;ISAR-COOL, Intracoronary Stenting With Antithrombotic 
Regimen Cooling-Off trial; LIPSIA-NSTEMI, Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl in 
NSTEMI; na, not available; PCI, percutaneous coronary intervention; RIDDLE-NSTEMI, Randomized study of ImmeDiate versus 
DeLayed invasivE intervention in patients with Non-ST-segment Elevation Myocardial Infarction; TIMACS, Timing of Intervention in 
Acute Coronary Syndrome.
a ELISA: Coronary angiography was not performed in 1 patient.
b ELISA-3: Coronary angiography were not performed in 5 and 8 patients randomised to the early invasive and delayed invasive 
group, respectivel
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Figure 2: Time to coronary angiography in the early invasive and delayed invasive group of 
included trials. Bars depict IQR and median time from randomisation to coronary angiography in 
the early invasive group (white) and delayed invasive group (grey). 
Overall, 338 (6%) of 5324 patients had a non-fatal myocardial infarction. We detected no 
significant difference for non-fatal myocardial infarction between an early and delayed 
invasive strategy during any follow-up period (HR for overall follow-up period 0·91, 95% 
CI 0·57–1·46; p=0·7014; appendix). Heterogeneity was high in all analyses of non-fatal 
myocardial infarction (I² >50%, and p<0·05 for heterogeneity for each period; figure 3, 
appendix). 
We detected no association between mortality and difference in time to angiography 
between the early invasive and delayed invasive group in post-hoc meta-regression anal-
ysis. We detected no significant effect among trials in which coronary angiography was 
done in most patients in the delayed invasive group within 24 h after randomisation; nor 
did we detect an effect among trials in which most patients in the delayed invasive group 
had coronary angiography later than 24 h after randomisation (appendix). However, we 
did observe a significant association in post-hoc meta-regression with regard to non-fatal 
myocardial infarction (appendix). 
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of coronary angiography in patients with NSTE-ACS 
consistently showed that an early invasive strategy is 
superior to a delayed invasive strategy on soft outcomes of 
refractory or recurrent ischaemia and length of hospital 
stay without an increase in adverse outcomes (ie, all-cause 
mortality, myocardial infarction, stroke, or bleeding).
Overall, neither treatment strategy was superior in 
reducing all-cause mortality or non-fatal myocardial 
infarction in our meta-analysis. In contrast to previous 
meta-analyses,4–8 we were able to categorise follow-up 
into distinct periods (ie, from randomisation to hospital 
discharge and from hospital discharge to end of follow-
up). No significant effect was apparent for either outcome 
in any follow-up period.
Our collaborative approach using individual patient 
data and standardised tabulated data enabled us to 
explore treatment effects in pre-specified high-risk 
subgroups. Biomarker positive patients represented 
the largest subgroup, containing 79% of all patients. 
However, individual trials were underpowered to detect a 
significant effect of an early invasive strategy compared 
with a delayed invasive strategy on all-cause mortality in 
such patients. Moreover, because of inconsistent trial 
reporting, previous meta-analyses4–8 based on published 
data were unable to detect such an effect. Hence, our 
collaborative meta-analysis is the first to suggest a 
mortality benefit of an early invasive strategy compared 
with a delayed invasive strategy in patients with NSTEMI 
at baseline. In line with this, two meta-analyses including 
trials comparing a routine versus a selective invasive 
strategy showed the superiority of a routine invasive 
strategy with regard to composite endpoints (ie, death or 
myocardial infarction25 and death, myocardial infarction, 
or readmission to hospital27) in patients with positive 
biomarkers at baseline.
The guidelines recommendation of performing 
coronary angiography within 24 h in patients with 
GRACE scores of more than 140 points is based on a 
pre-specified subgroup analysis of the TIMACS trial. 
Only patients in the highest GRACE score tertile 
benefited from an early invasive strategy compared 
with a delayed invasive strategy regarding the composite 
endpoint of death, myocardial infarction, or stroke.3 
Four of eight trials included in our meta-analysis 
prospectively calculated the GRACE risk score. Under 
these caveats, an early invasive strategy might be 
associated with lower mortality than a delayed invasive 
strategy in this high-risk group.
11·5% of patients in the ACOS registry28 and 25·0% in 
the Euroheart acute coronary syndrome survey were older 
than 75 years.29 Compared to these registries, patients 
older than 75 years were well represented in our meta-
analysis (1282 [24·1%] of 5325 patients) and accounted for 
almost half of deaths. Coronary angiography was less 
often done in older patients in different registries28,30,31 but 
registry data suggest that a routine invasive strategy is 
also beneficial in these patients.29,32 Our meta-analysis 
supports this observation, suggesting that patients aged 
older than 75 years assigned to the early invasive group 
might have lower mortality. No direct information in this 
population was available regarding fragility, which is 
strongly and independently associated with in-hospital 
mortality and 30-day mortality.33
In a pooled analysis of the TIMI study group trials, 
3457 (28·8%) of 12 002 patients with NSTE-ACS had 
diabetes. These patients had an increased risk for 
mortality at 30 days and at 1 year.34 Patients with diabetes 
and pre-diabetes were also at increased risk of death in 
other studies;35,36 therefore, the presence of diabetes 
identifies a high-risk subgroup of patients with NSTE-
ACS. The proportion of patients in our meta-analysis 
who had diabetes (27·1%) is close to that of the pooled 
TIMI trial analysis. Even though guidelines do not 
recommend basing the timing of coronary angiography 
on diabetes status and diabetes status is not a parameter 
Figure 3: Outcomes after an early invasive strategy versus a delayed invasive strategy
(A) All-cause mortality from randomisation to end of follow-up, (B) non-fatal myocardial infarction from 
randomisation to end of follow-up. Size of data markers indicates weight of study in the pooled analysis. 
HR=hazard ratio.
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(A) All-cause mortality fro  randomisati n to end of follow-up, (B) non-fatal myocardial infarction 
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Patients with elevated cardiac biomarkers at baseline (4206 [79·0%] of 5324) had 219 
(79·1%) of the 277 recorded deaths; patients with diabetes (1441 [27·1%] of 5324) had 105 
(37·9%) of the 277 deaths, and patients aged 75 years or older (1282 [24·1%] of 5324) had 
136 (49·1%) of the 277 deaths. Although there was no significant mortality reduction for the 
entire patient cohort, an early invasive strategy might be ssociated with lower mortality 
in these pre-specified high-risk subgroups compared with a delayed invasive strategy (for 
patients with elevated biomarkers, HR 0·761; 95% CI 0·581–0·996; for diabetes, HR 0·67, 
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of the GRACE risk score, an early invasive strategy might 
be associated with lower mortality than a delayed invasive 
strategy in patients with diabetes.
Although the timing of coronary angiography might 
reduce mortality, a routine invasive strategy compared 
with a selective invasive strategy did not.25,27 However, a 
routine invasive strategy reduced the composite endpoint 
of all-cause mortality or non-fatal myocardial infarction, 
predominantly in high-risk patients.25,26 High-risk char-
acteristics were more common in the present analysis 
than in previous reports (eg, elevated biomarkers at 
baseline 79% vs 55%;27 diabetes 24% vs 18%37). 
Accumulation of these risk factors might shift patients to 
benefit from routine invasive or early invasive strategy 
for NSTE-ACS.37 From a pathophysiological point of view, 
an early invasive strategy might limit infarct size, as in 
ST-elevation myocardial infarction, and reduce 
inflammation and other systemic stress responses. This 
might explain the suggested mortality benefit in high-
risk subgroups in our meta-analysis.
The following limitations should be acknowledged. 
First, TIMACS contributed 56·9% of patients and 
58·8% of deaths to our meta-analysis. Therefore, the 
statistical weight to the calculated models of TIMACS 
ranged between 43% and 84% for all mortality analyses. 
However, TIMACS alone was underpowered to detect 
differences in mortality. Second, timing of coronary 
angiography for the early invasive and delayed invasive 
groups varied between included studies. Although 
median time to angiography in the early invasive group 
was less than 3 h for most trials, it was 14 h for TIMACS. 
Moreover, the difference between early invasive and 
delayed invasive group was more than 24 h for all trials 
besides ABOARD and LIPSIA-NSTEMI. Our meta-
regression analysis did not reveal a significant assoc-
iation with mortality for the difference in time to 
coronary angiography in the early invasive and delayed 
invasive groups although such an effect was detected 
on non-fatal myocardial infarction. Third, coronary 
angiography was almost always performed within 24 h 
of randomisation in all trials, which could have masked 
detection of myocardial re-infarction due to already 
elevated cardiac biomarkers. Therefore, this outcome 
might be underdiagnosed. Fourth, tests for interaction 
were negative in all subgroup analyses. The significant 
HR within these high-risk strata should therefore be 
interpreted as exploratory and hypothesis-generating. 
Fifth, different biomarkers and assays were used to 
define biomarker positivity and most trials were done 
before high-sensitivity troponin assays became clinical 
Figure 4: Mortality after an early invasive strategy versus a delayed invasive 
strategy in different subgroups
(A) Patients with or without elevated cardiac biomarkers at baseline, (B) patients 
aged <75 years or ≥75 years, (C) patients with or without diabetes, (D) patients 
with GRACE risk score ≤140 or >140. Size of data markers indicates weight of 
study in the pooled analysis. HR=hazard ratio.
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Figure 4: Mortality after an early invasive strategy versus a delayed invasive strategy in dif-
ferent subgroups  (A) Patients with or without elevated cardiac biomarkers at baseline, (B) patients 
aged <75 years or ≥75 years, (C) patients with or without diabetes, (D) patients with GRACE risk 
score ≤140 or >140. Size of data markers indicates weight of study in the pooled analysis. HR=-
hazard ratio.
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of the GRACE risk score, an early invasive strategy might 
be associated with lower mortality than a delayed invasive 
strategy in patients with diabetes.
Although the timing of coronary angiography might 
reduce mortality, a routine invasive strategy compared 
with a selective invasive strategy did not.25,27 However, a 
routine invasive strategy reduced the composite endpoint 
of all-cause mortality or non-fatal myocardial infarction, 
predominantly in high-risk patients.25,26 High-risk char-
acteristics were more common in the present analysis 
than in previous reports (eg, elevated biomarkers at 
baseline 79% vs 55%;27 diabetes 24% vs 18%37). 
Accumulation of these risk factors might shift patients to 
benefit from routine invasive or early invasive strategy 
for NSTE-ACS.37 From a pathophysiological point of view, 
an early invasive strategy might limit infarct size, as in 
ST-elevation myocardial infarction, and reduce 
inflammation and other systemic stress responses. This 
might explain the suggested mortality benefit in high-
risk subgroups in our meta-analysis.
The following limitations should be acknowledged. 
First, TIMACS contributed 56·9% of patients and 
58·8% of deaths to our meta-analysis. Therefore, the 
statistical weight to the calculated models of TIMACS 
ranged between 43% and 84% for all mortality analyses. 
However, TIMACS alone was underpowered to detect 
differences in mortality. Second, timing of coronary 
angiography for the early invasive and delayed invasive 
groups varied between included studies. Although 
median time to angiography in the early invasive group 
was less than 3 h for most trials, it was 14 h for TIMACS. 
Moreover, the difference between early invasive and 
delayed invasive group was more than 24 h for all trials 
besides ABOARD and LIPSIA-NSTEMI. Our meta-
regression analysis did not reveal a significant assoc-
iation with mortality for the difference in time to 
coronary angiography in the early invasive and delayed 
invasive groups although such an effect was detected 
on non-fatal myocardial infarction. Third, coronary 
angiography was almost always performed within 24 h 
of randomisation in all trials, which could have masked 
detection of myocardial re-infarction due to already 
elevated cardiac biomarkers. Therefore, this outcome 
might be underdiagnosed. Fourth, tests for interaction 
were negative in all subgroup analyses. The significant 
HR within these high-risk strata should therefore be 
interpreted as exploratory and hypothesis-generating. 
Fifth, different biomarkers and assays were used to 
define biomarker positivity and most trials were done 
before high-sensitivity troponin assays became clinical 
Figure 4: Mortality after an early invasive strategy versus a delayed invasive 
strategy in different subgroups
(A) Patients with or without elevated cardiac biomarkers at baseline, (B) patients 
aged <75 years or ≥75 years, (C) patients with or without diabetes, (D) patients 
with GRACE risk score ≤140 or >140. Size of data markers indicates weight of 
study in the pooled analysis. HR=hazard ratio.
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Figure 4: Continued
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95% CI 0·45–0·99; for age ≥75 years, HR 0·65, 95% CI 0·46–0·93; figure 4). GRACE 
risk score was determined prospectively in four trials (ELISA-3, LIPSIA-NSTEMI, RID-
DLE-NSTEMI, and TIMACS). These trials included 4288 (80·5%) of the 5324 patients and 
239 (86·3%) of the 277 deaths. Patients with a GRACE risk score of more than 140 points 
(1519 of 4288 patients with 173 of 239 deaths) might also benefit from an early invasive 
strategy compared with a delayed invasive strategy (HR 0·70, 95% CI 0·52–0·95; figure 
4). However, the test for interaction was not significant in any subgroup analysis (figure 4).
Discussion 
This collaborative meta-analysis is the largest and first studying the optimal timing of 
coronary angiography with regard to deaths in high-risk subgroups of patients with NSTE-
ACS. For the entire NSTE-ACS patient cohort there was no significant mortality benefit 
with an early invasive strategy compared with a delayed invasive strategy. However, 
pre-defined subgroup analyses suggested lower mortality in four high-risk subgroups: 
those with elevated cardiac biomarkers at baseline, diabetes, GRACE risk score more 
than 140 points, and age 75 years or older, although tests for risk–treatment interactions 
were not statistically significant. 
Previous meta-analyses showed a benefit of a routine invasive strategy over a selec-
tive invasive (or conservative) strategy in patients with NSTE-ACS with regards to a 
composite endpoint of death or myocardial infarction (26,27). However, optimal timing 
of coronary angiography is less clearly defined. Guidelines recommend an immediate 
invasive strategy for all unstable very high-risk patients. For all other patients, an invasive 
strategy within 24–72 h is recommended depending on their risk level. An early invasive 
strategy within 24 h is recommended for high-risk patients with positive cardiac biomark-
ers, dynamic ST-T changes, or a GRACE risk score more than 140 points (1,2). Previous 
meta-analyses (4–7) on the timing of coronary angiography in patients with NSTE-ACS 
consistently showed that an early invasive strategy is superior to a delayed invasive 
strategy on soft outcomes of refractory or recurrent ischemia and length of hospital stay 
without an increase in adverse outcomes (ie, all-cause mortality, myocardial infarction, 
stroke, or bleeding). 
Overall, neither treatment strategy was superior in reducing all-cause mortality or non-fatal 
myocardial infarction in our meta-analysis. In contrast to previous meta-analyses (4–8) we 
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were able to categorise follow-up into distinct periods (ie, from randomisation to hospital 
discharge and from hospital discharge to end of follow-up). No significant effect was appar-
ent for either outcome in any follow-up period. 
Our collaborative approach using individual patient data and standardised tabulated data 
enabled us to explore treatment effects in pre-specified high-risk subgroups. Biomarker 
positive patients represented the largest subgroup, containing 79% of all patients. How-
ever, individual trials were underpowered to detect a significant effect of an early invasive 
strategy compared with a delayed invasive strategy on all-cause mortality in such patients. 
Moreover, because of inconsistent trial reporting, previous meta-analyses (4–8) based on 
published data were unable to detect such an effect. Hence, our collaborative meta-anal-
ysis is the first to suggest a mortality benefit of an early invasive strategy compared with 
a delayed invasive strategy in patients with NSTEMI at baseline. In line with this, two 
meta-analyses including trials comparing a routine versus a selective invasive strategy 
showed the superiority of a routine invasive strategy with regard to composite endpoints 
(ie, death or myocardial infarction (25) and death, myocardial infarction, or readmission to 
hospital (27) in patients with positive biomarkers at baseline. 
The guidelines recommendation of performing coronary angiography within 24 h in patients 
with GRACE scores of more than 140 points is based on a pre-specified subgroup analysis 
of the TIMACS trial. Only patients in the highest GRACE score tertile benefited from an 
early invasive strategy compared with a delayed invasive strategy regarding the composite 
endpoint of death, myocardial infarction, or stroke.(3). Four of eight trials included in our 
meta-analysis prospectively calculated the GRACE risk score. Under these caveats, an 
early invasive strategy might be associated with lower mortality than a delayed invasive 
strategy in this high-risk group. 
11·5% of patients in the ACOS registry(28) and 25·0% in the Euroheart acute coronary 
syndrome survey were older than 75 years (29). Compared to these registries, patients 
older than 75 years were well represented in our meta-analysis (1282 [24·1%] of 5325 
patients) and accounted for almost half of deaths. Coronary angiography was less often 
done in older patients in different registries (28,30,31) but registry data suggest that a 
routine invasive strategy is also beneficial in these patients (29,32). Our meta-analysis 
supports this observation, suggesting that patients aged older than 75 years assigned to the 
early invasive group might have lower mortality. No direct information in this population was 
available regarding fragility, which is strongly and independently associated with in-hospital 
mortality and 30-day mortality (33).
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In a pooled analysis of the TIMI study group trials, 3457 (28·8%) of 12 002 patients with 
NSTE-ACS had diabetes. These patients had an increased risk for mortality at 30 days and 
at 1 year (34). Patients with diabetes and pre-diabetes were also at increased risk of death 
in other studies (35,36). Therefore, the presence of diabetes identifies a high-risk subgroup 
of patients with NSTE-ACS. The proportion of patients in our meta-analysis who had dia-
betes (27·1%) is close to that of the pooled TIMI trial analysis. Even though guidelines do 
not recommend basing the timing of coronary angiography on diabetes status and diabetes 
status is not a parameter of the GRACE risk score, an early invasive strategy might be 
associated with lower mortality than a delayed invasive strategy in patients with diabetes. 
Although the timing of coronary angiography might reduce mortality, a routine invasive 
strategy compared with a selective invasive strategy did not.(25,27). However, a routine 
invasive strategy reduced the composite endpoint of all-cause mortality or non-fatal myo-
cardial infarction, predominantly in high-risk patients (25,26). High-risk characteristics were 
more common in the present analysis than in previous reports (eg, elevated biomarkers 
at baseline 79% vs 55%;27 diabetes 24% vs 18%37). Accumulation of these risk factors 
might shift patients to benefit from routine invasive or early invasive strategy for NSTE-
ACS (37) From a pathophysiological point of view, an early invasive strategy might limit 
infarct size, as in ST-elevation myocardial infarction, and reduce inflammation and other 
systemic stress responses. This might explain the suggested mortality benefit in high-risk 
subgroups in our meta-analysis. 
The following limitations should be acknowledged. First, TIMACS contributed 56·9% of 
patients and 58·8% of deaths to our meta-analysis. Therefore, the statistical weight to the 
calculated models of TIMACS ranged between 43% and 84% for all mortality analyses. 
However, TIMACS alone was underpowered to detect differences in mortality. Second, 
timing of coronary angiography for the early invasive and delayed invasive groups varied 
between included studies. Although median time to angiography in the early invasive 
group was less than 3 h for most trials, it was 14 h for TIMACS. Moreover, the difference 
between early invasive and delayed invasive group was more than 24 h for all trials 
besides ABOARD and LIPSIA-NSTEMI. Our meta-regression analysis did not reveal a 
significant association with mortality for the difference in time to coronary angiography 
in the early invasive and delayed invasive groups although such an effect was detected 
on non-fatal myocardial infarction. Third, coronary angiography was almost always per-
formed within 24 h of randomisation in all trials, which could have masked detection of 
myocardial re-infarction due to already elevated cardiac biomarkers. Therefore, this out-
come might be underdiagnosed. Fourth, tests for interaction were negative in all subgroup 
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analyses. The significant HR within these high-risk strata should therefore be interpreted 
as exploratory and hypothesis-generating. Fifth, different biomarkers and assays were 
used to define biomarker positivity and most trials were done before high-sensitivity tro-
ponin assays became clinical standard in Europe (38). These assays shift some patients 
with NSTE-ACS from unstable angina to NSTEMI (39). Use of high-sensitive troponin 
assays does not much change risk prediction by GRACE score (40). Therefore, it is highly 
probable that results of our meta-analysis will also apply in the high-sensitive troponin 
era. In general, biomarker positive patients are a high-risk subgroup vulnerable to cardi-
ovascular events (25). Sixth, three eligible trials were not included since the respective 
principal investigators did not respond to our request. However, these trials were only 
small and their quality difficult to assess. 
In conclusion, an early invasive strategy was not associated with a significant mortality 
reduction compared with a delayed invasive strategy in the overall NSTE-ACS population. 
However, an early invasive strategy might be beneficial in four pre-defined high-risk sub-
groups. Since this finding is exploratory in nature, a pragmatic large-scale confirmatory 
trial would be needed to obtain definitive evidence of whether an early invasive strategy is 
beneficial compared with a delayed invasive strategy in these high-risk subgroups.
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The central theme of this thesis is optimal timing of invasive treatment of high-risk patients 
with a non-ST-elevation acute coronary syndrome (NSTE-ACS). Chapter 1 gives a brief 
introduction on acute coronary syndromes, with the pathophysiological mechanism and 
epidemiological characteristics. Also, the background of the ELISA-3 trial, acronym for Early 
or Late Intervention in high-risk non-ST-elevation acute coronary syndromes is described 
and the outcome of clinical trials and meta-analysis conducted before the start of this study 
are summarised.
The first part of this thesis presents the results of the ELISA-3 trial. In this prospective, 
multicentre open label trial, 542 patients with NSTE-ACS were randomised to early or 
delayed invasive treatment strategy, defined as coronary angiography (CAG) within 12 
hours or after more than 48 hours from randomisation respectively. Patients were eligible 
if they had at least two of the following three high-risk characteristics: [1] evidence of exten-
sive myocardial ischemia on ECG (shown by new cumulative ST depression >5 mm or 
temporary ST-segment elevation in 2 contiguous leads < 30 min), [2] elevated biomarkers 
for myocardial necrosis (Troponin T >0.10 ug/l) and [3] age above 65 years. Chapter 2 
describes the main results of the trial. Median age was 71.9 years (Quartile (Q) 1 to 3= 
64.5-78.4 y), higher than in any other previous trial in this patient category . Median time 
between randomisation and start of CAG was 2.6 (Q1 to 3 = 1.2-6.2) hours in the early and 
54.9 (Q1-3= 44.2-74.5) hours in the delayed intervention group, with the primary compos-
ite endpoint of death, reinfarction or recurrent ischemia at 30 days follow-up occurring in 
9.9% and 14.2% respectively. This 30% relative risk reduction in the early group was not 
statically significant (p=0.135) and consistent over pre-defined subgroups. The secondary 
endpoints, enzymatic infarct size and incidence of bleeding complications were also com-
parable. Hospital stay in the early intervention group was significantly shorter (median 4.0 
versus 6.0 days, p<0.01). The main conclusion was that in high-risk NSTE-ACS patients, 
an invasive treatment within 12 hours of admission was safe and feasible but not superior 
to CAG after more than 48 hours. However, the study turned out to be underpowered due 
to a lower than expected incidence of the primary endpoint.
Chapter 3 presents the predefined long-term results of ELISA-3, that were comparable with 
short-term outcome. Endpoint status could be collected in 96.1% of patients. The composite 
endpoint of death or reinfarction after 2 years follow-up occurred in 11.8 % of the early and 
13.1% of the delayed treatment group. This difference was not statistically significant (Rel-
ative risk (RR)=0.90, 95% Confidence interval (CI) 0.37-1.42, p=0.14). Post-hoc subgroup 
analysis suggested that older patients might benefit more from early CAG. A statistically 
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significant interaction between age and treatment strategy (p=0.02) was found. In the 50% 
oldest patients (aged over 72 years), the combined endpoint occurred in 13.6% of patients 
with early intervention and 21.7% with delayed intervention, compared to 10.0% and 4.6% 
respectively in patients aged under 72 years.
In Chapter 4, the effect of timing of intervention in the ELISA-3 study population is compared 
between 444 patients included in a PCI (percutanuous coronary intervention) centre and 90 
in non-PCI centres. No significant difference in incidence of the combined primary endpoint 
was found: 11.9% in the PCI centre vs. 12.6% in the non-PCI centres (p=0.85), showing 
that initial medical stabilisation of high risk patients with NSTE-ACS in non PCI-centres is 
safe and feasible. However, patients in non PCI centres tended to benefit more from early 
invasive strategy; the relative risk reduction with early versus delayed invasive strategy for 
the incidence of the combined primary endpoint in these patient was 77% compared to 
15% in patients included in the PCI centre (p for interaction= 0.089). This was driven by a 
reduction in recurrent ischemia in these patients. A possible explanation for these unex-
pected results is the much longer time delay from CAG to revascularisation in patients in 
non-PCI centres randomised to delayed intervention. These patients underwent diagnostic 
angiography in the non-PCI centre. If revascularisation was indicated, they had to wait for 
transfer to the PCI centre. Patients randomised to early treatment were urgently referred 
for to the PCI centre and underwent revascularisation, if indicated, immediately following 
angiography. This difference between patients randomised to early and delayed intervention 
in the PCI centre did not exist because all patients could be revascularised immediately 
following coronary angiography. This delay between angiography and revascularisation in 
patients initially hospitalised in non-PCI centres also exists in daily practice. Agreements 
with PCI centres to assure short access time for revascularisation and application of infor-
mation technologies for fast distant evaluation of angiograms might therefore improve 
clinical outcome. 
Chapter 5 describes a subgroup analysis in patients from the ELISA-3 trial with transient 
ST-segment elevation (TSTE). These patients initially present with ST-segment elevation 
of 1 mm or more in 2 contiguous leads on ECG and are classified as having a ST-eleva-
tion ACS, but show complete resolution within 30 minutes and before revascularisation is 
initiated. Timing of revascularisation in this category of patients is not addressed in current 
guidelines.
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In ELISA-3, TSTE was seen in 129 patients (24.2%) in whom the percentage male gender 
and smoker was higher, median age was lower and GRACE (global registry of acute coro-
nary events) risk score higher. The incidence of the combined primary endpoint in patient 
with and without TSTE was comparable (8.9% and 13.0%, p=0.21). In patients with TSTE, 
no significant difference was seen between early and delayed invasive treatment strategy, 
with incidence of the primary combined outcome after 30 days follow-up in 5.8 and 12.7 
% respectively, p=0.21). Based on these data, the conclusion is drawn that the effect of 
timing of intervention in patients with TSTE-ACS is comparable with high-risk NSTE-ACS 
in general.
.
Chapter 6 focuses on patients from ELISA-3 with an ACS due to obstruction of the cir-
cumflex coronary (Cx) artery. In 383 patients (71%) of ELISA-3, the culprit vessel could be 
determined, with the Cx artery in 112 (29%) of them. From the literature it is known that 
these patients often present without characteristic ST-segment elevation on ECG, even 
with complete occlusion of the coronary artery. This could lead to delay in diagnosis and 
revascularisation, larger infarct size and worse prognosis. However, in ELISA-3 the primary 
endpoint occurred less often in Cx-related than in non-Cx related ACS. (9.0 and 16.5% 
respectively), a difference that was borderline significant (p=0.057). A possible explanation 
is that these patients had more often single vessel disease and underwent PCI more often 
and CABG (coronary bypass surgery) less often. Also, selection bias may have occurred 
because acute posterior infarction was an exclusion criterion in ELISA-3. Enzymatic infarct 
size, initial TIMI flow (measure of patency of the culprit vessel) and incidence of bleeding 
events were comparable. No difference was found in clinical outcome between early or 
delayed invasive treatment in patients with Cx-related ACS (primary combined endpoint 
9.7 vs 8.0% with early and delayed intervention respectively p=1.00). This might lead to 
the conclusion that timing of angiography is not that important for clinical outcome in these 
patients, but we cannot exclude the possibility that an even more early treatment (so called 
STEMI-like approach) might have improved outcome. 
In the second part (chapter 7), use, timing and outcome of coronary angiography in high-
risk NSTE-ACS patients in “real life” is discussed. From the database of a prospective 
registry of 9198 consecutive patients hospitalised between 2006 and 2014 with ACS in a 
large, non academic hospital, data of 2299 patients with a high-risk NSTE-ACS were ana-
lysed. The percentage of these patients that underwent coronary angiography significantly 
increased from 77% in 2006 to 90% in 2014 (p for trend <0.001) together with a decrease 
of median time from hospitalisation to coronary angiography from 23.3 to 14.5 hours (p for 
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trend <0.001). According to the guidelines, these high risk patients should undergo angi-
ography within 24 hours of admission, so called early invasive treatment. The percentage 
of patients that was treated this way increased from 50% to 60% in the study period (p for 
trend =0.002). Patient factors independently related to delayed angiography (after more 
than 24 hours) were higher GRACE risk score, higher age and presence of co-morbidities. 
This inverse relationship between risk profile and the use of early invasive treatment is in 
conflict with the guidelines that advise early invasive treatment especially in higher risk 
NSTE-ACS patients. This so called “risk paradox” was also seen in other observational 
studies. A possible explanation is that cardiologists have more safety concerns with early 
invasive treatment in older patients with NSTE-ACS, although invasive treatment has shown 
to have significant benefits independent of age. No differences were found in incidence 
of mortality, reinfarction and bleeding after 30 days between early and delayed invasive 
strategy. After 1 year follow-up, mortality in the delayed treatment group was higher (7.0 
vs 4.1%, p = 0.01) but this difference was no longer statistically significant after correction 
for confounding factors like GRACE risk score.
The last part of this thesis (chapter 8) presents a meta-analysis concerning optimal timing 
of intervention in NSTE-ACS patients. This is based on individual data of more than 5000 
patients from 8 randomised trials (a so called collaborative meta-analysis) including the 
ELISA-3 trial. Individual clinical trials were underpowered to detect benefit and previous 
meta-analysis based on published data did not detect a difference in “hard” clinical end-
points, like reinfarction or mortality, but only found reduction in recurrent ischemia and 
duration of hospital stay with early invasive treatment. 
Median follow-up of the included trials was 180 days. Overall, no significant difference 
in mortality was found between early and delayed invasive strategy (HR 0.81, 95% 
CI=0.64-1.03 p=0.088 in favour of early intervention). The same applied to the incidence 
of non-fatal myocardial infarction (HR 0.91, 95% CI 0.57-1.46 p=0.70). These results are in 
line with findings of earlier meta-analysis. Prespecified analysis of four high risk subgroups 
suggested lower mortality with early invasive strategy in patients with positive cardiac 
biomarkers for myocardial necrosis at baseline (HR 0.76, 95% CI 0.58-1.00), in patients 
with diabetes (HR 0.67, 95% CI 0.45-0.99), with GRACE risk score >140 (HR 0.70, 95% 
CI 0.52-0.95), and patients aged 75 or older (HR 0.65, 95% CI 0.46-0.93). However, for 
all these subgroups, tests for interaction were not statistically significant and the findings 
should therefore be interpreted with caution and considered as hypothesis generating 
only. The main conclusion of this collaborative meta-analysis is that most patients with 
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NSTE-ACS can be treated safely with either early or delayed invasive strategy. However, 
it should be accounted for that the trials included in this analysis were performed between 
2000 and 2016. In this period, treatment and diagnostics have changed considerably, like 
the introduction of new medication like ADP blockers, newer generations of stents and 
high-sensitive troponin assays. 
General discussion
Guidelines concerning treatment of patients with NSTE-ACS (1,2) recommend a routinely 
invasive treatment strategy if one or more intermediate or high risk factor are present. Sev-
eral meta-analyses of randomised trials have shown a reduction in mortality and recurrent 
myocardial infarction in the medium and long term in these patients (3-5). In the past two 
decades, numerous trials have investigated optimal timing of intervention in NSTE-ACS 
(6-11) with mixed results. Most individual trials were underpowered to detect a significant 
effect on hard clinical endpoints, like mortality or recurrent myocardial infarction. Several 
meta-analyses (12-14) of randomised trials did not detect a difference in these outcomes 
either, but only a reduction in endpoints like recurrent ischemia and duration of hospital 
stay with early invasive treatment.
Despite the effort to include high risk and elderly NSTE-ACS patients, the ELISA-3 trial (15) 
was unable to detect significant differences between early and delayed intervention in the 
composite endpoint of death, reinfarction or recurrent ischemia at 30 days or in death or 
reinfarction after 2 years follow-up. Also, the collaborative meta-analysis discussed in chap-
ter 8 (16), based on individual data of more than 5000 patients from 8 randomised trials did 
not find significant differences after 180 days follow-up in mortality or myocardial infarction.
Since the completion of the ELISA-3 trial, a number of new studies were published. The 
Riddle-NSTEMI study (17) was a single centre study, comparing an immediate to a delayed 
invasive treatment (median time to intervention 1.4 and 61 h respectively) in 323 NSTEMI 
(non-ST- elevation myocardial infarction) patients in one hospital. Patients were eligible 
if they had elevation of cardiac Troponin I above upper limit of normal on admission and 
new ST-segment depression > 1 mm or T-wave inversion in 2 contiguous leads. Immediate 
intervention resulted in a significant reduction in the composite endpoint of death or new 
myocardial infarctions after 30 days follow-up (HR 0.32, 95% CI 0.13-0.74 p=0.008), driven 
by a reduction in new myocardial infarctions in the pre-catheterisation period. A problem 
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with the interpretation of the results of this trial is the liberal definition of “new myocardial 
infarctions”, that –at least partially- could better be classified as recurrent ischemia. In the 
Sisca trial (18), 170 NSTE-ACS patients with NSTE-ACS and at least one risk factor were 
randomised to early or delayed intervention (median time to intervention 2.8 and 20.9 h 
respectively). The incidence of the composite endpoint of death, myocardial infarctions or 
urgent revascularisation at 30 days was significantly lower with early intervention (2.0 vs. 
24% respectively, P<0.001), but driven by more urgent revascularisations for recurrent 
ischemia in the delayed intervention group. 
Very recently, a non-randomised, post-hoc analysis of the TAO (Treatment of Acute coro-
nary syndrome with Otamixaban) trial was published (19). In 4071 NSTEMI patients with 
a GRACE score >140, outcome was compared of very early, early and delayed interven-
tion, defined as CAG within 12 hours, between 12-24 hours and after more than 24 hours 
since admission. The primary endpoint of incidence of all cause mortality and myocardial 
infarction at 180 day follow-up occurred in 10.7%, 13.5% and 13.7% of patients respec-
tively. After adjustment for potential confounders, very early CAG was associated with a 
statistically significant lower risk compared to delayed CAG (OR 0.71, 95% CI 0.55-0.91), 
while no difference was found between early and delayed CAG (OR 0.96, 95% CI 0.75-
1.23). Because this study was a post hoc analysis and timing of intervention was not 
randomised, the authors state that these results should be hypothesis generating only and 
deserve prospective conformation. Two recent meta-analysis of randomised trials (20,21) 
again showed only a reduction in recurrent ischemia and duration of hospital stay with early 
invasive treatment strategy but no difference in mortality or myocardial infarction.
Considering all available scientific evidence it is surprising that current guidelines (1) are 
that straightforward about the recommendations for timing of intervention. A class I–level 
of evidence A- recommendation is given that high-risk NSTE-ACS patients should undergo 
angiography within 24 hours of presentation (early invasive strategy). The statement that 
those patients, if admitted to a hospital without PCI facilities should be transferred to a 
PCI centre the same day, is also not based on solid scientific evidence, especially for the 
situation in The Netherlands. In our country, the majority of hospitals have coronary care 
units and catheterisation laboratories where diagnostic coronary angiography in patients 
with ACS can be performed without delay. The results are then discussed in the heart 
team of a nearby interventional centre. Patients feasible for revascularisation are trans-
ported by ambulance to an interventional centre and return to the non-PCI centre after 
treatment. Same day transfer of all high risk ACS patients would result in high additional 
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costs without evidence for health benefit. Also, performing all diagnostic angiographies in 
interventional centres, would impose a heavy burden on their capacities and endanger the 
care for patients that really need acute treatment, like STEMI patients. Therefore, as also 
stated by the ACS Working Group of the Netherlands Society of Cardiology (NVVC) (22), 
according to current evidence, hospitalisation and stabilisation in a nearby non-PCI centre 
is safe and feasible and immediate transfer of all high risk ACS patients to interventional 
centres is not desirable. However, as discussed in chapter 4, streamlining logistic processes 
between the referring and interventional centre might reduce waiting time and the incidence 
of recurrent ischemia (23).
Only if patients develop so called very high risk symptom during admission, like refractory 
angina or hemodynamic instability, urgent revascularisation is indicated and patients should 
be transported to an intervention centre without delay. Considering the small distances 
between hospitals and well equipped ambulance services, this can be done safely in our 
country.
Considering the neutral results of so many studies comparing early and delayed inter-
vention, it is unlikely that early timing of intervention in high-risk NSTE-ACS patients as a 
whole will result in a substantial reduction in hard clinical endpoints. Therefore, it seems 
more relevant to identify specific patient categories that might benefit from early invasive 
treatment. So far, only subgroup analysis of trials and meta-analysis have shown clues in 
this direction. In the TIMACS trial (9), a pre-specified subgroup analysis showed a signif-
icant reduction of 35% in the incidence of the combined endpoint for death, myocardial 
infarctions and stroke at six months in patients with a GRACE risk score > 140 with early 
invasive treatment. Subgroup analysis in the ELISA-3 trial suggested a reduction of 35% 
in incidence of death or reinfarction after 2 years follow-up with early invasive strategy in 
the oldest half patients, aged over 72 years (24). The study of Jobs at al (16) was the only 
meta-analysis capable to perform subgroup analysis because analysis was based on indi-
vidual patient data of the included trials. They found a trend for lower mortality with early 
intervention in 4 pre-specified high-risk subgroups: in patients aged 75 or older, patients 
with positive biomarkers for myocardial necrosis at baseline, patients with diabetes and 
patients with a GRACE risk score > 140. Results of subgroup analysis, however, can be 
hypothesis generating only and findings should be confirmed in a well designed and suffi-
cient large randomised trial in these specific patients. Use of state-of-the art diagnostic (like 
high sensitive troponin essays) and therapeutical techniques (pharmacotherapy, stents) 
should be applied for optimal external validity.
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A rapidly increasing and therefore important subgroup of patients with ACS are the elderly, 
in whom NSTE-ACS is the most common type (25). Because both ischemic and bleeding 
risks are higher in older patients (26), optimal treatment strategies may differ from those in 
younger patients, but no specific recommendations are given by the guidelines concerning 
treatment of this patient category. Although routinely invasive treatment in elderly ACS 
patients has proven to reduce mortality and non-fatal myocardial infarction (27), registries 
have shown that they are less likely to undergo an invasive treatment strategy. This so 
called “risk-treatment paradox”, the phenomenon that high risk patients are treated less 
invasive is in contradiction with the guidelines that advise early invasive strategy especially 
in higher risk NSTE-ACS patients. As already discussed, subgroup analysis of ELISA-3 
(24) and a meta-analysis from Jobs et al (16) suggested more benefit with early invasive 
treatment. 
Elderly are underrepresented in clinical trials and those included may not be representative 
due to selection bias (26, 27). Given this lack of evidence concerning optimal treatment 
of elderly NSTE-ACS patients, more research in this important subgroup of patients is 
needed. Until then, age itself should not be a reason for reluctancy for invasive treatment, 
especially if more sophisticated treatment is applied, like transradial catheterisation and 
new anticoagulants therapy with fewer bleeding complications. Frailty in elderly patients is 
probably more important when considering optimal treatment strategy (28) than age itself. 
Several important questions related to timing of intervention in patients with NSTE-ACS 
have not been addressed in this thesis and need further research. First of all, patients pref-
erences and the effect on patients satisfaction should be investigated. Ad hoc PCI (PCI in 
the same procedure as the diagnostic angiography) might save the patient an extra CAG 
procedure, but urgent transportation of patients without knowing if a revascularisation is 
necessary can be distressing.
Also, economic consequences of early and delayed intervention strategy should be com-
pared. Shorter hospital stay with early intervention and ad hoc PCI could reduce costs, 
but should be measured against the costs of 24 hours a day, every day availability of PCI 
facilities and emergency transportation of patients by ambulance to an intervention centre 
and back to referring hospital after the procedure. 
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Het centrale thema van dit proefschrift is optimale timing van invasieve behandeling van 
hoog-risico patiënten met een non-ST-elevatie acuut coronair syndroom (NSTE-ACS). 
Hoofdstuk 1 geeft een korte inleiding over het acuut coronair syndroom met het pathofy-
siologische mechanisme en de epidemiologische kenmerken. Tevens wordt de achtergrond 
van de ELISA-3 studie beschreven, acroniem voor “Early or Late Intervention in high-risk 
non-ST-elevation acute coronary syndromes” (vroege of late interventie bij hoog-risico 
non-ST-elevatie acuut coronair syndromen).
In het eerste deel van dit proefschrift worden de resultaten gepresenteerd van de ELISA-3 
studie. In deze prospectieve, multi-center, open label studie werden 542 patiënten met 
een NSTE-ACS gerandomiseerd naar vroeg of laat invasieve behandeling, gedefinieerd 
als coronair angiografie (CAG) binnen respectievelijk 12 uur of na meer dan 48 uur vanaf 
randomisatie. Patiënten waren geschikt wanneer ze voldeden aan tenminste twee van de 
volgende drie hoog-risico kenmerken: [1] aanwijzingen voor uitgebreide myocard ischemie 
op het ECG (gedefinieerd als nieuwe cumulatieve ST depressie > 5 mm of tijdelijke ST-seg-
ment elevatie in twee aangrenzende afleidingen < 30 minuten), [2] verhoogde biomarkers 
voor myocard necrose (troponine T > 0.10 ug/l) en [3] leeftijd boven 65 jaar. Hoofdstuk 
2 beschrijft de belangrijkste resultaten van het onderzoek. Mediane leeftijd was 71.9 jaar 
(eerste tot derde kwartiel [Q1-3]= 64.5-78.4), hoger dan in alle voorgaande studies in deze 
patiëntencategorie. Mediane tijd tussen randomisatie en start van de CAG was 2.6 (Q1-
3=1.2-6.2) uur in de vroege en 54.9 (Q1-3=44.2-74.5) uur in de late interventie groep. Het 
primaire gecombineerde eindpunt van de studie, het optreden van dood, re-infarcering of 
hernieuwde ischemie na 30 dagen follow-up trad op in respectievelijk 9.9 en 14.2% van de 
patiënten. Deze 30% relatieve risico reductie was niet statistisch significant (p=0.135) en 
consistent in alle vooraf gedefinieerde subgroepen. De secundaire eindpunten, enzymati-
sche infarct grootte en incidentie van bloedingen, waren ook vergelijkbaar tussen de twee 
groepen. Opnameduur in de vroege interventiegroep was significant korter (mediaan 4.0 
versus 6.0 dagen, p<0.01). De belangrijkste conclusie was dat een invasieve behandeling 
binnen 12 uur na opname veilig en haalbaar was, maar niet beter dan coronair angiografie 
na meer dan 48 uur. De studie bleek echter underpowerd te zijn ten gevolge van een lager 
dan verwachte incidentie van het primaire eindpunt.
In hoofdstuk 3 worden de vooraf gedefinieerde lange termijn resultaten van de ELISA-3 
studie gepresenteerd die vergelijkbaar waren met de korte termijn uitkomsten. Bij 96.1% 
van de patiënten kon de eindpuntstatus worden achterhaald. Het gecombineerde eind-
punt van dood en re-infarcering na 2 jaar follow-up trad op bij 11.8% van de patiënten uit 
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de vroege en 13.1% uit de late interventie groep. Dit verschil was niet statistisch signifi-
cant (Relatief Risico (RR) =0.90, 95% betrouwbaarheidsinterval (BI) 0.37-1.42, p=0.14). 
Post-hoc subgroep analyse suggereerde dat ouderen meer baat hadden bij een vroege 
CAG, blijkend uit een statistisch significante interactie tussen leeftijd en behandel strategie 
(p=0.02). Bij de 50% oudste patiënten (ouder dan 72 jaar) trad het primaire eindpunt op 
bij 13.6% na een vroege en 21.7% na een late interventie. Bij patiënten jonger dan 72 jaar 
waren deze percentages respectievelijk 10.0% en 4.6%.
In hoofdstuk 4 wordt het effect van timing van interventie vergeleken tussen de 444 
patiënten die in het PCI (percutane coronaire interventie) centrum en de 90 patiënten die 
in de niet-PCI centra werden geïncludeerd in de ELISA-3 studie. Er werd geen significant 
verschil in incidentie van het gecombineerde primaire eindpunt gevonden: 11.9% in het 
PCI centrum versus 12.6% in de niet PCI centra (p=0.85). Hieruit blijkt dat initiële medica-
menteuze stabilisatie van hoog-risico patiënten met NSTE-ACS in niet-PCI centra veilig en 
haalbaar is. Patiënten die werden geïncludeerd in niet PCI centra leken echter meer baat 
te hebben bij een vroeg invasieve behandeling. De relatieve risico reductie met vroege 
versus late invasieve behandeling voor de incidentie van het gecombineerde primaire 
eindpunt bij deze patiënten was 77% en in patiënten uit het PCI centrum 15% (p voor 
interactie = 0.089). Dit verschil werd veroorzaakt door een reductie in het optreden van 
recidief ischemie. Een mogelijke verklaring voor dit onverwachte resultaat is de veel lan-
gere wachttijd tussen angiografie en revascularisatie bij patiënten die in de niet-PCI centra 
werden gerandomiseerd naar late interventie. Deze patiënten ondergingen diagnostische 
angiografie in het niet-PCI centrum. Indien een interventie geïndiceerd was, moesten zij 
wachten op overplaatsing naar het PCI centrum. Patiënten die in niet-PCI centra werden 
gerandomiseerd naar vroege behandeling werden met spoed overgeplaatst naar het PCI 
centrum voor angiografie en konden direkt aansluitend gerevasculariseerd worden. Een 
dergelijk verschil tussen de naar vroege en late interventie gerandomiseerde patiënten in 
het PCI centrum bestond niet omdat zij allemaal aansluitend aan de CAG konden worden 
gerevasculariseerd. Ook in de dagelijkse praktijk bestaat deze wachttijd voor revascularisa-
tie bij patiënten die initieel worden opgenomen in niet-PCI centra. Afspraken met PCI centra 
over korte toegangstijden voor revascularisatie en het gebruik van technologie voor evalu-
atie van coronair angiografie op afstand zouden de klinische uitkomsten kunnen verbeteren.
 
Hoofdstuk 5 beschrijft een subgroep analyse bij patiënten uit de ELISA-3 studie met pas-
sagère ST-segment elevatie (Transient ST-segment elevation of TSTE). Deze patiënten 
hebben initieel ST-segment elevatie van 1 mm of meer in 2 aangrenzende afleidingen op 
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het ECG maar deze verdwijnt volledig binnen 30 minuten en voordat met een eventuele 
revascularisatie wordt begonnen. In de huidige richtlijn worden over deze groep patiënten 
geen specifieke adviezen gegeven met betrekking tot de timing van coronair angiografie.
In ELISA-3 werd bij 129 patiënten (24.2%) TSTE gezien. Het percentage mannen en rokers 
in deze groep lag hoger en de mediane leeftijd en GRACE risk score (global registry of 
acute coronary events, een gevalideerde risico score bij ACS patiënten) lager dan in de 
groep patiënten zonder TSTE. De incidentie van het gecombineerde primaire eindpunt 
was niet significant verschillend (respectievelijk 8.9% en 13.0%, p=0.21). Bij patiënten 
met TSTE werd geen verschil gezien tussen vroege en late invasieve behandelstrategie 
met een incidentie van het primaire eindpunt van 5.8% en 12.7% (p=0.21). Op basis van 
deze gegevens wordt geconcludeerd dat het effect van timing van interventie in deze groep 
patiënten vergelijkbaar is met die van hoog-risico NSTE-ACS patiënten in het algemeen.
Hoofdstuk 6 belicht de patiëntengroep van ELISA-3 met een acuut coronair syndroom 
(ACS) op basis van occlusie van de circumflex (Cx) coronair arterie. Bij 383 patiënten (71%) 
van de ELISA-3 kon de coronair arterie worden geïdentificeerd die het ACS had veroorzaakt 
(het zogenaamde “culprit” vat). Bij 112 patiënten (29%) was dit de Cx coronair arterie. Uit 
de literatuur is bekend dat deze patiënten zich vaak presenteren zonder de karakteristieke 
ST-segment elevatie op het ECG, zelfs bij complete occlusie van de coronair arterie. Dit 
kan leiden tot vertraging in de diagnostiek en revascularisatie, met als gevolg een groter 
infarct gebied en slechtere prognose. In de ELISA -3 studie lag de incidentie van het 
gecombineerde primaire eindpunt bij patiënten met een Cx-gerelateerd infarct met 9.0% 
echter lager dan bij patiënten met niet Cx-gerelateerde infarcten (16.5%), een verschil dat 
vrijwel statistisch significant was (p=0.057). Een mogelijke verklaring hiervoor is dat deze 
patiënten vaker éénvats lijden hadden en vaker een PCI en minder vaak een CABG (coro-
naire bypass operatie) ondergingen. Daarnaast kan selectie bias zijn opgetreden doordat 
verdenking op een acuut achterwandinfarct een exclusie criterium was in de ELISA-3 
studie. De enzymatische infarct grootte, initiële TIMI flow (mate van doorgankelijkheid 
van het culprit vat) en incidentie van bloedingen was vergelijkbaar. Er werd geen verschil 
gevonden in de klinisch uitkomst met vroege of late invasieve behandeling bij patiënten met 
een Cx-gerelateerd ACS (primaire gecombineerde eindpunt 9.7% vs. 8.0% met respectie-
velijk vroege en late interventie). Hieruit zou kunnen worden geconcludeerd dat de timing 
van coronair angiografie niet zo belangrijk is voor de klinische uitkomst bij deze patiënten, 
maar men kan de mogelijkheid niet uitsluiten dat een nòg vroegere interventie een beter 
resultaat zou hebben gegeven. 
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In het tweede deel van dit proefschrift (hoofdstuk 7) wordt de toepassing, timing en de uit-
komst van coronair angiografie bij hoog-risico NSTE-ACS patiënten in de dagelijkse praktijk 
beschreven. Uit de database van een prospectieve registratiestudie van 9198 opeenvol-
gende patiënten die tussen 2006 en 2014 werden opgenomen met een ACS in een groot, 
niet academisch ziekenhuis, werden gegevens van 2299 hoog-risico NSTE-ACS patiënten 
geanalyseerd. Het percentage patiënten dat coronair angiografie onderging steeg signifi-
cant van 77% in 2006 naar 90% in 2014 (ptrend < 0.001) met tegelijkertijd een afname van de 
mediane tijd tussen opname en angiografie van 23.3 naar 14.5 uur (ptrend < 0.001). Volgens 
de richtlijnen zouden deze hoog-risico patiënten binnen 24 uur na opname een coronair 
angiografie moeten ondergaan, zogenaamde vroeg-invasieve behandeling. Het percentage 
patiënten dat op deze manier werd behandeld steeg gedurende de studie periode van 
50% naar 60% (ptrend =0.002) . Patiënt gebonden factoren die onafhankelijk gerelateerd 
waren aan late angiografie (na meer dan 24 uur) waren een hogere GRACE risico score, 
hogere leeftijd en de aanwezigheid van co-morbiditeit. Deze omgekeerde relatie tussen 
risicoprofiel en de toepassing van vroeg invasieve behandeling is in tegenspraak met de 
richtlijnen die juist een vroeg invasieve behandeling adviseren bij hoog-risico NSTE-ACS 
patiënten. Deze zogenaamde “risico paradox” werd ook gezien in andere observationele 
studies. Een mogelijke verklaring hiervoor is dat cardiologen meer zorgen hebben over de 
veiligheid van invasieve behandeling bij oudere NSTE-ACS patiënten, ondanks het feit dat 
bewezen is dat deze significante voordelen biedt onafhankelijk van de leeftijd. Er werden 
geen verschillen gevonden in de incidentie van mortaliteit, re-infarcering en bloedingen met 
vroeg of laat invasieve behandeling na 30 dagen follow-up. Na 1 jaar was de mortaliteit in 
de laat invasieve behandelgroep hoger (7.0% vs. 4.1%, p=0.01) maar na correctie voor 
confounders als GRACE risicoscore was dit verschil niet meer statistisch significant.
 
In het laatste deel van dit proefschrift (hoofdstuk 8) wordt een meta-analyse besproken 
betreffende optimale timing van invasieve behandeling van patiënten met een NSTE-ACS. 
Deze is gebaseerd op de individuele data van meer dan 5000 patiënten uit 8 gerando-
miseerde trials (een zogenaamde collaboratieve meta-analyse), waaronder de ELISA-3 
studie. Individuele studies waren underpowerd om een eventueel positief effect vast te 
kunnen stellen. Eerdere meta-analyses gebaseerd op gepubliceerde data waren niet in 
staat om verschil aan te tonen op “harde” eindpunten, zoals re-infarcering en sterfte en 
vonden alleen reductie van hernieuwde ischemie en duur van ziekenhuis opname met 
vroeg invasieve behandeling.
 159
Nederlandse samenvatting en algemene discussie
10
De mediane follow-up van de geïncludeerde trials was 180 dagen. Er werd geen signi-
ficant verschil gevonden in mortaliteit tussen vroeg en laat invasieve strategie (Hazard 
Ratio (HR) = 0.81, 95% BI 0.64-1.03 p=0.088). Ook het optreden van niet-fatale myocard 
infarcten was vergelijkbaar in de twee behandel groepen (vroeg versus laat invasief HR 
=0.91, 95% BI 0.57-1.46 p=0.70). Deze resultaten zijn in overeenstemming met die van 
eerdere meta-analyses. Subgroepanalyse in 4 vooraf gedefinieerde hoog-risico groepen 
toonde aanwijzingen voor lagere mortaliteit met vroeg invasieve behandeling bij patiënten 
met positieve biomarkers voor myocard necrose bij opname (HR 0.76, 95% CI 0.58-1.00), 
bij patiënten met diabetes (HR 0.67, 95% CI 0.45-0.99), met een GRACE risico score 
>140 (HR 0.70, 95% CI 0.52-0.95), and bij patiënten van 75 jaar of ouder (HR 0.65, 95% 
CI 0.46-0.93). Omdat de statistische toetsen voor interactie in deze vier subgroepen niet 
significant waren, moeten deze uitkomsten met terughoudendheid worden geïnterpreteerd 
en alleen als hypothese genererend worden gezien. De belangrijkste conclusie van deze 
collaboratieve meta-analyse is dat de meeste patiënten met een NSTE-ACS veilig kunnen 
worden behandeld met zowel een vroeg invasieve als een laat invasieve behandelstrategie. 
Wel dient men zich te realiseren dat de trials uit deze meta-analyse werden verricht tussen 
2000 en 2016. In deze periode is de behandeling en diagnostiek aanzienlijk veranderd, 
zoals de introductie van nieuwe medicijnen als ADP-remmers, nieuwere generaties stents 
en hoog-sensitieve troponine test.
Discussie
Richtlijnen betreffende de behandeling van patiënten met NSTE-ACS (1,2) bevelen een 
routine invasieve behandelstrategie aan indien een of meer intermediaire of hoog-risico 
factoren aanwezig zijn. Verscheidene meta-analyses van gerandomiseerde trials hebben 
aangetoond dat hiermee de kans op mortaliteit en re-infarcering op de middellange en lange 
termijn wordt gereduceerd (3-5). In de afgelopen twee decennia is in veel trials onderzoek 
gedaan naar de optimale timing van interventie bij NSTE-ACS (6-11), met wisselende 
resultaten. De meeste individuele trials waren underpowerd om een significant effect op 
harde klinische eindpunten aan te kunnen tonen, zoals mortaliteit en re-infarcering. Ver-
schillende meta-analyses (12-14) van gerandomiseerde trials vonden geen verschil in deze 
uitkomsten maar alleen een reductie op eindpunten als hernieuwde ischemie en opname 
duur met vroege interventie.
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Ondanks dat bij de ELISA-3 studie (15) de inclusie van hoog-risico en oudere NSTE-ACS 
patiënten werd gestimuleerd, werd geen significant verschil gevonden tussen vroege en late 
interventie op het gecombineerde primaire eindpunt van dood, re-infarcering en hernieuwde 
ischemie na 30 dagen follow-up of in dood of re-infarcering na 2 jaar follow-up. Ook de 
collaboratieve meta-analyse (16) besproken in hoofdstuk 8 gebaseerd op individuele data 
van meer dan 5000 patiënten uit 8 gerandomiseerde trials vond geen significant verschil 
in mortaliteit of re-infarcering na 180 dagen follow-up. 
Sinds de afronding van de ELISA-3 studie zijn een aantal nieuwe studies gepubliceerd. 
De Riddle-NSTEMI studie (17) was een gerandomiseerde studie waarin een onmiddellijke 
interventie werd vergeleken met een uitgestelde (mediane tijd tot interventie respectievelijk 
1.4 en 61 uur) bij 323 patiënten met een NSTEMI (non-ST-elevatie myocard infarct) in één 
ziekenhuis. Patiënten konden worden geïncludeerd wanneer zij een verhoogd troponine I 
hadden bij opname en nieuwe ST segment depressie > 1 mm of T top inversie in 2 aangren-
zende ECG afleidingen. Onmiddellijke interventie resulteerde in een significante reductie 
op het gecombineerde eindpunt van dood of re-infarcering na 30 dagen follow-up (HR 0.32, 
95% BI 0.13-0.74, p=0.008) door reductie in re-infarcering in de periode voorafgaande 
aan de coronair angiografie. Een probleem bij de interpretatie van de resultaten van deze 
studie is de liberale definitie van re-infarcering, waardoor dit – in ieder geval deels – beter 
beschouwd kan worden als hernieuwde myocard ischemie. In de Sisca trial (18) werden 
170 patiënten met een NSTE-ACS en tenminste één risico criterium gerandomiseerd naar 
vroege of late interventie (mediane tijd tot interventie respectievelijk 2.8 en 20.9 uur). De 
incidentie van het gecombineerde eindpunt van dood, re-infarcering of spoed revascula-
risatie na 30 dagen follow-up was significant lager met vroege interventie (2.0 % versus 
24%, p,0.001) maar dit verschil werd veroorzaakt door minder spoed revascularisaties 
vanwege hernieuwde ischemie. 
Zeer recent werd een niet-gerandomiseerde post-hoc analyse gepubliceerd van de TAO 
(Treatment of Acute coronary syndrome with Otamixaban) trial (19). Bij 4017 NSTEMI 
patiënten met een GRACE risk score > 140 werd het resultaat vergeleken van zeer vroege, 
vroege en late interventie, gedefinieerd als een CAG <12 uur, tussen 12-24 uur en na > 
24 uur na opname. Het gecombineerde primaire eindpunt van de incidentie van sterfte of 
re-infarcering na 180 dagen follow-up trad op bij respectievelijk 10.7% 13.5% en 13.7% 
van de patiënten. Na correctie voor potentiële confounders was een zeer vroege interventie 
geassocieerd met een statistisch significant kleiner risico op het optreden van het primaire 
eindpunt in vergelijking met late interventie (OR 0.71, 95% BI 0.55-0.91 p<0.01) terwijl 
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geen significant verschil werd gevonden tussen vroege en late interventie (OR 0.96, 95% 
CI 0.75-1.23 p=0.76). Omdat deze studie een post-hoc analyse betrof en de timing van 
interventie niet gerandomiseerd was, stellen de auteurs terecht dat de resultaten slechts 
hypothese genererend zijn en moeten worden bevestigd in een nieuw prospectief geran-
domiseerd onderzoek. Twee recente meta-analyses (20,21) van gerandomiseerde trials 
toonden opnieuw slechts een reductie in hernieuwde ischemie en opname duur aan met 
een vroeg invasieve behandel strategie, maar geen verschil in sterfte of re-infarcering.
Gezien al het beschikbare wetenschappelijke bewijs, wekt het verbazing dat de huidige 
richtlijnen (1) zo stellig zijn wat betreft de aanbevelingen ten aanzien van de timing van inter-
ventie. De aanbeveling dat hoog-risico NSTE-ACS patiënten binnen 24 uur na presentatie 
een angiografie moeten ondergaan (vroeg invasieve behandel strategie) krijgt een klasse 
I – level of evidence A aanbeveling . De stelling dat deze patiënten, wanneer zij worden 
opgenomen in een ziekenhuis zonder PCI- faciliteiten de zelfde dag nog moeten worden 
overgeplaatst naar een PCI centrum is ook niet gebaseerd op hard wetenschappelijk bewijs. 
Dit geldt in het bijzonder voor de situatie in Nederland, omdat daar in de meeste zieken-
huizen een afdeling voor hartbewaking en een catheterisatie kamer aanwezig is waar op 
korte termijn diagnostische CAG’s kunnen worden verricht bij patiënten met een ACS. De 
resultaten hiervan worden vervolgens besproken met het hart-team van een nabij gelegen 
PCI centrum. Patiënten die in aanmerking komen voor revascularisatie worden per ambu-
lance naar het interventie centrum vervoerd en na behandeling weer teruggeplaatst voor 
nazorg in het perifere ziekenhuis. Routinematige overplaatsing van alle hoog-risico ACS 
patiënten naar een interventie centrum zou hoge kosten met zich meebrengen zonder dat 
er bewijs bestaat dat dit gezondheidswinst oplevert. Bovendien zou hierdoor een grote druk 
worden gelegd op de capaciteit van de interventie centra waardoor de zorg van patiënten 
die werkelijk een acute behandeling nodig hebben, zoals patiënten met een STEMI (ST-
elevatie myocard infarct) in gevaar kan komen. 
Terecht stelt de ACS werkgroep van de Nederlandse Vereniging Voor Cardiologie (NVVC) 
(22) dat opname en stabiliseren in een nabijgelegen niet-interventie ziekenhuis veilig en 
haalbaar is en het direct transporteren van alle hoog risico NSTE-ACS patiënten niet 
wenselijk is. Zoals echter reeds aangegeven in hoofdstuk 4, zou door stroomlijnen van 
de logistieke processen tussen verwijzend ziekenhuis en PCI centrum de wachttijd voor 
revascularisatie en daarmee de kans op het ontstaan van hernieuwde ischemie kunnen 
worden gereduceerd (23).
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Alleen als patiënten zogenaamde zeer hoog-risico symptomen ontwikkelen, zoals refractaire 
angina pectoris of haemodynamische instabiliteit, is spoed revascularisatie geïndiceerd en 
moeten zij zonder uitstel worden overgeplaatst naar een interventie centrum. Gezien de 
kleine afstanden tussen ziekenhuizen en de goed functionerende ambulance diensten, kan 
dit veilig gebeuren in ons land.
Gelet op de neutrale resultaten van zoveel onderzoeken waarin vroege en late interven-
tie is vergeleken, is het onwaarschijnlijk dat vroege angiografie in de gehele groep van 
hoog-risico NSTE-ACS patiënten zal resulteren in substantiële reductie op harde klini-
sche eindpunten. Het lijkt daarom zinvoller om specifieke groepen te identificeren die baat 
zouden kunnen hebben van vroege interventie. Tot dusverre hebben alleen subgroep analy-
ses van trials en meta-analyses aanwijzingen in die richting gegeven. In de TIMACS studie 
(9) bleek uit een tevoren gespecificeerde subgroep analyse een significante reductie van 
35% in de incidentie van het gecombineerde eindpunt van dood, re-infarcering en CVA na 
6 maanden follow-up bij patiënten met een GRACE risk score > 140. Subgroep analyse in 
de ELISA-3 studie toonde een reductie van 35% in incidentie van dood en re-infarcering 
na 2 jaar follow-up met vroeg invasieve therapie in de oudste helft van de patiënten met 
een leeftijd van 72 jaar en ouder (24). Het onderzoek van Jobs et al (16) was de enige 
meta-analyse waarbij het mogelijk was om subgroep-analyses uit te voeren, omdat deze 
gebaseerd was op individuele data van de geïncludeerde trials. Zij vonden in 4 vooraf 
gedefiniëerde hoog-risico subgroepen een trend naar lagere mortaliteit bij vroege interven-
tie: bij patiënten ouder dan 75, patiënten met positieve biomarkers voor myocard necrose, 
patiënten met diabetes en patiënten met een GRACE risico score > 140. Resultaten van 
subgroep analyses mogen echter slechts als hypothese genererend worden beschouwd en 
dienen bevestigd te worden in een voldoende grote gerandomiseerde studie in de betref-
fende patiënten categorie. Voor optimale externe validiteit moet hierbij gebruik gemaakt 
worden van moderne diagnostiek en therapie, zoals de laatste generatie stents en hoog 
sensitieve troponine tests. 
Ouderen vormen een steeds groter deel van ACS patiënten (25). Het NSTE-ACS is bij hen 
het meest voorkomende type. Omdat bij hen zowel het risico op ischemie als op bloedingen 
hoger is (26) kan de optimale behandelstrategie verschillen van die voor jongere patiënten. 
Desondanks worden er geen specifieke aanbevelingen gedaan in de richtlijnen voor deze 
patiënten categorie. Hoewel bewezen is dat een routine invasieve behandeling bij oudere 
ACS patiënten de kans op mortaliteit en re-infarcering verlaagt (27), blijkt uit registratie 
studies dat zij minder vaak invasief worden behandeld. Deze zogenaamde “risico-paradox”, 
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het fenomeen dat hoog risico patiënten minder vaak invasief worden behandeld, is in 
tegenspraak met de richtlijnen, die adviseren om vroeg invasieve behandeling juist in de 
hoger risico patiënten toe te passen. Zoals reeds eerder vermeld suggereren de subgroep 
analyses van de ELISA-3 en van de meta-analyse van Jobs et al (16) dat juist oudere 
NSTE-ACS patiënten baat hebben van een vroeg invasieve behandeling. 
In klinische trials zijn ouderen ondervertegenwoordigd en zij die wel worden geïncludeerd 
zijn mogelijk niet representatief door selectie bias (26,27). Hierdoor bestaat onvoldoende 
kennis met betrekking tot de optimale behandeling van oudere NSTE-ACS patiënten en 
meer onderzoek in deze belangrijke patiënten groep is dan ook noodzakelijk. Zo lang 
deze situatie blijft bestaan, zou leeftijd op zich geen reden mogen zijn voor terughoudend-
heid in invasieve behandeling, in het bijzonder als meer geavanceerde technieken worden 
gebruikt, zoals transradiale catheterisatie en nieuwe anti-coagulantia met minder kans op 
bloedingen. De mate van kwetsbaarheid (frailty index) is bij oudere patiënten waarschijnlijk 
belangrijker bij de keuze van de optimale behandeling dan de kalender leeftijd (28). 
Verschillende belangrijke onderwerpen die verband houden met de timing van interventie bij 
patiënten met NSTE-ACS zijn in dit proefschrift niet aan de orde gekomen en zouden nader 
onderzocht moeten worden. In de eerste plaats is de voorkeur van patiënten en het effect 
op patiënttevredenheid van belang. Een ad hoc PCI (een PCI in dezelfde procedure als de 
diagnostische angiografie) bespaart de patiënt een extra CAG en de kans op de hiermee 
samenhangende complicaties. Een spoed overplaatsing zonder dat tevoren bekend is of 
er een revascularisatie nodig is, kan echter ook belastend zijn voor de patiënt. Ook de 
economische aspecten van vroege en late interventie zouden moeten worden vergeleken. 
Kortere ziekenhuisopname en een ad hoc PCI in plaats van twee procedures sparen kosten 
uit, maar dit moet worden afgewogen tegen de extra kosten van continue beschikbaarheid 
van PCI faciliteiten en spoed ambulance vervoer van patiënten naar een interventie centrum 
en weer terug naar het verwijzende ziekenhuis na de procedure.
Referenties
Zie hoofdstuk 9.
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“Hoe lang ben je eigenlijk al bezig met je promotie onderzoek?” Deze vraag werd mij de 
afgelopen jaren regelmatig door familie, vrienden en collega’s gesteld. In feite is hier geen 
goed antwoord op te geven. Zoals bij veel “buiten promovendi” begint zoiets sluipenderwijs; 
en is het ook onduidelijk wanneer het “klaar” zal zijn.
In 2009 startte de ELISA-3 studie, een onderzoek naar de optimale timing van invasieve 
behandeling van patiënten met een non-ST-elevatie acuut coronair syndroom. Naast het 
Deventer Ziekenhuis deden hier Isala in Zwolle en nog 4 perifere ziekenhuizen aan mee. 
Aanvankelijk was ik als reserach arts betrokken bij deze studie door het includeren en 
begeleiden van patiënten, maar toen het onderzoek vorderde en mij gevraagd werd de 
publicatie te schrijven, raakte ik ook betrokken bij de data verzameling en analyse. Na 
een mooie publicatie in het tijdschrift EuroIntervention, met tegelijkertijd een presentatie 
op de Late Breaking Trials session van Euro-PCR in Parijs (het congres van de European 
Association of Percutanuous Cardiavascular Interventions) vroeg Arnoud van ’t Hof of 
het mij iets leek om te promoveren op het onderwerp van de timing van interventie bij het 
non-ST-elevatie acuut coronair syndroom. En zo is het gelopen: ruim 4 jaar na de eerste 
publicatie ligt hier nu mijn proefschrift.
Als eerste wil ik graag de patiënten bedanken die bereid waren om mee te doen aan de 
ELISA-3 studie. Patiënt gebonden medisch wetenschappelijk onderzoek is niet mogelijk 
zonder hun medewerking en vertrouwen. Ik vind het nog altijd bijzonder dat patiënten 
belangeloos meedoen aan onderzoek en bereid zijn om steeds weer naar het ziekenhuis 
te komen voor extra bloedafnames en controles. 
Onderzoek is teamwork. Als mij iets duidelijk is geworden tijdens het werken aan dit proef-
schrift, is het dat wel. Ik wil dan ook iedereen bedanken die mij geholpen heeft om dit 
project te laten slagen. 
In de eerste plaats mijn promotoren, professor dr. Harry Suryapranata en professor dr. 
Arnoud van ’t Hof. Harry, ik wil je hartelijk bedanken voor je vertrouwen toen ik je in 2015 
vroeg of ik bij jou aan de Radboud Universiteit mocht promoveren. Ondanks je drukke 
werkzaamheden, zowel in Nederland als ook in Indonesië, was je altijd goed bereikbaar 
en bereid mij te adviseren aangaande de publicaties. Arnoud, destijds cardioloog in Zwolle 
en initiator van de ELISA-3 studie. Het toeval wil dat wij in het zelfde jaar in Utrecht met 
onze studie geneeskunde begonnen. Jij was het die mij de kans gaf om het hoofdartikel 
te schrijven met de resultaten van de ELISA-3 studie en voorstelde om te promoveren. Ik 
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heb goede herinneringen aan de inspirerende besprekingen die we hadden, eerst in Isala 
in Zwolle en later bij “Zoethout Eigen Werk” in Hattem. Wat ik met name in je bewonder 
is dat je als interventie cardioloog ook oog hebt voor preventie en leefstijlfactoren. Een 
combinatie die niet zo heel veel voorkomt. Begin 2017 ben je hoogleraar geworden en 
naar het Maastricht Universitair Medisch Centrum vertrokken. Enerzijds jammer dat je 
nu zo ver weg zit, anderzijds erg leuk dat je nu in plaats van co-promotor, mijn (tweede) 
promotor kan zijn! Ik hoop dat we ondanks de afstand contact houden en samen kunnen 
blijven werken aan nieuwe projecten. 
Ook natuurlijk dank aan mijn co-promotoren: dr. Jan van Wijngaarden, cardioloog in het 
Deventer Ziekenhuis en dr. Esther van ’t Riet, epidemioloog en hoofd van het Wetenschaps-
bureau in het Deventer Ziekenhuis. Jan, jij was als hoofd onderzoeker voor het Deventer 
Ziekenhuis betrokken bij de opzet van de ELISA-3 studie. Ik heb veel geleerd van je posi-
tieve, maar altijd kritische houding aangaande de ELISA-3 en andere studies. Bedankt voor 
je adviezen bij het schrijven van de artikelen en dit proefschrift. Esther, jouw adviezen met 
betrekking tot de methodologische en statistische aspecten van onze publicaties hebben 
mij erg geholpen. Veel dank voor alle tijd die je de afgelopen maanden besteed hebt aan 
het samen met mij opnieuw doornemen van mijn proefschrift. Je kritische en frisse blik 
hebben mij erg geholpen bij de voorbereiding op de verdediging. Daarnaast dank dat je 
mij begeleidt bij de registratie tot epidemioloog B. 
Leden van de manuscriptcommissie: professor dr. M.J.R. Edwards, professor dr. R.J. van 
Geuns en professor dr. J.C.A. Hoorntje; hartelijk dank voor het beoordelen van het manus-
cript van mijn proefschrift. 
Ook wil ik mijn co-auteurs bedanken, die mij hebben geholpen bij het schrijven en gepubli-
ceerd krijgen van de artikelen. In het bijzonder wil ik hier noemen Hong Kie The, cardioloog 
in Hoogeveen; Hong Kie, jij was altijd de eerste die reageerde op mijn concept artikelen. 
En hoe goed ik ze ook had gecontroleerd, jij wist er altijd wel weer een paar foutjes uit te 
halen! Ik ben bang dat dit ook zal opgaan voor dit boekje….. Daarnaast ook een speciaal 
woord van dank voor Rik Hermanides, cardioloog in Isala in Zwolle. Hartelijk bedankt voor 
jouw hulp bij het verzamelen van de gegevens voor het artikel over de BAMI database en 
het schrijven van het artikel. De collega onderzoekers van de ELISA-3 studie en de mede-
werkers van de CCU- en hartcatheterisatie afdelingen in de deelnemende ziekenhuizen 
in Zwolle, Hoogeveen, Emmen, Heerenveen, Hardenberg en Deventer wil ik ook graag 
bedanken voor de prettige samenwerking. De ELISA-3 studie laat zien hoe samenwerking 
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tussen een interventie centrum en een aantal “perifere” klinieken tot mooi onderzoek kan 
leiden. Zonder jullie inzet was deze studie en dus ook dit boekje niet mogelijk geweest. 
Vera Derks en Yvonne Simons uit Isala wil ik bedanken voor hun hulp bij de communicatie 
en het maken van afspraken met de collega’s aldaar.
Een speciaal woord van dank natuurlijk voor Dirk Lok, “hoofd” van de research afdeling car-
diologie die mij in 1998 aannam als research arts op de afdeling cardiologie in het Deventer 
Ziekenhuis. Van het aanvaarden van deze functie heb ik nooit spijt gehad. Dirk, met jouw 
gedrevenheid en enthousiasme heb je een prachtig research team opgezet dat al jaren 
zowel nationaal als internationaal meetelt. Je gaf mij de ruimte en stimuleerde mij om me 
verder te ontwikkelen. In het dankwoord van jouw dissertatie uit 2013 vroeg je je af of ik de 
volgende promovendus van de Deventer cardiologie zou worden; het antwoord weet je nu! 
Naast Dirk Lok en Jan van Wijngaarden wil ik ook de andere cardiologen en oud-cardio-
logen in het Deventer Ziekenhuis bedanken (in alfabetisch volgorde): Willem Agema, Leo 
Bouwens, Henk Groeneveld, Fabrice Martens, Patrick Perik, Aize van der Sluis, Eric Tietge, 
Marieke Torn, Ype Tuininga en Ruben Uijlings, De open en informele sfeer in jullie vakgroep 
vind ik echt heel bijzonder. Een veilige omgeving is zeer belangrijk om te kunnen leren; al 
ben ik dan geen cardioloog, ik heb in de jaren dankzij jullie wel heel veel cardiologische 
kennis opgedaan. Jullie staan altijd open voor nieuwe ontwikkelingen en onderzoek. Ik had 
me als research arts geen betere werkplek kunnen wensen en hoop nog vele jaren met 
jullie te mogen samenwerken.
Mijn collega’s van de afdeling research cardiologie: Mieke van Buijsen, Rina Dommer-
holt, Lillian Ebels, Mayke Scholten, en Wendy Tousain; en oud collega’s Bea Hekkelman, 
Lydia Schoterman, Leon Schotman en Harald Verheij. We zijn met z’n allen een geweldig 
research team en hebben samen veel meegemaakt, zowel op persoonlijk als professioneel 
vlak. Dank voor jullie betrokkenheid en begrip als ik weer eens bezig was met een artikel of 
het voorbereiden van een presentatie. Ik hoop nog lang met jullie nieuwe studies te mogen 
opzetten en begeleiden. En een speciaal woord van dank voor Bea voor de hulp bij het 
realiseren van mijn idee voor de omslag van dit boekje. Eveneens gaan mijn gedachten uit 
naar dr. Pieta Bruggink, collega research arts, met wie ik vele jaren samen heb gewerkt en 
die helaas in 2016 is overleden. Pieta, jij promoveerde in 2009 in Utrecht en stimuleerde 
mij om jouw voorbeeld te volgen. Wat jammer dat je dit niet meer meemaakt.
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Collega’s van Diagram B.V. De statistici Evelien Kolkman en Petra Koopmans; bedankt 
voor de hulp bij de data verzameling en analyses van de Elisa-3 en de BAMI registry. Fijn 
dat ik jullie keer op keer mocht lastig vallen als ik weer eens vastliep in de brei van data. 
Linda van den Brink, directeur, hartelijk dank dat de deur bij Diagram altijd open stond voor 
overleg. Sonja Postma, jij ging mij voor als promovendus aan de Radboud Universiteit. 
Dank dat je mijn vraagbaak wilde zijn met betrekking tot een heleboel praktische zaken 
rondom de promotie. Jouw boekje was voor mij een mooie inspiratiebron!
Dr. Marieke de Visser, Scientific Manager Radboud Institute for Health Sciences en Mr. Nico 
Bouwman en Janny Rullmann van het Bureau van de Pedel van de Radboud Universiteit 
wil ik graag bedanken voor hun geduld waarmee ze mij hebben geholpen tijdens mijn 
promotietraject. Als buiten promovendus is het niet altijd even gemakkelijk om de juiste 
informatie te vinden omtrent alle gewoonten en regelgeving. 
Paranimfen Peter Berkelaar en Rob Gründeman, bedankt dat jullie mij terzijde willen staan 
bij de verdediging van mijn proefschrift. Peter, vriend sinds het eerste jaar van onze studie 
en sindsdien samen met Ineke betrokken bij alle belangrijke momenten in mijn leven. En 
vandaag zijn jullie er weer bij. Rob, kwartet- en orkestgenoot, jij hebt mij steeds gestimu-
leerd om naast mijn promotie ook met muziek bezig te blijven. Na vandaag is daar vast 
weer meer tijd voor.
Mijn schoonouders: Jacques en Gerda Weber-Engels, dank voor jullie betrokkenheid. 
Hoewel de laatste jaren voor jullie beiden niet gemakkelijk waren, bleven jullie geïnteres-
seerd in de voortgang van mijn proefschrift. (Schoon) zussen en –broers, neven en nichten, 
ook jullie bedankt voor jullie betrokkenheid 
Mijn moeder en - helaas veel te vroeg overleden- vader: dank voor de fijne jeugd die ik 
heb gehad. Ik heb groot respect voor de wijze waarop jullie - na de moeilijke tijd als kind in 
de Japanse interneringskampen in voormalig Nederlands-Indië - het leven hebben weten 
vorm te geven. Papa, interesse voor wetenschap heb ik van kleins af aan van jou mee 
gekregen. Ik kan mij jouw promotie aan de Landbouw Hogeschool te Wageningen in 1970 
nog goed herinneren; wat zou je de mijne graag hebben meegemaakt.
Zoals gebruikelijk in een dankwoord: als laatste de belangrijkste mensen in mijn leven: 
Pauline en onze kinderen Thom, Nienke en Matthijs; mijn thuisbasis. Uit de grond van mijn 
hart: dank dat jullie er voor mij zijn. Ik prijs mij gelukkig dat ik werk en privé altijd goed heb 
kunnen combineren en zodoende samen met Pauline de zorg voor jullie heb kunnen delen. 
Dat ik jullie heb zien opgroeien tot zelfstandige, evenwichtige volwassenen vervult mij met 
grote dankbaarheid. De discussies met jullie aan de eettafel houden mij scherp, ook belang-
rijk bij het schrijven van een proefschrift. Jullie hebben inmiddels grotendeels jullie eigen 
leven, maar toch is het gelukt om tussen al jullie tentamens, examens en reizen een datum 
te vinden voor mijn promotie. Fijn dat jullie er vandaag bij kunnen zijn. Pauline, mijn lief en 
maatje, al bijna 35 jaar. De afgelopen jaren hebben we samen vele uren doorgebracht op 
onze gezamenlijke studeerkamer van tien vierkante meter; jij bezig met je werk en ik met 
dit proefschrift. Bedankt dat jij er altijd was en er voor zorgde dat thuis alles door kon gaan 
wanneer ik weer eens op reis was voor een meeting of congres in binnen- of buitenland. 
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De schrijver van dit proefschrift werd geboren op 19 december 
1961 in Ede, destijds een mooi dorp op de Veluwe, waar hij ook 
opgroeide. Na het behalen van het diploma VWO in 1980 aan 
het Marnix College aldaar, studeerde hij een jaar humane voed-
ing aan de Landbouw Hogeschool te Wageningen. Zijn militaire 
dienstplicht vervulde hij als chauffeur-gewondenverzorger bij de 
Militair Geneeskundige Dienst van de Koninklijke Landmacht. In 
deze periode volgde hij een stage in het Sophia Ziekenhuis te Zwolle waardoor zijn inter-
esse in de gezondheidszorg werd versterkt. Vervolgens startte hij in 1982 met de studie 
geneeskunde aan de Rijksuniversiteit Utrecht waar hij in 1990 het arts examen behaalde. 
Na enkele jaren van klinisch werken (revalidatiegeneeskunde, orthopedie en ouderen 
geneeskunde) werkt hij sinds 1998 als arts-onderzoeker bij de afdeling cardiologie in het 
Deventer Ziekenhuis. In 2004 rondde hij de postacademische master opleiding epidemi-
ologie af. Naast zijn werk in het Deventer Ziekenhuis is hij actief binnen de Werkgroep 
Cardiologische Centra Nederland (WCN). Erik is getrouwd met Pauline Weber, samen 
hebben zij 3 kinderen. In zijn vrije tijd speelt hij altviool, geniet van muziek en is graag in 
de natuur, wandelend met de hond of op zijn mountainbike.
Fotografie: Bert de Graaf.
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